Compounds and pharmaceutical compositions thereof for the treatment of diseases

Novel ATPase inhibitor compounds targeting SMARCA2 and/or SMARCA4 are developed to treat or prevent cancers by enhancing biological activity, safety, and selectivity, addressing the need for effective therapeutic agents in diseases associated with these proteins.

WO2026234230A1PCT designated stage Publication Date: 2026-11-12ONCO3R THERAPEUTICS BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063405
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a need for therapeutic compounds that can inhibit SMARCA2 and/or SMARCA4 to treat or prevent diseases associated with these proteins, particularly in cancers where these proteins are mutated or deficient.

Method used

Development of novel compounds that act as ATPase inhibitors, specifically targeting SMARCA2 and/or SMARCA4, for use in pharmaceutical compositions to treat or prevent proliferative diseases.

Benefits of technology

The compounds demonstrate improved biological activity, safety, selectivity, and pharmacokinetic properties, effectively inhibiting SMARCA2 and/or SMARCA4, offering potential therapeutic benefits for various cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026063405_12112026_PF_FP_ABST
    Figure EP2026063405_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention discloses compounds according to Formula (I) wherein A, B, Cy, X, Y, L1, L2, R 1, R2, R3, R4a, R4b, R6, R7, m and n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of proliferative diseases by administering a compound of the invention.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASESFIELD OF THE INVENTION

[0001] The present invention relates to compounds, methods for the production of the compounds of the invention, pharmaceutical compositions comprising the compounds of the invention, uses and methods for the prophylaxis and / or treatment of proliferative diseases by administering the compounds of the invention. In particular, the compounds of the invention may inhibit SMARCA2 and / or SMARCA4.BACKGROUND OF THE INVENTION

[0002] The mammalian SWItch / Sucrose Non-Fermentable (SWI / SNF) complexes are large, ATP dependent chromatin remodelers with vital roles in various cellular processes, including transcription, DNA repair, and replication, achieved by regulating DNA accessibility.

[0003] Approximately 20% of all human cancers exhibit mutations in the genes encoding the nearly 20 canonical SWI / SNF subunits (Kadoch et al. 2013). These mutations are most frequently found in rhabdoid tumors, female-specific cancers (such as ovarian, uterine, cervical, and endometrial cancers), lung adenocarcinoma, gastric adenocarcinoma, melanoma, esophageal cancer, and renal clear cell carcinoma.

[0004] Within these SWI / SNF complexes, SWI / SNF -related, Matrix-associated, Actin -dependent Regulator of Chromatin, subfamily A member 2 (SMARCA2, Brahma, or BRM) and SWI / SNF -related, Matrix-associated, Actin-dependent Regulator of Chromatin, subfamily A, member 4 (SMARCA4 or BRG1) stand out as subunits that contain catalytic ATPase domains, essential for the SWI / SNF complex function. They perturb histone-DNA contacts, thereby providing access points fortranscription factors and DNA elements that regulate gene activation and repression.

[0005] SMARCA2 and SMARCA4 share a high degree of similarity, up to 75%, and both contain a DNA-stimulated, conserved ATPase domain driving chromatin -remodeling activity. In primary tumors, SMARCA4 is frequently mutated, particularly in lung, melanoma, liver, and pancreatic cancers. In SMARCA4-deleted cancer cells, SMARCA2's ATPase activity becomes critical for chromatin remodeling, which is essential for functions like cell proliferation, survival, and growth. Consequently, targeting SMARCA2 may hold promise as a therapeutic approach for SMARCA4-deleted or deficient cancers, e.g. non-small cell lung carcinoma, Burkitt lymphoma, childhood medulloblastoma, pancreatic adenocarcinoma, ovarian clear cell carcinoma, and melanoma (Wilson et al. 2014). Conversely, inhibition of SMARCA4 represents a therapeutic strategy for the treatment of SMARCA2 -deficient cancers (Ehrenhofer-Wolfer et al. 2019).

[0006] Hence, there is a need for therapeutic compounds that can inhibit SMARCA2 and / or SMARCA4 for the prophylaxis and / or treatment of the above-mentioned diseases.SUMMARY OF THE INVENTION

[0007] The present invention is based on the identification of novel compounds, and their use in the prophylaxis and / or treatment of proliferative diseases. In particular, the compounds of the invention may be ATPase inhibitors, and more particularly SMARCA2 and / or SMARCA4 inhibitors. The present invention also provides methods for the production of these compounds, pharmaceutical compositions comprising these compounds and methods for the prophylaxis and / or treatment of proliferative diseases by administering the compounds of the invention.

[0008] Accordingly, in a first aspect of the invention, the compounds of the invention are provided having a Formula I:wherein,A is 6-10 membered monocyclic or bicyclic aryl, or 5-10 membered monocyclic or bicyclic heteroaryl comprising one, two or three heteroatoms independently selected from N, O, and S;RyOv,0 N .0Y is independently selected from' * , ' ' andRyand Rzare each independently hydrogen or C 1-3 alkyl;X is N or CH;R1is Ci -e alkyl, C1-3 alkoxy(Ci-3)alkyl, 3-6 membered monocyclic cycloalkyl, 4-6 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, -NH2, -NH(CI-3alkyl), -N(CI-3alkyl)2, -NHC(=O)(Ci.3alkyl), -N(CI-3alkyl)C(=O)(Ci-3alkyl), or hydroxy(Ci.4)alkyl, wherein said cycloalkyl, heterocycloalkyl, alkyl and alkoxy groups are optionally substituted with one or more halogen, C1-6 alkoxy, -NH2, -NH(CI-3 alkyl), -N(CI-3 alkyl)2;n is 0, 1, or 2;each R2is independently selected from halogen and Ci-e alkyl, which alkyl is optionally substituted with halo or C1-4 alkoxy;or R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic cycloalkyl, or a fused 5-8 membered monocyclic heterocycloalkyl comprising Y in formula I and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro) or C1-4 alkyl;R3is hydrogen or C1-6 alkyl;R4aand R4bare each independently hydrogen or Ci-6 alkyl optionally substituted with one or more independently selected halo or C1-4 alkoxy;or R4aand R4b, together with the carbon to which they are attached, form a C3-6 cycloalkyl or 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, which cycloalkyl or heterocycloalkyl is optionally substituted with one or more halo or C1-4 alkoxy;Li is a bond or C1-4 alkyl;B is phenyl or 5-6 membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S,Cy is a 5 -membered monocyclic heteroaryl comprising one, two, or three heteroatoms independently selected from N, O, and S, which heteroaryl is optionally substituted with one or more independently selected -L2-R5groups;L2 is a bond or Ci-e alkyl;Each R5is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- -OS(O)2O(Ci.4 alkyl),- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CONR9aR9b,- -CO2R9a,- C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- C1-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9a, C1-4 alkoxy, or C3-6 cycloalkyl,- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, , -S(=O)2Ci-4alkyl, -C(=O)Ci-4alkyl, or -CO2R9a, and - 4-8 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, -S(=O)2Ci-4 alkyl, -C(=O)Ci-4 alkyl, or -CO2R9a, and- phenyl optionally substituted with one or more independently selected halo, -OH, -CN, C1-4 alkyl, Ci-4alkoxy, , -S(=O)2Ci.4alkyl, -C(=O)C 1.4 alkyl, or -CO2R9a;R6is hydrogen, halo, or C1-6 alkyl;The subscript m is 0, 1 or 2;Each R7is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CH=CHCO2R9a,- -CONR9aR9b,- -CO2R9a,- C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- C1-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or C1-4 alkoxy,- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and- 4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, andeach R8ais independently hydrogen or C1-4 alkyl;each R8bis independently hydrogen, C1-4 alkyl or -C(O)Ci.2alkyl;each R9ais independently selected from hydrogen and C1-4 alkyl; andeach R9bis hydrogen, C1-4 alkyl or C1-4 alkoxy; orR9aand R9btogether with the atoms onto which they are attached form a 4-7 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, whichheterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, Ci -4 alkyl.

[0009] In a particular aspect, the compounds of the invention are provided for use in the prophylaxis and / or treatment of proliferative diseases.

[0010] Certain compounds according to the invention may also exhibit one or more benefits including, inter alia, advantageous levels of biological activity which may be useful in the prophylaxis and / or treatment of one or more disease, improved safety characteristics (e.g. relating to hERG inhibition, drugdrug interaction (DDI) or CYP-interaction characteristics, etc), improved selectivity for one or more disease-associated biological target (e.g. reduced off-target effects, etc), improved pharmacokinetic properties (e.g. relating to dosing, solubility, absorption, etc), improved pharmacodynamic properties (e.g. relating to permeability, efflux, etc) or superior properties for use as pharmaceutical active ingredients alone or in pharmaceutical compositions (e.g. stability), or advantageous physico-chemical properties useful in the manufacturability of such aforementioned pharmaceutical compositions.

[0011] In a further aspect, the present invention provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutical carrier, excipient or diluent. In a particular aspect, the pharmaceutical composition may additionally comprise further therapeutically active ingredients suitable for use in combination with the compounds of the invention. In a more particular aspect, the further therapeutically active ingredient is an agent for the treatment of proliferative diseases.

[0012] Moreover, the compounds of the invention, useful in the pharmaceutical compositions and treatment methods disclosed herein, are pharmaceutically acceptable as prepared and used.

[0013] In a further aspect of the invention, this invention provides a method of treating a mammal, in particular humans, afflicted with a condition selected from among those listed herein, and particularly proliferative diseases, which method comprises administering an effective amount of the pharmaceutical composition or compounds of the invention as described herein.

[0014] The present invention also provides pharmaceutical compositions comprising a compound of the invention, and a suitable pharmaceutical carrier, excipient or diluent for use in medicine. In a particular aspect, the pharmaceutical composition is for use in the prophylaxis and / or treatment of proliferative diseases.

[0015] In additional aspects, this invention provides methods for synthesizing the compounds of the invention, with representative synthetic protocols and pathways disclosed later on herein.

[0016] Certain compounds according to the invention may exhibit one or more benefits including, inter alia, advantageous levels of biological activity which may be useful in the prophylaxis and / or treatment of one or more disease, improved safety characteristics (e .g. relating to hERG inhibition, drug -drug interaction (DDI) or CYP-interaction characteristics, etc), improved selectivity for one or more disease -associated biological target (e.g. reduced off-target effects, etc), improved pharmacokinetic properties (e.g. relating to dosing, solubility, absorption, etc), improved pharmacodynamic properties (e.g. relating to permeability, efflux, etc) or superior properties for use as pharmaceutical active ingredients alone or in pharmaceuticalcompositions (e.g. stability), or advantageous physico-chemical properties useful in the manufacturability of such aforementioned pharmaceutical compositions.

[0017] Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing detailed description.

[0018] It will be appreciated that compounds of the invention may be metabolized to yield biologically active metabolites.DETAILED DESCRIPTION OF THE INVENTIONDefinitions

[0019] The following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present invention.

[0020] When describing the invention, which may include compounds, pharmaceutical compositions containing such compounds and methods of using such compounds and compositions, the following terms, if present, have the following meanings unless otherwise indicated. It should also be understood that when described herein any of the moieties defined forth below may be substituted with a variety of substituents, and that the respective definitions are intended to include such substituted moieties within their scope as set out below. Unless otherwise stated, the term “substituted” is to be defined as set out below. It should be further understood that the terms “groups” and “radicals” can be considered interchangeable when used herein.

[0021] The articles ‘a’ and ‘an’ may be used herein to refer to one or to more than one (i.e. at least one) of the grammatical objects of the article. By way of example ‘an analogue’ means one analogue or more than one analogue.

[0022] A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONH2 is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning.

[0023] A wavy line drawn through a line in a structure indicates a point of attachment of a group. Similarly, a squiggly line on a chemical group as shown, for exampleindicates a point of attachment, i.e., it shows the broken bond by which the group is connected to another described group.

[0024] The prefix “Cu-v” indicates that the following group has from u to v carbon atoms. For example, “C1-8 alkyl” indicates that the alkyl group has from 1 to 8 carbon atoms.

[0025] Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. In certain embodiments, the term “about” includes the indicated amount ± 10%. In other embodiments, the term “about” includes the indicated amount ± 5%. In certain other embodiments, the term “about” includes the indicated amount ± 1%. Also, to the term “about X” includes description of “X”. Also, the singular forms "a" and "the" include plural references unless thecontext clearly dictates otherwise. Thus, e.g., reference to "the compound" includes a plurality of such compounds and reference to "the assay" includes reference to one or more assays and equivalents thereof known to those skilled in the art.

[0026] Unless indicated explicitly otherwise, where combinations of groups are referred to herein as one moiety, e.g. arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.

[0027] ‘Alkyl’ means straight or branched aliphatic hydrocarbon having the specified number of carbon atoms. Particular alkyl groups have 1 to 6 carbon atoms or 1 to 4 carbon atoms. Branched means that one or more alkyl groups such as methyl, ethyl or propyl is attached to a linear alkyl chain. Particular alkyl groups are methyl (-CH3), ethyl (-CH2-CH3), w-propyl (-CH2-CH2-CH3), isopropyl (-CH(CH3)2), w-butyl (-CH2-CH2-CH2-CH3), tert-butyl (-C(CH3)3), sec-butyl (-CH(CH3)-CH2CH3), isobutyl (-CH2-CH(CH3)2), w-pcntyl (-CH2-CH2-CH2-CH2-CH3), w-hcx l (-CH2-CH2-CH2-CH2-CH2-CH3), and 1,2-dimethylbutyl (-CH(CH3)-CH(CH3)-CH2-CH3). Particular alkyl groups have between 1 and 4 carbon atoms.

[0028] ‘hydroxyalkyl’ refers to an alkyl group with the number of carbon atoms specified, substituted with an -OH group. For example, hydroxy(Ci-4)alkyl refers to carbon chain straight or branched wherein one carbon atom is substituted with an -OH group. Examples of such hydroxyalkyl include without limitation -CH2-OH, -CH(CH3)-OH, -CH2-CH2CH2-OH, or -C(CH3)2-OH.

[0029] ‘Alkylene’ refers to divalent alkene radical groups having the number of carbon atoms specified, in particular having 1 to 6 carbon atoms and more particularly 1 to 4 carbon atoms which can be straight-chained or branched. This term is exemplified by groups such as methylene (-CH2-), ethylene (-CH2-CH2-), or -CH(CH3)- and the like.

[0030] ‘Alkoxy’ refers to the group O-alkyl, where the alkyl group has the number of carbon atoms specified. In particular the term refers to the group -O-Ci e alkyl. Particular alkoxy groups are methoxy, ethoxy, w-propoxy. isopropoxy, w-butoxy. tert-butoxy, scc-butoxy. w-pcntoxy. w-hcxoxy. and 1,2-dimethylbutoxy. Particular alkoxy groups are lower alkoxy, i.e. with between 1 and 6 carbon atoms. Further particular alkoxy groups have between 1 and 4 carbon atoms.

[0031] ‘ Amino’ refers to the radical -NH2.

[0032] ‘Aryl’ refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. In particular aryl refers to an aromatic ring structure, monocyclic or fused polycyclic, with the number of ring atoms specified. Specifically, the term includes groups that include from 6 to 10 ring members. Particular aryl groups include phenyl, and naphthyl.

[0033] “Aryl” also covers partially aromatic bi- or polycyclic ring systems wherein at least one ring is an aromatic ring and one or more of the other ring(s) is a non-aromatic, saturated or partially saturated ring. Partially aromatic aryl bicyclic ring systems can be vicinally fused, i.e., where the rings are linked to each other through two adjacent carbon atoms. Examples of partially aromatic heteroaryl groups include for example:

[0034] ‘Cycloalkyl’ refers to a non-aromatic hydrocarbyl ring structure, monocyclic, fused polycyclic, bridged polycyclic, or spirocyclic, with the number of ring atoms specified. A cycloalkyl may have from 3 to 12 carbon atoms, in particular from 3 to 10, and more particularly from 3 to 7 carbon atoms. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

[0035] ‘Cyano’ refers to the radical -CN.

[0036] ‘Halo’ or ‘halogen’ refers to fluoro (F), chloro (Cl), bromo (Br) and iodo (I). Particular halo groups are either fluoro or chloro.

[0037] As used herein, term ‘polycyclic’ refers to chemical groups featuring several closed rings of atoms. In particular it refers to groups featuring two, three or four rings of atoms, more particularly two or three rings of atoms, most particularly two rings of atoms.

[0038] ‘Hetero’ when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described previously such as alkyl, e.g. heteroalkyl, cycloalkyl, e.g. heterocycloalkyl, aryl, e.g. heteroaryl, and the like having from 1 to 4, and particularly from 1 to 3 heteroatoms, more typically 1 or 2 heteroatoms, for example a single heteroatom.

[0039] ‘Heteroaryl’ means an aromatic ring structure, monocyclic or fused polycyclic, that includes one or more heteroatoms independently selected from O, N and S and the number of ring atoms specified. In particular, the aromatic ring structure may have from 5 to 9 ring members. The heteroaryl group can be, for example, a five membered or six membered monocyclic ring or a fused bicyclic structure formed from fused five and six membered rings or two fused six membered rings or, by way of a further example, two fused five membered rings. Each ring may contain up to four heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically the heteroaryl ring will contain up to 4 heteroatoms, more typically up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non -basic as in the case of an indole or pyrrole nitrogen. In general the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.

[0040] Examples of five membered monocyclic heteroaryl groups include but are not limited to pyrrolyl, furanyl, thiophenyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups.

[0041] “Heteroaryl” also covers partially aromatic bi- or polycyclic ring systems wherein at least one ring is an aromatic ring and one or more of the other ring(s) is a non-aromatic, saturated or partially saturated ring, provided at least one ring contains one or more heteroatoms selected from nitrogen, oxygen or sulfur. Partially aromatic heteroaryl bicyclic ring systems can be vicinally fused, i.e., where the rings are linked toeach other through two adjacent carbon and / or nitrogen atoms. Examples of partially aromatic heteroaryl groups include for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo-l, 2,3,4-tetrahydroquinolinyl, dihydrobenzthienyl, dihydrobenzfuranyl, 1,3-dihydroisobenzofuran, 2,3-dihydro-benzo[l,4]dioxinyl, benzo[l,3]dioxolyl, 2,2-dioxo-l,3-dihydro-2-benzothienyl, 4, 5,6,7-tetrahydrobenzofuranyl, indolinyl, l,2,3,4-tetrahydro-l,8-naphthyridinyl, l.2.3.4-tctrahydropyrido|2.3- / ?|pyrazinyl and 3.4-dihydro-2 / / -pyrido|3.2- / ?|| l,4]oxazinyl.

[0042] Examples of five membered monocyclic heteroaryl groups include but are not limited to pyrrolyl, furanyl, thiophenyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups.

[0043] Examples of six membered monocyclic heteroaryl groups include but are not limited to pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl and triazinyl.

[0044] Particular examples of bicyclic heteroaryl groups containing a five membered ring fused to another five-membered ring include but are not limited to imidazothiazolyl and imidazoimidazolyl.

[0045] Particular examples of bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzofuranyl, benzothiophenyl, benzoimidazolyl, benzoxazolyl, isobenzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, purinyl (e.g. adenine, guanine), indazolyl, pyrazolopyrimidinyl, triazolopyrimidinyl, and pyrazolopyridinyl groups.

[0046] Particular examples of bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinolinyl, isoquinolinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, and pteridinyl groups. Particular heteroaryl groups are those derived from thiophenyl, pyrrolyl, benzothiophenyl, benzofuranyl, indolyl, pyridinyl, quinolinyl, imidazolyl, oxazolyl and pyrazinyl.

[0047] Examples of representative heteroaryls include the following:wherein each Y is selected from >C=O, NH, O and S.

[0048] ‘Heterocycloalkyl’ means a non-aromatic fully saturated ring structure, monocyclic, fused polycyclic, spirocyclic, or bridged polycyclic, that includes one or more heteroatoms independently selected from O, N and S and the number of ring atoms specified. The heterocycloalkyl ring structure may have from 4 to 12 ring members, in particular from 4 to 10 ring members and more particularly from 4 to 7 ring members. Each ring may contain up to four heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically the heterocycloalkyl ring will contain up to 4 heteroatoms, more typically up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. Examples of heterocyclic rings include,but are not limited to azetidinyl, oxetanyl, thietanyl, pyrrolidinyl (e.g. 1-pyrrolidinyl, 2-pyrrolidinyl and 3-pyrrolidinyl), tetrahydrofuranyl (e.g. 1 -tetrahydrofuranyl, 2 -tetrahydrofuranyl and 3 -tetrahydrofuranyl), tetrahydrothiophenyl (e.g. 1 -tetrahydrothiophenyl, 2 -tetrahydrothiophenyl and 3 -tetrahydrothiophenyl), piperidinyl (e.g. 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), tetrahydropyranyl (e.g. 4-tetrahydropyranyl), tetrahydrothiopyranyl (e.g. 4-tetrahydrothiopyranyl), morpholinyl, thiomorpholinyl, dioxanyl, or piperazinyl.

[0049] Particular examples of monocyclic rings are shown in the following illustrative examples:wherein each W and Y is independently selected from -CH2-, -NH-, -O- and -S-.

[0050] Particular examples of fused bicyclic rings are shown in the following illustrative examples:wherein each W and Y is independently selected from -CH2-, -NH-, -O- and -S-.

[0051] Particular examples of bridged bicyclic rings are shown in the following illustrative examples:wherein each W and Y is independently selected from -CH2-, -NH-, -O- and -S- and each Z is selected from N or CH.

[0052] Particular examples of spirocyclic rings are shown in the following illustrative examples:wherein each Y is selected from -CH2-, -NH-, -O- and -S-.

[0053] ‘Hydroxyl’ refers to the radical -OH.

[0054] ‘Oxo’ refers to the radical =0.

[0055] ‘ Substituted’ refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s).

[0056] As used herein, term ‘substituted with one or more’ refers to one to four substituents. In particular, it refers to one to three substituents. More particularly, it refers to one or two substituents. Most particularly, it refers to one substituent.

[0057] One having ordinary skill in the art of organic synthesis will recognize that the maximum number of heteroatoms in a stable, chemically feasible heterocyclic ring, whether it is aromatic or non-aromatic, is determined by the size of the ring, the degree of unsaturation and the valence of theheteroatoms. In general, a heterocyclic ring may have one to four heteroatoms so long as the heteroaromatic ring is chemically feasible and stable.

[0058] ‘Pharmaceutically acceptable’ means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.

[0059] ‘Pharmaceutically acceptable salt’ refers to a salt of a compound of the invention that is pharmaceutically acceptable and that retains the biological activity of the given compound, and which are is not biologically or otherwise undesirable. In particular, such salts may be inorganic or organic acid addition salts and base addition salts. For example, pharmaceutically acceptable salts are described in Handbook of Pharmaceutical Salts: Properties, Selection, and Use (Stahl & Wermuth 2011). The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately, e.g., by reacting the free base group with a suitable inorganic or organic acid. The compounds of the invention may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of the compounds of the invention be prepared from inorganic or organic bases. Frequently, the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases are well known in the art, such as, e.g., hydrochloric acid for forming acid addition salts, and such as, e.g., sodium hydroxide for forming basic salts. The term ‘pharmaceutically acceptable cation’ refers to an acceptable cationic counter-ion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like.

[0060] ‘Pharmaceutically acceptable vehicle’ refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.

[0061] ‘Prodrugs’ refers to compounds, including derivatives of the compounds of the invention, which have cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like.

[0062] ‘ Solvate’ refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. This physical association includes hydrogen bonding. Conventional solvents include water, EtOH, acetic acid and the like. The compounds of the invention may be prepared e.g. in crystalline form and may be solvated or hydrated. Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non -stoichiometric solvates. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. ‘Solvate’ encompasses both solution -phase and isolable solvates. Representative solvates include hydrates, ethanolates and methanolates.

[0063] ‘Subject’ includes humans. The terms ‘human’, ‘patient’ and ‘subject’ are used interchangeably herein.

[0064] ‘ Effective amount’ means the amount of a compound of the invention that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease. The “effective amount” can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated.

[0065] ‘Preventing’ or ‘prevention’ refers to a reduction in risk of acquiring or developing a disease or disorder (i.e. causing at least one of the clinical symptoms of the disease not to develop in a subject that may be exposed to a disease-causing agent, or predisposed to the disease in advance of disease onset.

[0066] The term ‘prophylaxis’ is related to ‘prevention’, and refers to a measure or procedure the purpose of which is to prevent, rather than to treat or cure a disease. Non -limiting examples of prophylactic measures may include the administration of vaccines; the administration of low molecular weight heparin to hospital patients at risk for thrombosis due, for example, to immobilization; and the administration of an anti-malarial agent such as chloroquine, in advance of a visit to a geographical region where malaria is endemic or the risk of contracting malaria is high.

[0067] ‘Treating’ or ‘treatment’ of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (z. e. arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof). In another embodiment ‘treating’ or ‘treatment’ refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, ‘treating’ or ‘treatment’ refers to modulating the disease or disorder, either physically, (e.g. stabilization of a discernible symptom), physiologically, (e.g. stabilization of a physical parameter), or both. In a further embodiment, “treating” or “treatment” relates to slowing the progression of the disease.

[0068] As used herein the term ‘proliferative disease(s)’ refers to diseases associated with excessive proliferation of cells and turnover of cellular matrix. In particular, the term refers to conditions such as cancer (e.g. uterine leiomyosarcoma or prostate cancer), myeloproliferative disorders (e.g. polycythemia vera, essential thrombocytosis and myelofibrosis), leukemia (e.g. acute myeloid leukemia, acute and chronic lymphoblastic leukemia), multiple myeloma, psoriasis, restenosis, scleroderma or fibrosis. In particular, the term refers to cancer, leukemia, and multiple myeloma.

[0069] Certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, selectively target SMARCA2. For example, certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, selectively target SMARCA2 over SMARCA4. For example, certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, are at least about 3 fold (e.g. at least about 4-, 5- , 6-, 7-, 8-, 9-, 10-, 15-, 20-, 30-, 40-, 50-fold, or more) more selective for SMARCA2 than for SMARCA4.

[0070] As used herein, the term "selectivity" of a compound refers to the compound having more potent activity at the first target than the second target. A fold selectivity can be calculated by any method known in the art. For example, a fold selectivity can be calculated by dividing the IC50 value of a compound for the second target (e.g., SMARCA4) by the IC50 value of the same compound for the first target (e.g.,SMARCA2). An IC50 value can be determined by any method known in the art. For example, an IC50 value can be determined as described in the assays below.

[0071] As used herein, the term ‘cancer’ refers to a malignant or benign growth of cells in skin or in body organs, for example but without limitation, breast, prostate, lung, kidney, pancreas, stomach or bowel. A cancer tends to infdtrate into adjacent tissue and spread (metastasize) to distant organs, for example to bone, liver, lung or the brain. As used herein the term cancer includes both metastatic tumour cell types (such as but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, and uterine leiomyosarcoma). In particular, the term ‘cancer’ refers to acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, Ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi’s sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms tumor.

[0072] As used herein the term ‘leukemia’ refers to neoplastic diseases of the blood and blood forming organs. Such diseases can cause bone marrow and immune system dysfunction, which renders the host highly susceptible to infection and bleeding. In particular the term leukemia refers to acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).

[0073] ‘Compound(s) of the invention’, and equivalent expressions, are meant to embrace compounds of the Formula(e) as herein described, which expression includes the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, and the solvates of the pharmaceutically acceptable salts where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits.

[0074] When ranges are referred to herein, for example but without limitation, Ci-s alkyl, the citation of a range should be considered a representation of each member of said range.

[0075] Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but in the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (Bundgaard 1985). Prodrugs include acid derivatives well know to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are particularly useful prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters. Particular such prodrugs are the Ci-s alkyl, C2-8 alkenyl, Ce-io optionally substituted aryl, and (C6-ioaryl)-(Ci-4 alkyl) esters of the compounds of the invention.

[0076] The present disclosure includes all isotopic forms of the compounds of the invention provided herein, whether in a form (i) wherein all atoms of a given atomic number have a mass number (or mixture of mass numbers) which predominates in nature (referred to herein as the “natural isotopic form”) or (ii) wherein one or more atoms are replaced by atoms having the same atomic number, but a mass number different from the mass number of atoms which predominates in nature (referred to herein as an “unnatural variant isotopic form”). It is understood that an atom may naturally exists as a mixture of mass numbers. The term “unnatural variant isotopic form” also includes embodiments in which the proportion of an atom of given atomic number having a mass number found less commonly in nature (referred to herein as an “uncommon isotope”) has been increased relative to that which is naturally occurring e.g. to the level of >20%, >50%, >75%, >90%, >95% or> 99% by number of the atoms of that atomic number (the latter embodiment referred to as an "isotopically enriched variant form"). The term “unnatural variant isotopic form” also includes embodiments in which the proportion of an uncommon isotope has been reduced relative to that which is naturally occurring. Isotopic forms may include radioactive forms (i.e. they incorporate radioisotopes) and non-radioactive forms. Radioactive forms will typically be isotopically enriched variant forms.

[0077] An unnatural variant isotopic form of a compound may thus contain one or more artificial or uncommon isotopes such as deuterium (2H or D), carbon-11 (nC), carbon-13 (13C), carbon-14 (14C), nitrogen-13 (13N), nitrogen-15 (15N), oxygen-15 (15O), oxygen-17 (17O), oxygen-18 (18O), phosphorus-32 (32P), sulfur-35 (35S), chlorine-36 (36C1), chlorine-37 (37C1), fluorine-18 (18F) iodine-123 (123I), iodine-125 (125I) in one or more atoms or may contain an increased proportion of said isotopes as compared with the proportion that predominates in nature in one or more atoms.

[0078] Unnatural variant isotopic forms comprising radioisotopes may, for example, be used for drug and / or substrate tissue distribution studies. The radioactive isotopes tritium, i.e.3H, and carbon- 14, i.e.14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Unnatural variant isotopic forms which incorporate deuterium i.e2H or D may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Further, unnatural variant isotopic forms may be prepared which incorporate positron emitting isotopes, such asnC,18F,15O and13N, and would be useful in Positron Emission Tomography (PET) studies for examining substrate receptor occupancy.

[0079] The selective replacement of hydrogen with deuterium in a compound may modulate the metabolism of the compound, the PK / PD properties of the compound and / or the toxicity of the compound. For example, deuteration may increase the half-life or reduce the clearance of the compound in vivo. Deuteration may also inhibit the formation of toxic metabolites, thereby improving safety and tolerability. It is to be understood that the invention encompasses deuterated derivatives of compounds of any of formulae I-XVIII. As used herein, the term deuterated derivative refers to compounds of the invention where in a particular position at least one hydrogen atom is replaced by deuterium. Accordingly, in a compound of the invention one or more hydrogen atom is optionally replaced by deuterium. For example, one or more hydrogen atoms in a Ci-4-alkyl group may be replaced by deuterium to form a deuterated C1-4-alkyl group. By way of example, if any of Ry, Rz, R1, R2, R3, R4a, R4b, R5, R6, R7, R8a, R8b, R9a, R9b, R10, R10a, R10b, Rlla, Rllb, R12a, or R12b, is methyl, the invention also encompasses -CD3, -CHD2and -CH2D. Similarly Ry, Rz, R3, R4a, R4b, R5, R6, R8a, R8b, R9a, R9b, Rlla, Rllb, R12a, or R12bmay be D.

[0080] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed ‘isomers’. Isomers that differ in the arrangement of their atoms in space are termed ‘stereoisomers’.

[0081] Stereoisomers that are not mirror images of one another are termed ‘diastereomers’ and those that are non-superimposable mirror images of each other are termed ‘enantiomers’. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn, Ingold and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e. as (+) or (-)-isomersrespectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a ‘racemic mixture’.

[0082] ‘ Tautomers’ refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of 71 electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane that are likewise formed by treatment with acid or base.

[0083] Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.

[0084] The compounds of the invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)- stereoisomers or as mixtures thereof.

[0085] An optical isomer with unknown absolute configuration may be depicted with an asterix (*) at the | A |# 1 * I*chiral center, e.g.,and / or and / or ' ''' and / or ' . Likewise, when a chemical structure possessing one or more asymmetric centers is described using its chemical name, stereocenters with unknown absolute configuration may be depicted with an asterix (*), e.g. R* and / or S*. Alternatively, if stereochemistry has been depicted but the phrase “stereochemistry arbitrary assigned”, or something to that effect, is present then this indicates an optical isomer with unknown absolute configuration.

[0086] Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.

[0087] It will be appreciated that compounds of the invention may be metabolized to yield biologically active metabolites.THE INVENTION

[0088] The present invention is based on the identification of novel compounds, and their use in the prophylaxis and / or treatment of proliferative diseases. In particular, the compounds of the invention may be SMARCA2 and / or SMARCA4 inhibitors, and more particularly SMARCA2 inhibitors.

[0089] The present invention also provides methods for the production of these compounds, pharmaceutical compositions comprising these compounds and methods for the prophylaxis and / or treatment of proliferative diseases by administering the compounds of the invention.

[0090] Accordingly, in a first aspect of the invention, the compounds of the invention are provided having a Formula I:wherein,A is 6-10 membered monocyclic or bicyclic aryl, or 5-10 membered monocyclic or bicyclic heteroaryl comprising one, two or three heteroatoms independently selected from N, O, and S;Rk N .O. .0 N ORZV' XV' \ / KY is independently selected from' * , ' ' and ' * ;Ryand Rzare each independently hydrogen or C 1-3 alkyl;X is N or CH;R1is Ci -e alkyl, C1-3 alkoxy(Ci-3)alkyl, 3-6 membered monocyclic cycloalkyl, 4-6 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, -NH2, -NH(CI.3 alkyl), -N(CI_3alkyl)2, -NHC(=O)(CI_3alkyl), -N(CI_3alkyl)C(=O)(Ci_3alkyl), or hydroxy(Ci.4)alkyl, wherein said cycloalkyl, heterocycloalkyl, alkyl and alkoxy groups are optionally substituted with one or more halogen, C1-6 alkoxy, -NH2, -NH(CI-3 alkyl), -N(CI-3 alkyl)2;n is 0, 1, or 2;each R2is independently selected from halogen and Ci-e alkyl, which alkyl is optionally substituted with halo or C1-4 alkoxy;or R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic cycloalkyl, or a fused 5-8 membered monocyclic heterocycloalkyl comprising Y in formula I and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro) or C1-4 alkyl;R3is hydrogen or C1-6 alkyl;R4aand R4bare each independently hydrogen or C1-6 alkyl optionally substituted with one or more independently selected halo or C1-4 alkoxy;or R4aand R4b, together with the carbon to which they are attached, form a C3-6 cycloalkyl or 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, which cycloalkyl or heterocycloalkyl is optionally substituted with one or more halo or C1-4 alkoxy;Li is a bond or C1-4 alkyl;B is phenyl or 5-6 membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S,Cy is a 5 -membered monocyclic heteroaryl comprising one, two, or three heteroatoms independently selected from N, O, and S, which heteroaryl is optionally substituted with one or more independently selected -L2-R5groups;L2 is a bond or Ci-e alkyl;Each R5is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- -OS(O)2O(Ci.4 alkyl),- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CONR9aR9b,- -CO2R9a,- C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- C1-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9a, C1-4 alkoxy, or C3-6 cycloalkyl,- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, , -S(=O)2Ci-4alkyl, -C(=O)Ci-4alkyl, or -CO2R9a, and - 4-8 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, -S(=O)2Ci-4 alkyl, -C(=O)Ci-4 alkyl, or -CO2R9a, and- phenyl optionally substituted with one or more independently selected halo, -OH, -CN, C1-4 alkyl, Ci-4alkoxy, , -S(=O)2Ci.4alkyl, -C(=O)C 1.4 alkyl, or -CO2R9a;R6is hydrogen, halo, or C1-6 alkyl;The subscript m is 0, 1 or 2;Each R7is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CH=CHCO2R9a,- -CONR9aR9b,- -CO2R9a,- Ci-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- Ci-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or C1-4 alkoxy,- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and- 4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, andeach R8ais independently hydrogen or C1-4 alkyl;each R8bis independently hydrogen, C1-4 alkyl or -C(O)Ci.2alkyl;each R9ais independently selected from hydrogen and C1-4 alkyl; andeach R9bis hydrogen, C1-4 alkyl or C1-4 alkoxy; orR9aand R9btogether with the atoms onto which they are attached form a 4-7 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, Ci -4 alkyl.

[0091] Certain compounds according to the invention may exhibit one or more benefits including, inter alia, advantageous levels of biological activity which may be useful in the prophylaxis and / or treatment of one or more disease, improved safety characteristics (e .g. relating to hERG inhibition, drug -drug interaction (DDI) or CYP -interaction characteristics, etc), improved selectivity for one or more disease -associated biological target (e.g. reduced off-target effects, etc), improved pharmacokinetic properties (e.g. relating to dosing, solubility, absorption, etc), improved pharmacodynamic properties (e.g. relating to permeability, efflux, etc) or superior properties for use as pharmaceutical active ingredients alone or in pharmaceutical compositions (e.g. stability), or advantageous physico-chemical properties useful in the manufacturability of such aforementioned pharmaceutical compositions.

[0092] In certain embodiments, the compound of the formula (I) is a compound of the formula (II):(II)wherein A, Y, B, Cy, R1, R2, R3, R4a, R4b, R6, R7, Li, m and n are as defined for formula (I).

[0093] In certain embodiments, the compound of the formula (I) is a compound of the formula (III):CyO R4a. R4b[f\'\R1X JI v C;AR3r r6[ ]MH(HI)wherein A, Y, B, Cy, R1, R2, R3, R4a, R4b, R6, R7, m and n are as defined for formula (I).

[0094] In certain embodiments, the compound of the formula (I) is a compound of the formula (IVa) or (IVb):Cy Cy(IVa) (IVb) wherein A, Y, Cy, R1, R2, R3, R4a, R4b, R6, R7, m and n are as defined for formula (I).

[0095] In certain embodiments, the compound of the formula (I) is a compound of the formula (V):Cy(V)wherein A, Y, Cy, R1, R2, R3, R4a, R4b, R6, R7, and n are as defined for formula (I).

[0096] In certain embodiments, the compound of the formula (I) is a compound of the formula (VI):Cy(VI)wherein A, Y, Cy, R1, R2, R3, R4a, R4b, R6, and n are as defined for formula (I).

[0097] In certain embodiments, the compound of the formula (I) is a compound of the formula (VII):(VII)wherein A, B, Cy, R1, R2, R3, R4a, R4b, R6, R7, Li, m and n are as defined for formula (I).

[0098] In certain embodiments, the compound of the formula (I) is a compound of the formula (VIII):(VIII)wherein A, B, Cy, R1, R2, R3, R4a, R4b, R6, Li, m and n are as defined for formula (I).

[0099] In certain embodiments, the compound of the formula (I) is a compound of the formula (VIII):(VIII)wherein A, B, Cy, R1, R2, R3, R4a, R4b, R6, Li, m and n are as defined for formula (I).

[0100] In certain embodiments, the compound of the formula (I) is a compound of the formula (IXa):whereinnl is 0 or 1;n2 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl; andwherein B, Cy, R2, R3, R4a, R4b, R6, Li, m and n are as defined for formula (I).

[0101] In certain embodiments, the compound of the formula (I) is a compound of the formula (IXb):whereinnl is 0 or 1;n2 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl; andwherein B, Cy, R2, R3, R4a, R4b, R6, Li, m and n are as defined for formula (I).

[0102] In certain embodiments, the compound of the formula (I) is a compound of the formula (X):(X)wherein A, B, R1, R2, R3, R4a, R4b, R5, R6, Rz, Cy, Li, and n are as defined for formula (I).

[0103] In certain embodiments, the compound of the formula (I) is a compound of the formula (XI):N(XI)whereinn3 is 0 or 1;n4 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl; andRz, R2, R3, R4a, R4b, R5, R6, R7, Cy, Li, and m are as defined for formula (I).

[0104] In certain embodiments, the compound of the formula (I) is a compound of the formula (XII):wherein R1, R2, R3, R4a, R4b, R6, R7, Cy, and n are as defined for formula (I).

[0105] In certain embodiments, the compound of the formula (I) is a compound of the formula (XIII):(XIII)wherein R1, R2, R3, R4a, R4b, R6, R7, Cy, and n are as defined for formula (I).

[0106] In certain embodiments, the compound of the formula (I) is a compound of the formula (XIV a):whereinnl is 0 or 1;n2 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and C1-4 alkyl; andR2, R3, R4a, R4b, R6, R7, and Cy are as defined for formula (I).

[0107] In certain embodiments, the compound of the formula (I) is a compound of the formula (XlVb):(XlVb)whereinnl is 0 or 1;n2 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and C1-4 alkyl; andR2, R3, R4a, R4b, R6, R7, and Cy are as defined for formula (I).

[0108] In certain embodiments, the compound of the formula (I) is a compound of the formula (XV):wherein R1, R2, R3, R4a, R4b, R6, R7, Rz, Cy, and n are as defined for formula (I).

[0109] In certain embodiments, the compound of the formula (I) is a compound of the formula (XVI):whereinn3 is 0 or 1;n4 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and C1-4 alkyl; andR2, R3, R4a, R4b, R6, R7, Rz, and Cy are as defined for formula (I).

[0110] The following embodiments apply to compounds of any of Formulae I-XVI. These embodiments are independent and interchangeable. Any one embodiment may be combined with any other embodiment, where chemically allowed. In other words, any of the features described in the following embodiments may (where chemically allowable) may be combined with the features described in one or more other embodiments. In particular, where a compound is exemplified or illustrated in this specification, any two or more of the embodiments listed below, expressed at any level of generality, which encompass that compound may be combined to provide a further embodiment which forms part of the present disclosure.[OlH] In some embodiments, the compound is according to any one of Formulae I-XVI, wherein R3is hydrogen.

[0112] In some embodiments, the compound is according to any one of Formulae I-XVI, wherein R4aand R4bare hydrogen.

[0113] In some embodiments, the compound is according to any one of Formulae I-XVI, wherein R3, R4aand R4bare hydrogen.

[0114] In some embodiments, the compound is according to any one of Formulae I-XVI, wherein R6is hydrogen.

[0115] In some embodiments, the compound is according to any one of Formulae I-XVI, wherein R3, R4a, R4b, and R6are hydrogen.

[0116] In some embodiments, A is 6-10 membered monocyclic or bicyclic aryl. In some embodiments, A is phenyl. In some embodiments, A is 9-10 membered bicylic aryl.is selected from:is selected from:

[0119] In some embodiments, A is 5-10 membered monocyclic or bicyclic heteroaryl comprising one, two or three heteroatoms independently selected from N, O, and S.

[0120] In some embodiments, A is 5-membered monocyclic heteroaryl. In some embodiments, A is 6-membered monocyclic heteroaryl. In some embodiments, A is 9 -membered bicyclic heteroaryl. In some embodiments, A is 10-membered bicyclic heteroaryl.

[0123] In some embodiments, Y is independently selected fromand

[0124] In some embodiments,Y is

[0125] In some embodiments, Y is. In some embodiments, Ryis hydrogen. In some embodiments, Ryis methyl. In some embodiments, Ryis ethyl.

[0126] In some embodiments, Y is. In some embodiments, Rzis hydrogen. In some embodiments, Rzis methyl. In some embodiments, Rzis ethyl.

[0127] In some embodiments, R1is Ci-6 alkyl, C1-3 alkoxy(Ci-3)alkyl, 3-6 membered monocyclic cycloalkyl, 4-6 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, -NH2, -NH(CI-3 alkyl), -N(CI-3 alkyl)2, -NHC(=O)(CI-3 alkyl), -N(CI-3 alkyl)C(=O)(Ci-3 alkyl), or hydroxy(Ci-4)alkyl, wherein said cycloalkyl, heterocycloalkyl, alkyl and alkoxy groups are optionally substituted with one or more halogen, C1-6 alkoxy, -NH2, -NH(CI-3 alkyl), -N(CI-3 alkyl)2.

[0128] In some embodiments, R1is C1-3 alkyl, C1-3 alkoxy(Ci-3)alkyl, -N(CI-3 alkyl )2or hydroxy(Ci-3)alkyl, wherein said alkyl and alkoxy groups are optionally substituted with one or more halogen.

[0129] In some embodiments, R1is C1-3 alkyl, C1-3 alkoxy(Ci-3)alkyl, or hydroxy(Ci-3)alkyl, wherein said alkyl and alkoxy groups are optionally substituted with one or more halogen.

[0130] In some embodiments, R1is C1-3 alkyl or C1-3 alkoxy(Ci-3)alkyl, wherein said alkyl and alkoxy groups are optionally substituted with one or more halogen.

[0131] In some embodiments, R1is C1-3 alkyl, wherein said alkyl group is optionally substituted with one or more halogen. In some embodiments, R1is C1-3 alkyl, wherein said alkyl group is optionally substituted with one or more fluoro.

[0132] In some embodiments, R1is methyl.

[0133] In some embodiments, R1is C1-3 alkoxy(Ci-3)alkyl, wherein said alkyl and alkoxy groups are optionally substituted with one or more halogen. In some embodiments, R1is C1-3 alkoxy(Ci-3)alkyl, wherein said alkyl and alkoxy groups are optionally substituted with one or more fluoro.

[0134] In some embodiments, R1is -NH2.

[0135] In some embodiments, R1is -NH(CI-3 alkyl).

[0136] In some embodiments, R1is -N(CI-3 alkyl)2.

[0137] In some embodiments, R1is hydroxy(Ci-3)alkyl.

[0138] In some embodiments, R1is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl.

[0139] In some embodiments, R1is -N(CH3)C(=O)(CI-3 alkyl).

[0144] In some embodiments,

[0145] In some embodiments,

[0146] In some embodiments,

[0147] In some embodiments,

[0148] In some embodiments,

[0149] In some embodiments,

[0150]

[0151] In some embodiments,

[0152] In some embodiments,

[0153] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

[0154] In some embodiments, R2is independently selected from halogen and C1-3 alkyl, which alkyl is optionally substituted with halo or C1-4 alkoxy.

[0155] In some embodiments, R2is halogen. In some embodiments, R2is fluoro. In some embodiments, R2is chloro.

[0156] In some embodiments, R2is C1-3 alkyl, which alkyl is optionally substituted with halo or C1.4 alkoxy.

[0157] In some embodiments, R2is C1-3 alkyl, which alkyl is optionally substituted with halo. In some embodiments, R2is C1-3 alkyl, which alkyl is optionally substituted with fluoro.

[0158] In some embodiments, R2is methyl, which methyl is optionally substituted with halo. In some embodiments, R2is methyl, which alkyl is optionally substituted with fluoro.

[0159] In some embodiments, R2is methyl.

[0160] In some embodiments, R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic cycloalkyl, or a fused 5-8 membered monocyclic heterocycloalkyl comprising Y in formula I and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro) or Ci-4 alkyl.N \Rz

[0161] In some embodiments, Y is' * and R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic cycloalkyl, or a fused 5-8 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro-) or Ci-4 alkyl.N \Rz

[0162] In some embodiments, Y is' * and R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, wherein the heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro-) or Ci-4 alkyl.

[0163] In some embodiments,is 0 or 1, n4 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.

[0164] In some embodiments,wherein n3 is 0 or 1, n4 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.

[0167] In some embodiments,wherein n3 is 0 or 1, n4 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.

[0168] In some embodiments,wherein n3 is 0 or 1, n4 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.RyN .o'

[0169] In some embodiments, Y is 'S* and R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic heterocycloalkyl comprising the S atom of Y and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro-) or Ci-4 alkyl.

[0170] In some embodiments, Y isand R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic heterocycloalkyl comprising the S atom ofY and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro-) or Ci-4 alkyl.R1

[0171] In some embodiments,; wherein nl is 0 or 1, n2 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.R1

[0172] In some embodiments,n1; wherein nl is 0 or 1, n2 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.R1

[0173] In some embodiments,; wherein nl is 0 or 1, n2 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.OR1

[0174] In some embodiments,; wherein nl is 0 or 1, n2 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.R1

[0175] In some embodiments,1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and C1.4 alkyl.R1

[0176] In some embodiments,; wherein nl is 0 or 1, n5 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and C1-4 alkyl.

[0177] In some embodiments,; wherein nl is 0 or 1, n6 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and C1-4 alkyl.R1

[0178] In some embodiments,; wherein nl is 0 or 1, n6 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and C1.4 alkyl.N

[0179] In some embodiments,n1; wherein nl is 0 or 1, n7 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.o„,,?R1

[0180] In some embodiments,; wherein nl is 0 or 1, n7 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.

[0181] In some embodiments,; wherein nl is 0 or 1, n8 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.oj?R1

[0182] In some embodiments,is n1 ; wherein nl is 0, or 1, n8 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.

[0183] In some embodiments nl is 0. In some embodiments nl is 1

[0184] In some embodiments n2 is 0. In some embodiments n2 is 1

[0185] In some embodiments n3 is 0. In some embodiments n3 is 1

[0186] In some embodiments n4 is 0. In some embodiments n4 is 1

[0187] In some embodiments n5 is 0. In some embodiments n5 is 1

[0188] In some embodiments n6 is 0. In some embodiments n6 is 1

[0189] In some embodiments n7 is 0. In some embodiments n7 is 1

[0190] In some embodiments n8 is 0. In some embodiments n8 is 1

[0191] In some embodiments, R2ais fluoro.

[0192] In some embodiments, R2ais methyl. In such embodiments, R2amay be a substituent on nitrogenwithin the ring, e.g., where , the -N(H)- may be -N(R2a)-.R1

[0193] In some embodiments,is selected from:

[0197] In some embodiments, R3is hydrogen.

[0198] In some embodiments, R3is Ci-6 alkyl. In some embodiments, R3is methyl. In some embodiments, R3is ethyl.

[0199] In some embodiments, R4ais hydrogen.

[0200] In some embodiments, R4ais C1-6 alkyl. In another embodiment, R4ais -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CH2CH2CH3, -CH2CH(CH3)2, -CH(CH3)CH2CH3, -CH2C(CH3)3, -CH(CH3)CH(CH3)2, -C(CH3)2CH2CH3, -CH(CH3)C(CH3)3, or -C(CH3)2C(CH3)2.

[0201] In some embodiments, R4ais -CH3, -CH2CH3, -CH(CH3)2, -CH2CH2CH3, -CH2CH(CH3)2, or -CH(CH3)CH2CH3. In a most particular embodiment, R4ais -CH3.

[0202] In some embodiments, R4bis hydrogen.

[0203] In some embodiments, R4bis C1-6 alkyl. In another embodiment, R4bis -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CH2CH2CH3, -CH2CH(CH3)2, -CH(CH3)CH2CH3, -CH2C(CH3)3, -CH(CH3)CH(CH3)2, -C(CH3)2CH2CH3, -CH(CH3)C(CH3)3, or -C(CH3)2C(CH3)2.

[0204] In some embodiments, R4bis -CH3, -CH2CH3, -CH(CH3)2, -CH2CH2CH3, -CH2CH(CH3)2, or -CH(CH3)CH2CH3. In a most particular embodiment, R4bis -CH3.

[0205] In some embodiments, R4aand R4bare each hydrogen.

[0206] In some embodiments, R4aand R4btogether with the carbon to which they are attached, form a C3-e cycloalkyl or 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, which cycloalkyl or heterocycloalkyl is optionally substituted with one or more halo or C1.4 alkoxy.

[0207] In some embodiments, R4aand R4btogether with the carbon to which they are attached, form the structure:LHpCCJ' * ; wherein C is a C3-6 cycloalkyl or 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S; p is 0, 1, or 2; and R4cis independently selected from halo or C1.4 alkoxy .

[0208] In some embodiments, C is C3-6 cycloalkyl. In some embodiments, C is cyclopropyl. In some embodiments, C is cyclobutyl. In some embodiments, C is cyclopentyl.

[0209] In some embodiments, C is 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S. In some embodiments, C is 4-membered heterocycloalkyl comprising one heteroatom independently selected from N, O, and S. In some embodiments, C is 5-membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S .

[0210] In some embodiments, C is selected from:

[0211] In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 0.

[0212] In some embodiments, R4cis halo. In some embodiments, R4cis fluoro.

[0213] In some embodiments, R4cis C1-4 alkoxy. In some embodiments, R4cis -O-methyl. In some embodiments, R4cis -O-ethyl.

[0214] In some embodiments, C is selected from:

[0216] In some embodiments, X is N. In some embodiments, X is CH.

[0217] In some embodiments, R6is hydrogen.

[0218] In some embodiments, R6is halo. In some embodiments, R6is fluoro.

[0219] In some embodiments, R6is Ci-6 alkyl. In some embodiments, R6is C1-3 alkyl. In some embodiments, R6is methyl.

[0220] In some embodiments, Li is a bond.

[0221] In some embodiments, Bis1 m,Wherein m is 0, 1, 2, 3, or 4.

[0222] In some embodiments,B is ' * .

[0223] In some embodiments, B is 5-6 membered monocyclic or bicyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S. In some embodiments, Li is a bond and B is 5-10 membered monocyclic or bicyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S.

[0224] In some embodiments, B is imidazolyl, pyrazolyl, oxazolyl, pyridyl, pyridinyl, or pyrazinyl. In a particular embodiment, B is pyridinyl.

[0225] In some embodiments, B is selected from:

[0227] In some embodiments, m is 2.

[0228] In some embodiments, m is 3.

[0229] In some embodiments, m is 4.

[0230] In some embodiments, m is 1.

[0231] In some embodiments,B is

[0232] In some embodiments, R7is selected from:oxo,- -OH,- -CN,- -P(O)(Ci.4alkyl)2,halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CH=CHCO2R9a,- -CONR9aR9b,- -CO2R9a,Ci-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci .4 alkoxy,Ci-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or Cn 4 alkoxy,C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, Cn4alkyl, or C1-4 alkoxy,

[0233] In some embodiments, R7is selected from:- -OH,- -CN,halo,Ci-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,Ci-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or Ci- 4 alkoxy,C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy.

[0234] In some embodiments, R7is selected from:- -CN,halo,C1.4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or Ci- 4 alkoxy, and4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy.

[0235] In some embodiments, R7is -CN.

[0236] In some embodiments, R7is halo. In some embodiments, R7is fluoro. In some embodiments, R7is chloro.

[0237] In some embodiments, R7is C1-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or C1.4 alkoxy.

[0238] In some embodiments, R7is C1-4 alkoxy optionally substituted with one or more independently selected -OH or C 1.4 alkoxy.

[0239] In some embodiments, R7is C1-4 alkoxy optionally substituted with one or more independently selected -OH or C 1.2 alkoxy.

[0240] In some embodiments, R7is C1-2 alkoxy optionally substituted with one or more independently selected -OH or C 1.2 alkoxy.

[0241] In some embodiments, R7is -OCH3. In some embodiments, R7is -OCH2CH3. In some embodiments, R7is -OCH2CH2OH. In some embodiments, R7is -OCH2CH2OCH3.

[0242] In some embodiments, R7is 4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, or C1.4 alkoxy.

[0243] In some embodiments, R7is 4-membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy.

[0244] In some embodiments, R7is 5 -membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, or C1.4 alkoxy.

[0245] In some embodiments, R7is 6-membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, or C1.4 alkoxy.

[0246] In some embodiments, R7is 4-membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected halo, -OH, -CN, or C 1.2 alkyl.

[0247] In some embodiments, R7is 5 -membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected halo, -OH, -CN, or C 1.2 alkyl.

[0248] In some embodiments, R7is 6-membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected halo, -OH, -CN, or C 1.2 alkyl.

[0249] In some embodiments, R7is selected from:optionally substituted with one or more independently selected halo, -OH, -CN, or C1-2 alkyl.

[0251] In some embodiments,[R7]m is Cy

[0252] In some embodiments, Cy is a 5-membered monocyclic heteroaryl comprising one, two, or three heteroatoms independently selected from N, O, and S, which heteroaryl is optionally substituted with one or more independently selected R5groups. In a particular embodiment, Cy is imidazolyl or pyrazolyl, each of which is optionally substituted with one or more independently selected R5groups.

[0253] In some embodiment, Cy isR5b✓ N— R5aN, wherein each R5aand R5bis as defined for R5in formula (I).

[0254] In some embodiments, each R5, R5aand R5bis independently selected from- Ci-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and- 4-8 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, -S(=O)2Ci-4 alkyl, -C(=O)Ci-4 alkyl, or -CO2R9a,- phenyl optionally substituted with one or more independently selected halo, -OH, -CN, C1-4 alkyl, Ci-4alkoxy, , -S(=O)2Ci.4alkyl, -C(=O)Ci.4alkyl, or -CO2R9a, and- 5-6 membered heteroaryl comprising one, two or three heteroatoms independently selected from N, O, and S, which heteroaryl is optionally substituted with one or more independently selected halo, -OH, -CN, Ci.4alkyl, C1.4 alkoxy, , -S(=O)2Ci.4alkyl, -C(=O)Ci.4alkyl, or -CO2R9a;

[0255] In some embodiments, one or more independently selected R5, R5aand R5bis selected from C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor C1-4 alkoxy.

[0256] In some embodiments, one or more independently selected R5, R5aand R5bis selected from C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, or -CN.

[0257] In some embodiments, one or more independently selected R5, R5aand R5bis selected from C1-4 alkyl optionally substituted with one or more -OH.

[0258] In some embodiments, one or more independently selected R5, R5aand R5bis selected from 4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, or -CO2R9a.

[0259] In some embodiments, one or more independently selected R5, R5aand R5bis selected from 4-6 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, or -CO2R9a.In some embodiments, one or more independently selected R5, R5aand R5bis phenyl optionally substituted with one or more independently selected halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, , -S(=O)2Ci-4 alkyl, -C(=O)Ci-4 alkyl, or -CO2R9a. In a particular embodiment, one or more independently selected R5, R5aand R5bis phenyl.

[0260] In some embodiments, R8ais hydrogen. In some embodiments, R8ais C1-4 alkyl. In some embodiments, R8ais methyl. In some embodiments, R8ais ethyl.

[0261] In some embodiments, R8bis hydrogen. In some embodiments, R8bis -C(O)Ci-2 alkyl. In some embodiments, R8bis C1.4 alkyl. In some embodiments, R8bis methyl. In some embodiments, R8bis ethyl.

[0262] In some embodiments, R9ais hydrogen. In some embodiments, R9ais C1-4 alkyl. In some embodiments, R9ais methyl. In some embodiments, R9ais ethyl.

[0263] In some embodiments, R9bis hydrogen. In some embodiments, R9bis C1-4 alkyl. In some embodiments, R9bis methyl. In some embodiments, R9bis ethyl. In some embodiments, R9bis C1-4 alkoxy. In some embodiments, R9bis C1-2 alkoxy. In some embodiments, R9bis -OCH3. In some embodiments, R9bis -OCH2CH3.

[0264] In some embodiments, Cy2 is selected from:

[0265] In one embodiment, a compound of the invention is provided in a natural isotopic form.

[0266] In one embodiment, a compound of the invention is provided in an unnatural variant isotopic form. In a specific embodiment, the unnatural variant isotopic form is a form in which deuterium (z. e.2H or D) is incorporated where hydrogen is specified in the chemical structure in one or more atoms of a compound of the invention. In one embodiment, the atoms of the compounds of the invention are in an isotopic form which is not radioactive. In one embodiment, one or more atoms of the compounds of the invention are in an isotopic form which is radioactive. Suitably radioactive isotopes are stable isotopes. Suitably, the unnatural variant isotopic form is a pharmaceutically acceptable form.

[0267] In one embodiment, a compound of the invention is provided whereby a single atom of the compound exists in an unnatural variant isotopic form. In another embodiment, a compound of the invention is provided whereby two or more atoms exist in an unnatural variant isotopic form.

[0268] Unnatural isotopic variant forms can generally be prepared by conventional techniques known to those skilled in the art or by processes described herein e.g. processes analogous to those described in the accompanying Examples for preparing natural isotopic forms. Thus, unnatural isotopic variant forms could be prepared by using appropriate isotopically variant (or labelled) reagents in place of the normal reagents employed in the illustrative example as examples.

[0269] In one aspect a compound of the invention according to any one of the embodiments herein described is present as the free base.

[0270] In one aspect a compound of the invention according to any one of the embodiments herein described is a pharmaceutically acceptable salt of the compound.

[0271] In one aspect a compound of the invention according to any one of the embodiments herein described is a solvate of the compound.

[0272] In one aspect a compound of the invention according to any one of the embodiments herein described is a solvate of a pharmaceutically acceptable salt of the compound.

[0273] While specified groups for each embodiment have generally been listed above separately, a compound of the invention includes one in which several or each embodiment in the above Formula, as well as other formulae presented herein, is selected from one or more of particular members or groupsdesignated respectively, for each variable. Therefore, this invention is intended to include all combinations of such embodiments within its scope.

[0274] While specified groups for each embodiment have generally been listed above separately, a compound of the invention may be one for which one or more variables (for example, R groups) is selected from one or more embodiments according to any of the Formula(e) listed above. Therefore, the present invention is intended to include all combinations of variables from any of the disclosed embodiments within its scope.

[0275] Alternatively, the exclusion of one or more of the specified variables from a group or an embodiment, or combinations thereof is also contemplated by the present invention.

[0276] In certain aspects, the present invention provides prodrugs and derivatives of the compounds according to the formulae above. Prodrugs are derivatives of the compounds of the invention, which have metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention, which are pharmaceutically active, in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, A-alkylmorpholine esters and the like.

[0277] Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (Bundgaard 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxy carbonyl)oxy)alkylesters. Particularly useful are the Ci to Cs alkyl, C2-C8 alkenyl, aryl, C7-C12 substituted aryl, and C7-C12 arylalkyl esters of the compounds of the invention.PHARMACEUTICAL COMPOSITIONS

[0278] When employed as a pharmaceutical, a compound of the invention is typically administered in the form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound of the invention according to Formula I. Generally, a compound of the invention is administered in a pharmaceutically effective amount. The amount of compound of the invention actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound of the invention administered, the age, weight, and response of the individual patient, the severity of the patient’s symptoms, and the like.

[0279] In one embodiment, the present invention provides pharmaceutical compositions comprising a compound of the invention and another therapeutic agent.

[0280] In one embodiment, the present invention provides pharmaceutical compositions comprising a compound of the invention and another therapeutic agent, which other therapeutic agent is a proliferative diseases treatment agent. In particular, the term proliferative diseases refers to cancer, myeloproliferative disorders, leukemia, multiple myeloma, psoriasis, restenosis, scleroderma or fibrosis. More particularly, the term refers to cancer, leukemia, and multiple myeloma.

[0281] In a particular embodiment, the present invention provides pharmaceutical compositions comprising a compound of the invention and another therapeutic agent, which other therapeutic agent is a cancer treatment agent. In particular, the term refers to both metastatic tumour cell types (such as but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, and uterine leiomyosarcoma). More particularly, the term refers to acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, Ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi’s sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer,vulvar cancer, and Wilms tumor. Most particularly, the term refers to non-small cell lung cancer, Burkitt lymphoma, medulloblastoma, pancreatic cancer, ovarian cancer, and melanoma

[0282] In a further particular embodiment, the present invention provides pharmaceutical compositions comprising a compound of the invention and another therapeutic agent, which other therapeutic agent is a leukemia treatment agent. In particular, the term refers to neoplastic diseases of the blood and blood forming organs. More particularly, the term refers to acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).

[0283] The pharmaceutical compositions of this invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intra-articular, intravenous, intramuscular, and intranasal. Depending on the intended route of delivery, a compound of the invention is preferably formulated as either injectable or oral compositions or as salves, as lotions or as patches all for transdermal administration.

[0284] The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term ‘unit dosage forms’ refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient, vehicle or carrier. Typical unit dosage forms include prefdled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the compound of the invention according to Formula I is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.

[0285] Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. Solid forms may include, for example, any of the following ingredients, or compound of the inventions of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or com starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint or orange flavoring.

[0286] Injectable compositions are typically based upon injectable sterile saline or phosphate -buffered saline or other injectable carriers known in the art. As before, the active compound of the invention according to Formula I in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like.

[0287] Transdermal compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight. When formulated as an ointment, the active ingredients will typically be combined with either a paraffinic or a water-miscible ointment base. Alternatively, theactive ingredients may be formulated in a cream with, for example an oil-in-water cream base. Such transdermal formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration or stability of the active ingredients or the formulation. All such known transdermal formulations and ingredients are included within the scope of this invention.

[0288] A compound of the invention can also be administered by a transdermal device. Accordingly, transdermal administration can be accomplished using a patch either of the reservoir or porous membrane type, or of a solid matrix variety.

[0289] The above-described components for orally administrable, injectable or topically administrable compositions are merely representative. Other materials as well as processing techniques and the like are set forth in Part 8 of Remington’s Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.

[0290] A compound of the invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can be found in Remington’s Pharmaceutical Sciences (Remington & Gennaro 1985).

[0291] The following formulation examples illustrate representative pharmaceutical compositions that may be prepared in accordance with this invention. The present invention, however, is not limited to the following pharmaceutical compositions.Formulation 1 - Tablets

[0292] A compound of the invention according to Formula I may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate may be added as a lubricant. The mixture may be formed into 240-270 mg tablets (80-90 mg of active compound of the invention according to Formula I per tablet) in a tablet press.Formulation 2 - Capsules

[0293] A compound of the invention according to Formula I may be admixed as a dry powder with a starch diluent in an approximate 1:1 weight ratio. The mixture may be fdled into 250 mg capsules (125 mg of active compound of the invention according to Formula I per capsule).Formulation 3 - Liquid

[0294] A compound of the invention according to Formula I (125 mg), maybe admixed with sucrose (1.75 g) and xanthan gum (4 mg) and the resultant mixture may be blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg) in water. Sodium benzoate (10 mg), flavor, and color may be diluted with water and added with stirring. Sufficient water may then be added with stirring. Further sufficient water may be then added to produce a total volume of 5 mL.Formulation 4 - Tablets

[0295] A compound of the invention according to Formula I may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate may be added as a lubricant. The mixture may be formed into 450-900 mg tablets (150-300 mg of active compound of the invention according to Formula I) in a tablet press.Formulation 5 - Injection

[0296] A compound of the invention according to Formula I may be dissolved or suspended in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg / mL.Formulation 6 - Topical

[0297] Stearyl alcohol (250 g) and a white petrolatum (250 g) may be melted at about 75 °C and then a mixture of a compound of the invention according to Formula I (50 g) methylparaben (0.25 g), propylparaben (0.15 g), sodium lauryl sulfate (10 g), and propylene glycol (120 g) dissolved in water (about 370 g) may be added and the resulting mixture may be stirred until it congeals.METHODS OF TREATMENT

[0298] In one embodiment, the present invention provides compounds of the invention, or pharmaceutical compositions comprising a compound of the invention, for use in medicine.

[0299] In one embodiment, the present invention provides compounds of the invention or pharmaceutical compositions comprising a compound of the invention, for use in the prophylaxis and / or treatment of proliferative diseases. In particular, the term proliferative diseases refers to cancer, myeloproliferative disorders, leukemia, multiple myeloma, psoriasis, restenosis, scleroderma or fibrosis. More particularly, the term refers to cancer, leukemia, and multiple myeloma.

[0300] In another embodiment, the present invention provides the use of compounds of the invention or pharmaceutical compositions comprising a compound of the invention in the manufacture of a medicament for the prophylaxis and / or treatment of proliferative diseases. In particular, the term proliferative diseases refers to cancer, myeloproliferative disorders, leukemia, multiple myeloma, psoriasis, restenosis, scleroderma or fibrosis. More particularly, the term refers to cancer, leukemia, and multiple myeloma.

[0301] In additional methods of treatment aspects, this invention provides methods of prophylaxis and / or treatment of a mammal afflicted with proliferative diseases, which methods comprise the administration of an effective amount of a compound of the invention or one or more of the pharmaceutical compositions herein described for the treatment or prophylaxis of said condition. In particular, the term proliferative diseases refers to cancer, myeloproliferative disorders, leukemia, multiple myeloma, psoriasis, restenosis, scleroderma or fibrosis. More particularly, the term refers to cancer, leukemia, and multiple myeloma.

[0302] In a particular embodiment, the present invention provides compounds of the invention or pharmaceutical compositions comprising a compound of the invention, for use in the prophylaxis and / ortreatment of cancer. In particular, the term refers to both metastatic tumour cell types (such as but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, and uterine leiomyosarcoma). More particularly, the term refers to acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, Ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi’s sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms tumor. Most particularly, the term refers to non-small cell lung cancer, Burkitt lymphoma, medulloblastoma, pancreatic cancer, ovarian cancer, and melanoma.

[0303] In another embodiment, the present invention provides the use of compounds of the invention or pharmaceutical compositions comprising a compound of the invention in the manufacture of a medicament for the prophylaxis and / or treatment of cancer. In particular, the term refers to both metastatic tumour cell types (such as but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer,small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, and uterine leiomyosarcoma). More particularly, the term refers to acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, Ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi’s sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Hodgkin lymphoma, non -Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms tumor. Most particularly, the term refers to non-small cell lung cancer, Burkitt lymphoma, medulloblastoma, pancreatic cancer, ovarian cancer, and melanoma.

[0304] In additional method of treatment aspects, this invention provides methods of prophylaxis and / or treatment of a mammal afflicted with cancer, which methods comprise the administration of an effective amount of a compound of the invention or one or more of the pharmaceutical compositions herein described for the treatment or prophylaxis of said condition. In particular, the term refers to both metastatic tumour cell types (such as but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, and uterineleiomyosarcoma). More particularly, the term refers to acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, Ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi’s sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms tumor. Most particularly, the term refers to non-small cell lung cancer, Burkitt lymphoma, medulloblastoma, pancreatic cancer, ovarian cancer, and melanoma.

[0305] In a particular embodiment, the present invention provides compounds of the invention or pharmaceutical compositions comprising a compound of the invention, for use in the prophylaxis and / or treatment of leukemia. In particular, the term refers to neoplastic diseases of the blood and blood forming organs. More particularly, the term refers to acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).

[0306] In another embodiment, the present invention provides the use of compounds of the invention or pharmaceutical compositions comprising a compound of the invention in the manufacture of a medicament for the prophylaxis and / or treatment of leukemia. In particular, the term refers to neoplastic diseases of the blood and blood forming organs. More particularly, the term refers to acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).

[0307] In additional method of treatment aspects, this invention provides methods of prophylaxis and / or treatment of a mammal afflicted with leukemia, which methods comprise the administration of an effective amount of a compound of the invention or one or more of the pharmaceutical compositions herein described for the treatment or prophylaxis of said condition. In particular, the term refers to neoplastic diseases of the blood and blood forming organs. More particularly, the term refers to acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).

[0308] Injection dose levels range from about 0.1 mg / kg / h to at least 10 mg / kg / h, all for from about 1 to about 120 h and especially 24 to 96 h. A preloading bolus of from about 0.1 mg / kg to about 10 mg / kg or more may also be administered to achieve adequate steady state levels. The maximum total dose is not expected to exceed about 1 g / day for a 40 to 80 kg human patient.

[0309] For the prophylaxis and / or treatment of long-term conditions, such as degenerative conditions, the regimen for treatment usually stretches over many months or years so oral dosing is preferred for patient convenience and tolerance. With oral dosing, one to four (1-4) regular doses daily, especially one to three (1-3) regular doses daily, typically one to two (1-2) regular doses daily, and most typically one (1) regular dose daily are representative regimens. Alternatively for long lasting effect drugs, with oral dosing, once every other week, once weekly, and once a day are representative regimens. In particular, dosage regimen can be every 1-14 days, more particularly 1-10 days, even more particularly 1-7 days, and most particularly 1-3 days.

[0310] Using these dosing patterns, each dose provides from about 1 to about 1000 mg of a compound of the invention, with particular doses each providing from about 10 to about 500 mg and especially about 30 to about 250 mg.

[0311] Transdermal doses are generally selected to provide similar or lower blood levels than are achieved using injection doses.

[0312] When used to prevent the onset of a condition, a compound of the invention will be administered to a patient at risk for developing the condition, typically on the advice and under the supervision of a physician, at the dosage levels described above. Patients at risk for developing a particular condition generally include those that have a family history of the condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the condition.

[0313] A compound of the invention can be administered as the sole active agent or it can be administered in combination with other therapeutic agents, including other compound of the inventions that demonstrate the same or a similar therapeutic activity and that are determined to be safe and efficacious for such combined administration. In a specific embodiment, co-administration of two (or more) agents allows for significantly lower doses of each to be used, thereby reducing the side effects seen.

[0314] In one embodiment, a compound of the invention or a pharmaceutical composition comprising a compound of the invention is administered as a medicament. In a specific embodiment, said pharmaceutical composition additionally comprises a further active ingredient.

[0315] In one embodiment, a compound of the invention is co -administered with another therapeutic agent for the treatment and / or prophylaxis of proliferative disorders, particular agents include but are not limited to: methotrexate, leucovorin, adriamycin, prednisone, bleomycin, cyclophosphamide, 5 -fluorouracil, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, doxorubicin, tamoxifen, toremifene, megestrol acetate, anastrozole, goserelin, anti-HER2 monoclonal antibody (e.g. Herceptin®), capecitabine, raloxifene hydrochloride, EGFR inhibitors (e.g. Iressa®, Tarceva®, Erbitux®), VEGF inhibitors (e.g. Avastin®), proteasome inhibitors (e.g. Velcade®), Glivec® and hsp90 inhibitors (e.g. 17-AAG). Additionally, the compound of the invention according to Formula I may be administered in combination with other therapies including, but not limited to, radiotherapy or surgery. In a specific embodiment the proliferative disorder is selected from cancer, myeloproliferative disease or leukemia.

[0316] By co-administration is included any means of delivering two or more therapeutic agents to the patient as part of the same treatment regime, as will be apparent to the skilled person. Whilst the two or more agents may be administered simultaneously in a single formulation, i. e. as a single pharmaceutical composition, this is not essential. The agents may be administered in different formulations and at different times.CHEMICAL SYNTHETIC PROCEDURESGeneral

[0317] The compound of the invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e. reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

[0318] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art (Wuts & Greene 2006).

[0319] The following methods are presented with details as to the preparation of a compound of the invention as defined hereinabove and the comparative examples. A compound of the invention may be prepared from known or commercially available starting materials and reagents by one skilled in the art of organic synthesis.

[0320] All reagents are of commercial grade and are used as received without further purification, unless otherwise stated. Commercially available anhydrous solvents are used for reactions conducted under inert atmosphere. Reagent grade solvents are used in all other cases, unless otherwise specified. Column chromatography is performed on silica gel 60 (35-70 pm) or with Biotage® Sfar KP -Amino D, Biotage® Sfar HC D, or Interchim® PuriFlash® Si HC flash chromatography cartridges. Thin layer chromatographyis carried out using pre-coated silica gel F-254 plates (thickness 0.25 mm). Biotage® ISOLUTE® phase separators (e.g. , Cat# 120-1907-E) are used for aqueous phase separation. ’H NMR spectra are recorded on a Bruker Avance NEO 400 NMR spectrometer (400 MHz), a Bruker Avance 400 NMR spectrometer (400 MHz), a Bruker Avance III HD NMR spectrometer (400 MHz), or a Bruker Avance DRX 500 spectrometer (500 MHz). Chemical shifts (5) for ’H NMR spectra are reported in parts per million (ppm) relative to tetramethylsilane (50.00) or the appropriate residual solvent peak, e.g. CHCL (57.26), MeOH (53.31), or DMSO (5 2.50 ppm), as internal reference. Multiplicities are given as singlet (s), doublet (d), triplet (t), multiplet (m) and broad (br). LCMS : Electrospray MS spectra are obtained on a Waters Acquity H-Class UPLC system coupled to a UV PDA detector and to a Waters SQD or SQD2 mass spectrometer. Columns used: Waters Acquity UPLC BEH C18 1.7 pm, 2.1 mm ID x 30 / 50 mm L; Waters Acquity UPLC CSH C18 1.7 pm, 2.1 mm ID x 50 / 100 mm L; Waters Acquity UPLC CSH PhenylHexyl 1.7 pm, 2.1 mm ID x 100 mm L; Waters Acquity UPLC HSS PFP 1.8 pm, 2.1 mm ID x 100 mm L. The methods are using ACN / water or MeOH / water gradients with either 0.1% formic acid in both mobile phases, 0.05% NH4OH in both mobile phases, or 10 mM NH4HCO3 in water (adjusted to pH 10 with ammonia). Preparative HPLC is performed on a Waters AutoPurification system with UV and MS detection using Waters XBridge BEH C18 OBD 30 mm ID x 100 / 150 mm L columns and ACN / water gradients with either 0.1% formic acid in both mobile phases, 0.1% diethylamine in both mobile phases, 0.1% formic acid in water, or 10 mM NH4HCO3 in water (adjusted to pH 10 with ammonia), or on a Buchi® Pure C-850 Flash with UV and ESDL detection using Buchi® C18 AQ 100 A 250 x 20 mm column and using ACN / water gradients with either 0.1% formic acid in both mobile phases or 0.05% NH4OH in both mobile phases. Chiral SFC : Electrospray MS spectra are obtained on a Waters Acquity UPC2 system coupled to a UV PDA detector and to a Waters QDA mass spectrometer. Columns used: Daicel CHIRALPAK AD-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK AS-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK IC-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK IH-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALCEL OD-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALCEL OD-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK IG-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK IA-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK IBN-3 3 pm, 4.6 mm ID x 100 mm L ; Phenomenex Lux Cellulose-2 3 pm, 4.6 mm ID x 100 mm L ; Phenomenex Lux Cellulose-43 pm, 4.6 mm ID x 100 mm L ; Phenomenex Lux Amylose-23 pm, 4.6 mm ID x 100 mm L. The methods are using CCL / MeOH or CCL / EtOH or CCL / iPrOH gradients or isocratics with sometimes 0.3% iPrNH2 in alcohol. Preparative SFC is performed on a PIC SOLUTIION PREP200 or PREP 100 systems with UV detection using same stationary phases as the analytical scale (listing above) but with 2 different dimensions 5 pm, 20 mm ID ; 250 mm L or 5 pm, 30 mm ID ; 250 mm L and CCF / McOH or CCMEtOH or CO2 / iPrOH gradients or isocratics with sometimes 0.3% iPrNH2 in alcohol. Achiral SFC ; Electrospray MS spectra are obtained on a Waters Acquity UPC2 system coupled to a UV PDA detector and to a Waters QDA mass spectrometer. Columns used PrincetonSFC 2-Ethylpyridine 3 pm, 4.6 mm ID x 100 mm L ; PrincetonSFC Cyano 3 pm, 4.6 mm ID x 100 mm L ; PrincetonSFC Amino 3 pm, 4.6 mm ID x 100 mm L ; PrincetonSFC Diethylaminopropyl 3 pm, 4.6 mmID x 100 mm L ; PrincetonSFC Diol 3 irn, 4.6 mm ID x 100 mm L . The methods are using CO2 / MeOH gradients or isocratics with sometimes 0.3% iPrNH2 in alcohol. Preparative SFC is performed on a PIC SOLUTIION PREP200 or PREP 100 systems with UV detection using same stationary phases as the analytical scale (listing above) but with a different dimensions 5pm, 20 mm ID ; 250 mm L and CCf / McOH gradients or isocratics with sometimes 0.3% iPrNFE in alcohol.Table I. List of abbreviations used in the experimental section:Abbreviation Definition Abbreviation Definition ACN acetonitrile CV column volume AcOH acetic acid Cy cyclohexyl AcOK potassium acetate d doublet aq. aq. 1,4- diazabicyclo [2.2.2] octan atm atmosphere DABCOe 4,4,5,5-tetraethyl-2- (CAS# 280-57-9) (4,4,5,5-tetraethyl-l,3,2- 1 ,2-dichloroethane B2EPin2dioxaborolan-2-yl)-l,3,2- DCE(CAS# 107-06-2) dioxaborolane(CAS# 2247367-07-1) DCM dichloromethane (±)-2,2'- dd doublet of doublets bis(diphenylphosphino)- diisobutylaluminum BINAP1 , 1 '-binaphthalene DIBAL hydride (CAS# 98327-87-8) (CAS# 1191-15-7) bis(pinacolato)diboron N,N- B2Pin2(CAS# 73183-34-3) DIPEA diisopropylethylamine Boc tert-butyloxy-carbonyl (CAS# 7087-68-5) di-tert-butyloxy- 4- BOC2O carbonate DMAP (dimethylamino)pyridine (CAS# 24424-99-5) (CAS# 1122-58-3) cyanomethylene)tributyl DMF N, A'-di m ethyl form am ide CMBP phosphorane DMSO dimethylsulfoxide(CAS# 157141-27-0)Cpd compoundAbbreviation Definition Abbreviation Definition 1,1'- 3 -chloroperoxybenzoic bis(diphenylphosphino) m-CPBA acid dppfferrocene (CAS# 937-14-4) (CAS# 12150-46-8) iodomethane Melncc dextran sodium sulfate (CAS# 74-88-4) dt doublet of triplets MeOH methanol A-ethyl-A'-(3- 2-MeTHF 2-methyltetrahydrofuran dimethylaminopropyl)car min minute EDCI HC1bodiimide hydrochloridemmol millimole (CAS# 25952-53-8)MS mass spectrometry eq- equivalentmethanesulfonyl chloride EtOAc ethyl acetate MsCl(CAS# 124-63-0) Et2O diethyl ether Mtd method EtOH ethanol MW molecular weight h hour molecular weight MW (calcd)1- calculated [bis(dimethylamino)meth molecular weight MW (obsd)ylene]-lH-l,2,3- observed HATE triazolo [4,5 -b]pyridinium NA not available 3-oxidsodium ethoxide hexafluorophosphate NaOEt(CAS# 141-52-6) (CAS# 148893-10-1)sodium1 -HydroxybenzotriazoleHOBt NaBH(OAc)3triacetoxyborohydride (CAS# 2592-95-2)(CAS# 56553-60-7) high-performance liquidHPLC butyl lithium chromatography w-BuLi(CAS# 109-72-8) Int intermediate 1 -methyl -2 -pyrrolidone NMPliquid chromatography(CAS# 872-50-4) LCMSmass spectrometry (methanesulfonato- lithium KO)[2'-(methylamino- LiHMDS bis(trimethylsilyl)amide KN) [1,1 '-biphenyl] -2-yl- Pd(Cy)3Pd G4(CAS# 4039-32-1) KC] (tricyclohexylphosph m multiplet ine)-palladium(CAS# 2195390-53-3)Abbreviation Definition Abbreviation Definition tris(dibenzylideneaceton td triplet of doublets Pd2(dba)3e)dipalladium(O)TEA triethylamine (CAS# 51364-51-3)TFA trifluoroacetic acid [1,1'- bis(diphenylphosphino) THF tetrahydrofuran Pd(dppf)Cl2ferrocene] dichloropalladi [(4,5- um(II) (CAS# 72287-26- bis(diphenylphosphino)- 4) 9,9-dimethylxanthene)-2- [1,1'- XantPhos Pd G3 (2'-amino-l,l'- bis(diphenylphosphino) biphenyl)]palladium(II) ferrocene] dichloropalladi methanesulfonate Pd(dppf)Cl2DCMum(II) complex with (CAS# 1445085-97-1) dichloro methane (SP-4-3)-[[5- (CAS# 95464-05-4) (diphenylphosphino)-9,9- palladium(II) acetate dimethyl-9H-xanthen-4- Pd(OAc)2(CAS# 3375-31-3) yl]diphenylphosphine- XantPhos Pd G4 KP] (methanesulfonato- PPm parts-per-millionK<9)|2'-(mcthylamino- p-TsOH H2O p-toluenesulfonic acidKN) [1,1 '-biphenyl] -2-yl- (CAS# 6192-52-5) monohydrateKC]- Palladium q quartet(CAS# 1621274-19-8) RT room temperature(2- s singlet dicyclohexylphosphino- sat. saturated 2',4',6'-triisopropyl-l,l'- biphenyl)[2-(2'-amino- SM starting material XPhos Pd G31,1'- t tripletbiphenyl)]palladium(II) anhydride 1- methanesulfonate T3P® propanephosphonique (CAS# 1445085-55-1)(CAS# 68957-94-8)SYNTHETIC PREPARATION OF THE COMPOUNDS OF THE INVENTIONExample 1. General synthetic methods1.1. Synthetic methods overviewGeneral method Al: Amide coupling with HATUGeneral method A2: Amide coupling with T3PGeneral method A3: Amide coupling with EDCI / HOBtGeneral method Bl: Suzuki couplingGeneral method B2: Suzuki coupling (one pot)General method C: CMBP MitsunobuGeneral method DI: Saponification LiOHGeneral method D2: Saponification NaOHGeneral method E: Oxydation mcpbaGeneral method F: Carbonylation with MoGeneral method G: Carbonylation with COGeneral method H: Substitution nucleophile with amineGeneral method Hl: Substitution nucleophile with thiolGeneral method II: Miyaura borylation under microwaveGeneral method 12: Miyaura borylation into BEPinGeneral method 13: Miyaura borylation into BPinGeneral method J: One-pot Miyaura borylation and Suzuki couplingGeneral method K: MesylationGeneral method L: Boc removal with TFA1.2. General methods1.2.1. Gen er al meth od Al: amide coupling with HA TUoH2N'R2- ►

[0321] To a solution of carboxylic acid (0.87 to 1.5 eq.) and amine (0.9 to 1.3 eq.) in DCM or alternatively DMF is added HATU (1.1 to 1.5 eq.). The reaction mixture is stirred at RT for 10 min and DIPEA (2.5 to 10.0 eq.) is then added. The reaction is stirred at RT for 25 min to 18 h. The crude is directly evaporated to dryness or poured out into water, extracted with DCM or EtOAc, the organic layers are combined, washed with water and brine, dried over Na2SC>4 or MgSCE, filtered and evaporated to dryness. Alternatively, after evaporation, the residue was taken up into EtOAc and washed with citric acid sat. NaHCOs, brine, driedwith Na2SC>4, filtered and evaporated. The residue is purified either by column chromatography on silica gel and / or if needed, by preparative HPLC to give the desired amide.1.2.1.1. Illustrative synthesis oflnt-lBr

[0322] To a solution of 3-methanesulfonyl-4-methylbenzoic acid (CAS# 51522-22-6; 1.0 g, 4.67 mmol, 1 eq.) and l-(4-bromopyridin-2-yl)methanamine (CAS# 865156-50-9; 0.96 g, 5.13 mmol, 1.1 eq.) in DMb (10 mb) were added HATU (2.31 g, 6.07 mmol, 1.3 eq.) and DIPEA (2.4 mb, 11.67 mmol, 2.5 eq.). The reaction was stirred at RT for 18 h. The reaction mixture was evaporated to dryness and the residue was purified by column chromatography on silica gel (eluting with DCM / MeOH from 100 / 0 to 99 / 1) to afford Int-1.1.2.1.2. Illustrative synthesis of Cpd-39Int-6 Cpd-39

[0323] A mixture of 4-chloro-3-methanesulfonylbenzoic acid (CAS# 51522-07-7; 50.0 mg, 0.21 mmol, 1 eq.), Int-6 (76.9 mg, 0.26 mmol, 1.2 eq.), HATU (97.2 mg, 0.26 mmol, 1.2 eq.) and DIPEA (0.093 mb, 0.53 mmol, 2.5 eq.) in DCM (1.07 mb) was stirred at RT for 2 h. NH4CI 10% aq. solution and DCM were added, the organic layer was separated by hydrophobic frit and evaporated till dryness. The residue was purified by column chromatography on silica gel (eluting with DCM / MeOH from 100 / 0 to 96 / 4). The residue was freeze-dried with ACN / water to afford Cpd-39 (44 mg, 0.091 mmol, 43%).1.2.1.3. Illustrative synthesis of Cpd-28Int-6 Cpd-28

[0324] A solution of Int-6 (0.050 g, 0.092 mmol, 1.0 eq.) and DIPEA (0.081 m , 0.46 mmol, 5.0 eq.) in DCM (0.5 m ) was added to a solution of 3 -(methylsulfamoyl)benzoic acid (CAS# 35623-11-1; 0.031 g, 0.14 mmol, 1.5 eq.) and HATU (0.054 g, 0.14 mmol, 1.5 eq.) in DCM (0.5 mb) under N2. Then, DIPEA (0.081 mb, 0.46 mmol, 5.0 eq.) was added to the reaction mixture under N2. The reaction mixture was stirred at rt for 1 h. The solvent was evaporated and the crude product was dissolved in EtOAc, washed with citric acid (x3), sat. NaHCCf (x3), brine (x3), dried with Na2SC>4, filtered and evaporated to dryness. Purified by normal phase chromatography (Interchim 12 g, from 0 to 100% of EtOAc in Heptane, 10 CV,from 0 to 10% of MeOH in DCM, 10 CV), then, purified by preparative HPLC using basic gradient to afford Cpd-28.1.2.1.4. Illustrative synthesis of Cpd-58

[0325] A solution of Int-6 (50 mg, 0.17 mmol, 1.0 eq.) and DIPEA (145 pL, 0.83 mmol, 5.0 eq.) in anhydrous DCM (1.7 mL) was added to a stirred solution of l-methyl-5 -sulfamoyl- lH-pyrrole-3-carboxylic acid (CAS# 1515029-32-9; 39.0 mg, 0.18 mmol, 1.1 eq.) and HATU (77 mg, 0.20 mmol, 1.2 eq.) in anhydrous DCM (1.7 mL) atRT. Then, DIPEA (145 pL, 0.83 mmol, 5.0 eq.) was added and the mixture stirred for 45 min at rt. water was added and the aq. layer was extracted with DCM. The combined organic layers were washed with water and brine, dried over Na2SC>4 and evaporated to dryness. Purified by preparative HPLC (basic conditions) to afford Cpd-58.1.2.2. General method A2: Amide coupling with T3PoH2N'R2- ►

[0326] To a solution of carboxylic acid (1 eq.), amine (1.0 to 1.1 eq.) and DIPEA (5.0 to 10.0 eq.) in DCM is added T3P in solution in EtOAc (1.3 to 1.5 eq.). The reaction mixture is stirred at RT for 1 h to 18 h. The reaction mixture is poured out into water, extracted with DCM or EtOAc, the organic layers are combined, washed with brine, dried over Na2SO4 or MgSO4, filtered and evaporated to dryness. The residue is purified either by column chromatography on silica gel and / or if needed, by preparative HPLC to give the desired amide.1.2.2.1. Illustrative synthesis ofInt-49lnt-49

[0327] T3P 50% in EtOAc (380.84 mg, 0.36 mL, 0.6 mmol, 1.3 eq.) was added dropwise to a solution of (4R)-4-cyano-4-methyl-3,4-dihydro-lH-2-benzopyran-6-carboxylic acid (CAS# 2677883-72-4; 100 mg, 0.46 mmol, 1.0 eq.), l-(4-bromopyridin-2-yl)methanamine (CAS# 865156-50-9; 94.72 mg, 0.506 mmol, 1.1 eq.) and DIPEA (297.5 mg, 0.400 mL, 2.302 mmol, 5.0 eq.) in DCM (2.20 mL) then the reaction mixture was stirred at RT for 1 h.Water and DCM were added. The organic layer was separated (Chromabond®filter) and concentrated in vacuo. The residue was purified by column chromatography on silica gel (eluting with DCM / MeOH from 100 / 0 to 98 / 2) to afford Int-49 (117 mg, 0.304 mmol, 66%).1.2.3. Gen er al meth od A3: Amide coupling with EDCI / H OBtO oR / SPH H2N'R2

[0328] To a solution of carboxylic acid (1 eq ), EDCI HC1 (1.1 eq.) and DIPEA (7.0 eq.) in DCM are added HOBt (1.1 eq.) and amine (1 eq.). The reaction mixture is stirred at RT for 4 h. The reaction mixture is poured out into water, extracted with DCM and evaporated to dryness. The residue is purified either by column chromatography on silica gel and / or if needed, by preparative HPLC to give the desired amide.1.2.3.1. Illustrative synthesis of Cpd-78lnt-78 Cpd-78

[0329] HOBt (l.l eq., 19.4 mg, 0.14 mmol) followed by lnt-78 (1 eq., 150 mg, 0.13 mmol) were added to a solution of (4R)-9-chloro-4-fluoro-5,5-dioxo-3,4-dihydro-2H-l,5X6-benzoxathiepine-7-carboxylic acid (CAS# 3008582-46-2; 1 eq., 38.4 mg, 0.13 mmol), EDCI HC1 (1.1 eq., 27.5 mg, 0.14 mmol) and DIPEA (7 eq., 117.9 mg, 0.16 mL, 0.91 mmol) in DCM (0.63 mL) at rt. The reaction mixture was stirred at rt for 4 h, quenched with water and extracted with DCM. The organic layer was evaporated to dryness. The crude residue was purified by column chromatography on silica gel (eluting with DCM / MeOH 100 / 0 to 96 / 4) then via by preparative HPLC (eluting with aq. NH4HCO3 0.2% (pH=7.9) / ACN from 35 / 65 to 60 / 40) to afford Cpd-78 (40 mg, 0.066 mmol, 50%).1.2.4. Gen er al meth od Bl: Suzuki couplingR2Rl X +,R4O O33"Rl R2

[0330] To a stirred solution of the iodo, bromo, or chloro derivative (1.0 to 2.0 eq.) and the boronic acid or ester derivative (1.0 to 2.0 eq.) in 1,4-dioxane is added either CS2CO3 or K2CO3 or K3PO4 previously diluted in water or alternatively K2CO3 2M in water (2.0 to 3.0 eq.). The mixture is degassed either with argon or nitrogen for 5 min. Pd(dppf)C12'DCM or Pd(dppf)C12 (0.05 eq. or 0.10 eq.) or XPhos Pd G3 (0.05 to 0.1 eq) or Pd(Cy)3 Pd G4 (0.10 eq.) or Pd(OAc)2 (0.05 eq.) / P(Cy)3 HBF4 (0.1 eq.) is then added and the reaction is stirred from 50 °C to 110 °C (conventional or microwave heating) for 1 h to 3 days. The crude is either directly evaporated to dryness or treated by DCM or EtOAc and NH4CI solution or water and evaporated. The residue was purified either by column chromatography on silica gel or by preparativeHPLC. Alternatively filtered over celite®, evaporated and purified by preparative HPLC to give the desired compound.1.2.4.1. Illustrative synthesis oflnt-15Int-14lnt-15

[0331] Pd(dppf)C12 (0.31 g, 0.43 mmol, 0.10 eq.) was added to an nitrogen purged mixture of Int-14 (1.5 g, 4.3 mmol, 1.0 eq.), l-methyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazole (CAS# 1020174-04-2; 0.89 g, 4.3 mmol, 1.0 eq.) and K2CO3 (0.85 g, 8.6 mmol, 2.0 eq.) in 1,4-dioxane (43.0 mb) containing H2O (11 mb). The reaction mixture was heated at 80 °C for 1 h. The mixture was extracted by EtOAc then the organic layer was washed sat. NaHCOs brine, dried with Na2SC>4, and filtered. The solvent was evaporated to dryness. The crude was purified by column chromatography on silica gel (eluting with Heptane / EtOAc from 100 / 0 to 0 / 100) to afford Int-15.1.2.4.2. Illustrative synthesis oflnt-18Int-18

[0332] To a stirred solution of 3 -bromoiodobenzene (CAS# 591-18-4 ; 1.1 eq., 368 mg, 0.17 mL, 1.3 mmol) and Int-7 (1 eq., 575 mg, 1.18 mmol) in dioxane (9 mL) was added CS2CO3 (2 eq., 770 mg, 2.36 mmol) in water (1 mL) at RT. The reaction mixture was degassed with argon for 5 minutes. Pd(dppf)C12 • DCM (0.05 eq., 48.27 mg, 0.059 mmol) was added and the reaction mixture was stirred at 80 °C for 2 h. The reaction mixture was evaporated to dryness. The residue was purified on a 25g Sfar HC column (Biotage), eluted with 3% MeOH in CH2CI2 (Biotage Isolera One device). The product fraction was evaporated to dryness to afford Int-18 (433 mg, 0.94 mmol, 80%) as a yellow oil.1.2.4.4. Illustrative synthesis of Cpd-32lnt-21 Cpd-32

[0333] To a stirred solution of lnt-21 (30.0 mg, 0.053 mmol, 1.0 eq.) and 3-bromo-l-(oxan-4-yl)-lH-pyrazole (CAS# 1227954-60-0; 12.0 mg, 0.053 mmol, 1.0 eq.) in dioxane (1.0 mL) was added CS2CO3 (35.0 mg, 0.107 mmol, 2.0 eq.) in water (0.1 mL) at RT. The reaction mixture was degassed with nitrogen for 5 minutes. XPhos Pd G3 (2.26 mg, 0.0027 mmol, 0.05 eq.) was added and the reaction mixture was stirred at 90 °C for 2 h. The reaction mixture was evaporated to dryness. The residue was purified by column chromatography on a Biotage® Star HC 5 g chromatography cartridge (eluting with DCM to DCM / MeOH 90 / 10), then by preparative HPLC to afford Cpd 32 (21 mg, 0.04 mmol, 74%).1.2.5. Gen er al meth od B2: Suzuki coupling (one pot)

[0334] To a stirred solution of the dihalogenoaryl (iodo, bromo derivative) (1.0 eq.) and the boronic ester derivative (1.0 eq.) in 1,4-dioxane is added K2CO3 (2.0 eq.) previously diluted in water. The mixture is degassed either with argon or nitrogen for 5 min. Pd(dppf)C12 (0.10 eq.) is then added, and the reaction is stirred at 60 °C or 80 °C for 2 h to 4 h. Then boronic acid or ester derivative (1.2 to 1.3 eq.) and Pd(dppf)C12 (0.10 eq.). The reaction is purged under nitrogen or argon flux and is stirred at 100 °C for Ih to 16 h. A saturated NaHCCf aq. solution is added, and the mixture is extracted with EtOAc. The organic layer is dried, and the solvent is evaporated to dryness and purified either by column chromatography on silica gel and / or by preparative HPLC to give the desired compound1.2.5.1. Illustrative synthesis of Cpd-19

[0335] Pd(dppf)C12 (7.5 mg, 0.010 mmol, 0.10 eq.) was added to an N2-purged mixture of Int 50 (50 mg, 0.10 mmol, 1.00 eq.), 2-bromo-4-iodopyridine (CAS# 100523-96-4; 30 mg, 0.10 mmol, 1.0 eq.) and K2CO3 (20 mg, 0.21 mmol, 2.0 eq.) in 1,4-dioxane (2 mL) containing H2O (0.6 mL) and the reaction mixture was heated at 60 °C for 2 h. Then, l-methyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole(CAS# 1020174-04-2; 28 mg, 0.13 mmol, 1.3 eq.) and Pd(dppf)C12 (8 mg, 0.010 mmol, 0.10 eq.) were added to the N2-purged mixture and the resulting mixture was stirred at 100 °C for 1 h. A saturated NaHCOs solution and EtOAc were added to the reaction mixture. The organic layer was separated and washed with saturated NaHCOs aq. solution, brine, dried with Na2SC>4 and filtered. The solvent was evaporated to dryness. The crude was purified by column chromatography on silica gel (eluting with Heptane / EtOAc from 100 / 0 to 0 / 100 then with DCM / MeOH from 100 / 0 to 90 / 10), then by preparative HPLC-to afford Cpd-19.1.2.6. General method B3: anhydrous Suzuki couplingoBKRR2

[0336] In a microwave vial, a solution of boronate (Ri-BPin) (1.5 eq.), Br-R2 (1 eq.) and CsF (3 eq.) in methanol and DME (ratio 3:7) was purged with N2. tetrakis(triphenylphosphine)palladium (0.1 eq.) was added, the mixture was purged again with N2 again. The mixture was then heated at 130 °C using using one single mode microwave (Biotage Initiator EXP 60) with a power output ranging from 0 to 400 W for 30 minutes. The reaction mixture was diluted with water and extracted with DCM. The combined organic layers were dried over MgSCE, filtered and evaporated. The residue was purified by normal phase preparative LC. The fractions containing compound were combined and evaporated in vacuo to give the expected product1.2.6.1. Illustrative synthesis ofInt-86lnt-80

[0337] In a microwave vial, a solution of tert-butyl N-({4-[4-methoxy-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]pyridin-2-yl}methyl)carbamate (1.5 eq., 1058.35 mg, 1.66 mmol), 3-bromo-l-methyl-lH-pyrazole (1 eq., 178 mg, 1.106 mmol) and CsF (3 eq., 503.82 mg, 3.32 mmol) in methanol (3.2 mb) and DME (7.99 mb) was purged withN2. tetrakis(triphenylphosphine)palladium (0.1 eq., 127.76 mg, 0.11 mmol) was added, the mixture was purged again with N2 again. The mixture was then heated at 130 °C using using one single mode microwave (Biotage Initiator EXP 60) with a power output ranging from 0 to 400 W for 30 minutes. The reaction mixture was quenched with water and extracted with DCM three times. The combined organic layers were dried over MgSCE, filtered and evaporated. The residue was purified by normal phase preparative LC (regular SiOH, 15 pm, 40 g agela, liquid loading (DCM), mobile phase gradient: from DCM / MeOH 100 / 0 to 95 / 05 over 10 CV then isocratic over 5 CV). The fractionscontaining compound were combined and evaporated in vacuo to give tert-butyl N-({4-[4-methoxy-3-(l-methyl-lH-pyrazol-3-yl)phenyl]pyridin-2-yl}methyl)carbamate Int-86 (374 mg, 0.95 mmol, 86%) as a pale-red foam.1.2.7. General method C: CMBP MitsunobuHO

[0338] To a solution of diol (1 eq.) in toluene is added cyanomethylenetri -w-butylphosphoranc CMBP, (1.1 to 2.5 eq.) at RT. The reaction mixture is stirred at 70 to 90 °C for 16 to 36 h. The reaction mixture is evaporated to dryness. The crude is purified by column chromatography on silica gel to give the desired oxetane.1.2.7.1. Illustrative synthesis ofInt-66

[0339] CMBP in toluene (3 M) (0.25 mb, 0.77 mmol, 3.00 eq.) was added to a stirred solution of Int-65 (0.082 g, 0.25 mmol, 1.0 eq.) in anhydrous toluene (1.0 mL) and the reaction mixture was stirred for 18 h at 70 °C. The mixture was evaporated to dryness and purified by column chromatography on silica gel (eluting with Heptane / EtOAc from 100 / 0 to 70 / 30) to afford Int-66.1.2.8. Gen er al meth od DI: Sapon ification LiOHRi^ / <? -LiOHRl^ / ?O-R2OH

[0340] To a stirred solution of ester (1 eq.) in a mixture of water and THF and / or MeOH is added LiOH TO (1.5 to 2 eq.) at rt then the solution is stirred at rtto 50 °C for 2 to 18 h. HC1 (IN) and DCM are added, the layers are separated (hydrophobic frit) and evaporated till dryness. Alternatively, HC1 (3 N) is added to the reaction mixture until pH = 3. The solid formed is filtered, washed with water and dried under high vacuum at 50 °C for 5 h to give the desired carboxylic acid. Alternatively, the reaction mixture is evaporated to dryness to give the desired lithium carboxylate.1.2.8.1. Illustrative synthesis ofInt-44

[0341] To a solution of Int-43 (84 mg, 0.29 mmol, 1.0 eq.) in MeOH (2.0 mL) was added at room temperature LiOH (44.11 mg, 0.59 mmol, 2.0 eq.) in H2O (1.0 mL); The mixture was stirred at RT for 2 h. The mixture was concentrated under reduced pressure to afford Int-44 (82 mg, 0.29 mmol, quant.) as lithium salt.1.2.8.2. Illustrative synthesis ofCpd-38

[0342] To a stirred solution of Cpd-37 (64.0 mg, 0.11 mmol, 1.0 eq.) in THF (0.94 mL) and MeOH (0.23 mL) was added LiOH (9.61 mg, 0.23 mmol, 2.0 eq.) in water (0.21 mL). The reaction mixture was stirred at RT for 18 h. HC1 (3 N) aq. solution (3.0 mL) was added to the reaction mixture until pH = 3. The solid formed was filtered, washed with water (5.0 mL) and dried under high vacuum at 50 °C for 5 h to afford compound Cpd-38 (36 mg, 0.068 mmol, 59%).1.2.9. General method D2: Saponification NaOHNaOHO-R2OH

[0343] NaOH 1 N (15.0 eq.) is added to a stirred solution of ester (1.0 eq.) in MeOH and THF and the reaction mixture is stirred at RT for 16 h. HC12 N is added to reach pH 3 and the solvents were evaporated. The aq. mixture was extracted with EtOAc (3x) and Me-THF. The combined organic layers were washed with brine, dried with Na2SO4, filtered, and evaporated to afford the desired carboxylic acid.1.2.9.1. Illustrative synthesis ofInt-62NaOH MeOH / THF, rtlnt-61 lnt-62

[0344] NaOH (1 mol / L) in water (5.0 mb, 5.0 mmol, 10.0 eq.) was added to a stirred solution of lnt-61 (104 mg, 0.50 mmol, 1.0 eq.) in THF (10.0 mb) and MeOH (3.0 mb) and the reaction mixture was stirred at RT for 48 h. The reaction mixture was concentrated to dryness. The residue was dissolved in water (2 mb), HOAc (600 mg, 10.0 mmol, 20.0 eq.) and ACN (2 ml) were added and purified by reverse phase chromatography (XSelect CSH Prep C18 10 m OBD acidic, liquid injection in ACN, from 20 to 45% ACN in 0.1% HCOOH in H2O, 15CV) to afford lnt-62.1.2.10. General method E: Oxydation m-CPBAo„oRi R2 Ri R2

[0345] To a solution of aromatic sulfide (1.0 eq.) in DCM at 0 °C is added m-CPBA (2.1 to 3.5 eq.). The reaction mixture is stirred at RT for 2 to 18 h. The reaction mixture is quenched with NaOH (3N) or sat. Na2COs or sat. NaHCOs and extracted with DCM (3x). The combined organic layers are washed with water, dried over Na2SO4 and evaporated to dryness. The crude residue is purified by column chromatography on silica gel to give the desired aryl sulfone.1.2.10.1. Illustrative synthesis of lnt-27lnt-26 lnt-27

[0346] m-CPBA (1.64 g, 9.48 mmol, 3.5 eq.) was added in one portion to a solution of lnt-26 (744 mg, 2.71 mmol, 1.0 eq.) in DCM (135 mb) at 0 °C. The mixture was allowed to warm to rt and stirred for 2 h. The reaction mixture was washed with sat. Na2COs and water, dried over Na2SC>4 and concentrated to afford lnt-27.1.2.10.2. Illustrative synthesis of lnt-40O iilnt-39 lnt-40

[0347] To a solution of Int-39 (260 mg, 1.052 mmol, 1.0 eq.) in DCM (5.45 mL) cooled at 0 °C was added m-CPBA (544.6 mg, 2.209 mmol, 2.1 eq.), then, the mixture was stirred at RT for 18 h. The reaction was quenched with NaOH (3N) and extracted with DCM, the organic layer was washed with water, dried over Na2SC>4 and concentrated under reduced pressure. This residue was purified by column chromatography on silica gel (eluting with heptane / EtOAc 100 / 0 to 50 / 50) to afford Int-40.1.2.11. General method F: Carbonylation with Mo(CO)6

[0348] Aryl bromide (1.0 eq.), Mo(CO)e (0.5 eq.), Na2COs (3.0 eq.) andXantPhos PdG3 or G4 (0.06 eq.) are placed in a vial under N2. 1,4-dioxane and water are added and the mixture is heated to 120 °C for 30 to 90 min. 2 N HC1 is added, the mixture is filtered over a PTFE filter, washed with MeOH (2x) and evaporated to dryness. Alternatively, the reaction mixture is quenched with sat. NaHCOs, the aq. layer is extracted with EtOAc (2x). Then, the aq. layer is acidified with aq. 2 N HC1 to pH 3 and is extracted with EtOAc (3x). The combined organic layers are washed brine, dried over Na2SC>4 and evaporated to dryness. If needed, the crude residue is purified by reverse phase chromatography to give the desired carboxylic acid.1.2.11.1. Illustrative synthesis ofInt-28Br HO^OMO(CO)K XanthPhos Pd G3Na2CO3dioxane, H2O, 120 °C, 30 min | Q>X'Qlnt-27 lnt-28

[0349] lnt-27 (75.0 mg, 0.26 mmol, 1.0 eq.), Mo(CO)e (34 mg, 0.13 mmol, 0.5 eq.), Na2COs (83 mg, 0.78 mmol, 3.0 eq.) and XantPhos Pd G3 (15 mg, 0.02 mmol, 0.06 eq.) were placed in a vial under nitrogen.1,4-dioxane (11.7 mL) and water (1.3 mL) were added and the mixture was heated to 120 °C for 30 min. the mixture was cooled to rt, 2 N HC1 (4.0 eq.) was slowly added and the mixture evaporated to dryness. Purified by RP chromatography (XSelect CSH Prep C18 10 m OBD acidic / / 20 to 55% ACN in 0.1% HCOOH in H2O) to lnt-28 (26 mg, 0.09 mmol, 33%) as a colorless foam.1.2.11.2. Illustrative synthesis oflnt-31XantPhos Pd G4CN MO(CO)6INa2CO3ONlnt-30 lnt-31

[0350] lnt-30 (145 mg, 0.61mmol, 1.0 eq.), Mo(CO)e (80 mg, 0.30 mmol, 0.5 eq.), Na2COs (193 mg, 1.82 mmol, 3.0 eq.) and XantPhos Pd G4 (36 mg, 0.03 mmol, 0.06 eq.) were placed in a vial under nitrogen. Degassed dioxane (2 mL) and H2O (3 mL) were added and the mixture was heated to 120 °C for 30 min. After full conversion monitored by UPLC / MS, the mixture was cooled to rt, sat. NaHCCh was added and the aq. layer was extracted with EtOAc (2x). Then, the aq. layer was acidified with aq. 2 N HC1 to pH 3 and was extracted with EtOAc (3x). The combined organic layers were washed brine and dried over Na2SO4 and evaporated to dryness to afford lnt-311.2.12. General method G: Carbonylation with CO

[0351] In a sealed bomb are added aryl bromide (1.0 eq.) and TEA (6.0 eq.) in H2O and dioxane then PdC12(dppf) DCM (0.1 eq.). The sealed bomb is filled with CO (5 bar). The mixture is heated at 120 °C for 18 h. HC1 IM is added and the mixture is extracted with EtOAc (3x). The combined organic layers are washed with brine, dried over MgSO4, filtered and concentrated in vacuo to afford the desired carboxylic acid.1.2.12.1. Illustrative synthesis oflnt-41

[0352] In a sealed bomb were added Int-40 (120 mg, 0.43 mmol, 1.0 eq.) and TEA (263.64 mg, 0.36 mL, 2.58 mmol, 6.0 eq.) in H2O (0.71 mL) and Dioxane (4.44 mL) then PdC12(dppf) DCM (0.1 eq., 35.105 mg, 0.043 mmol). The sealed bomb was filled with CO (5 bar). The mixture was heated at 120 °C for 18 h. HC1 IM was added and the mixture was extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated in vacuo to afford Int-41.1.2.13. General method H: Substitution nucleophile with amine

[0353] To a solution of amine (1 eq) in DMF is added K2CO3 (2.0 to 3.0 eq) or t-BuOK (1.5 eq). This reaction mixture is stirred at RT for 5 minutes then alkyl halide (1.0 to 1.5 eq) is added and the reaction mixture is stirred at 25 °C for 18 h or 70 °C to 100 °C for 1.5 h to 3 days . The reaction mixture is evaporated to dryness. The residue is purified either by column chromatography on silica gel or by preparative HPLC to afford the desired compound.1.2.13.1. Illustrative synthesis of Cpd-44Cpd-11 Cpd-44

[0354] To a stirred solution of Cpd-11 (50.0 mg, 0.11 mmol, 1 eq.) in DMF (1.0 mb) was added t-BuOK (0.17 mb, 0.17 mmol, 1.5 eq.). The reaction was stirred at room temperature for 5 min then bromoacetonitrile (20.15 mg, 0.012 mb, 0.17 mmol, 1.5 eq.) was added and stirred for 18 h. The reaction mixture was evaporated to dryness. The residue was purified on a Biotage® Star HC column (eluting with DCM / MeOH 100 / 0 to 90 / 10) to afford Cpd-44 (25 mg, 0.051 mmol, 46%).1.2.13.2. Illustrative synthesis of Cpd-52Cpd-11 Cpd-52

[0355] To a stirred solution of Cpd-11 (50 mg, 0.11 mmol, 1 eq.) in DMF (1 mb) was added K2CO3 (46.43 mg, 0.34 mmol, 3 eq.). The reaction was stirred at room temperature for 5 min then 2 -bromoethanol (CAS# 540-51-2; 20.99 mg, 0.012 mb, 0.17 mmol, 1.5 eq.) was added. The reaction was stirred at 75 °C over 3 d then cooled down to RT. The reaction mixture was evaporated to dryness. The residue was purified on Biotage® Star HC column (eluting with DCM / MeOH 100 / 0 to 90 / 10) and then by preparative HPLC to afford Cpd-52 (3 mg, 0.006 mmol, 5%).1.2.13.3. Illustrative synthesis of Int-9lnt-9

[0356] To a stirred solution of 3-bromo-lH-pyrazole (CAS# 14521-80-3; 100 mg, 0.68 mmol, 1.0 eq.) K2CO3 (188.1 mg, 1.36 mmol, 2.0 eq.) in DMF (2.00 mL) was added 3 -(bromomethyl)oxetane (CAS# 1374014-30-8; 102.7 mg, 0.68 mmol, 1 eq.). The reaction was stirred at 70 °C for 22 h. The solvent was evaporated until dryness. The crude was purified on Biotage® Star, (eluting from Heptane / EtOAc 100 / 0 to 0 / 100) to afford Int-9.General method Hl: Substitution nucleophile with thiolRdRIXxSH+X'R3- *1S

[0357] To a solution of thiol (1.0 eq.) and DIPEA (1.6 eq.) in DCM dry cooled at 0 °C is added dropwise alkyl halide (1.2 to 1.82 eq.) The reaction mixture was stirred at RT for 18 h. The mixture was quenched with water and extracted with DCM. The organic layer is dried, filtrated and the solvent was evaporated to dryness. The crude was purified by column chromatography on silica gel to afford the desired compound.1.2.13.4. Illustrative synthesis of Int-26^O^BrInt-26

[0358] A solution of 5-bromo-2-methylbenzene-l-thiol (CAS# 69321-55-7; 150 mg, 0.1 mL, 0.702 mmol, 1.0 eq.) and DIPEA (0.2 mL, 1.12 mmol, 1.6 eq.) in dry DCM (5.0 mL) was cooled at 0 °C, then bromo(methoxy)methane (CAS# 13057-17-5; 105.21 mg, 0.069 mL, 0.84 mmol, 1.2 eq.) was added dropwise, then the mixture was left to warmed up at RT for 18h. Water was added, the organic layer was decanted and dried with a chromabond® PTS and evaporated to dryness. The crude was purified by column chromatography on silica gel (eluting with Heptane / EtOAc 100 / 0 to 80 / 20) to give Int-26.1.2.13.5. Illustrative synthesis of Int-39Int-39

[0359] To a solution of 5-bromo-2-methylbenzene-l-thiol (CAS# 69321-55-7; 300 mg, 1.403 mmol, 1 eq.) and DIPEA (290.19 mg, 0.39 mL, 2.25 mmol, 1.6 eq.) in DCM dry (10 mL) cooled at 0 °C was added dropwise 2-bromoethanol (CAS# 540-51-2; 320 mg, 0.18 mL, 2.56 mmol, 1.82 eq.) The reaction mixture was warmed up at RT for 18 h. The mixture was quenched with water and extracted with DCM (3 x). The combined organic layers were dried under Na2SC>4, filtrated and the solvent was evaporated to dryness. The crude was purified by column chromatography on silica gel (eluting with Heptane / EtOAc from 100 / 0 to 70 / 30) to afford Int-39.General method II: Miyaura borylation under microwaveRsO

[0360] To a stirred solution of the halide substrate (1 eq.) and bis(pinacolato)diboron (CAS# 73183-34-3; 2.0 eq.) in 1,4-dioxane is added AcOK (3 eq.). The mixture is degassed with nitrogen for 5 min and cataCXium A Pd G3 (0.1 eq.) is added. The resulting mixture was heated at 150 °C using one single mode microwave (Anton Paar) with a power output ranging from 0 to 850 W for 30 min. The mixture was filtered over celite® and then concentrated under reduced pressure to afford the desired boronate.1.2.13.6. Illustrative synthesis of Int-52

[0361] In a microwave tube, to Int-51 (63 mg, 0.13 mmol, 1.0 eq.) in 1,4-dioxane (0.64 mb) was added bis(pinacolato)diboron (64.98 mg, 0.26 mmol, 2.0 eq.) and AcOK (37.67 mg, 0.38 mmol, 3.0 eq.). The resulting mixture was degassed with N2 and catacxium A Pd G3 (9.32 mg, 0.013 mmol, 0.1 eq.) was added. The resulting mixture was heated at 150 °C using one single mode microwave (Anton Paar) with a power output ranging from 0 to 850 W for 30 min. The mixture was filtered over celite® and then concentrated under reduced pressure to afford Int-52 (43 mg, 0.081 mmol, 63%).General method 12: Miyaura borylation into BEPin

[0362] To a stirred solution ofthe halide substrate (1 eq.) and 4,4,5,5-tetraethyl-2-(4,4,5,5-tetraethyl-l,3,2-dioxaborolan-2-yl)-l,3,2- dioxaborolane (CAS# 2247367-07-1; 1.4 to 1.5 eq.) in 1,4-dioxane is added AcOK (3 eq.). The mixture is degassed with nitrogen for 5 min. Pd(dppf)C12'DCM (0.05 to 0.1 eq.) is then added and the reaction is stirred at 80 to 90 °C for 16 to 19 h. The reaction mixture is filtered through Celite, the cake is washed with EtOAc and the filtrate evaporated to dryness. Alternatively, the reaction mixture is poured out into water, extracted with EtOAc, the organic layers are combined, washed with sat brine, dried over Na2SO4 or MgSO4, filtered and evaporated to dryness. The crude is purified by column chromatography on silica gel or triturated with Et2O and filtered to give the desired boronate.1.2.13.7. Illustrative synthesis of lnt-50lnt-49 lnt-50

[0363] A mixture of Int-49 (1 eq., 127 mg, 0.306 mmol), 4,4,5,5-tetraethyl-2-(4,4,5,5-tetraethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (1.5 eq., 167.95 mg, 0.46 mmol), AcOK (3 eq., 90.032 mg, 0.92 mmol) and Pd(dppf)C12'DCM (0.1 eq., 24.97 mg, 0.0306 mmol) in 1,4-dioxane (3.14 m ) was purged with N2 for 5 min then stirred at 90 °C for 16 h. After cooling down, the reaction mixture was filtered over Celite, the cake was washed with EtOAc and the filtrate was concentrated in vacuo. The crude residue was purified by column chromatography on silica gel (DCM / MeOH from 100 / 0 to 96 / 4). Fractions containing product were combined and evaporated to dryness to give lnt-50 (82.31 mg, 0.17 mmol, 55%).General method 13: Miyaura borylation into BPinB2Pin2

[0364] To a stirred solution of the halide substrate (1 eq.) and bis(pinacolato)diboron (CAS# 73183-34-3; 1.4 eq.) in 1,4-dioxane is added AcOK (3 eq.). The mixture is degassed with nitrogen for 5 min. Pd(dppf)C12-DCM (0.1 eq.) is then added and the reaction is stirred at 100 °C for 20 h. The reaction mixture was fdtered through Celite and the cake was washed with EtOAc. The fdtrate was evaporated to dryness. The crude is purified by column chromatography on silica gel to give the desired compound.1.2.13.8. Illustrative synthesis of Int- 74

[0365] To a solution of Int-70 (1 eq., 100 mg, 0.19 mmol) and bis(pinacolato)diboron (1.4 eq., 68.7 mg, 0.27 mmol) in 1,4-dioxane (1.99 mb) was added AcOK (3 eq., 56.9 mg, 0.58 mmol) & Pd(dppf)C12 • DCM (0.1 eq., 15.78 mg, 0.019 mmol). The mixture is degassed with nitrogen for 5 min. Pd(dppf)C12 DCM (0.1 eq.) is then added and the reaction is stirred at 100 °C for 20 h. The reaction mixture was diluted with EtOAc and filtered over a pad of celite. The pad was eluted with EtOAc. The filtrate was concentrated in vacuo. The crude residue was purified by column chromatography on silica gel (DCM / MeOH 100:0 to 95:5) to afford Int-74 (66 mg, 0.12 mmol, 61%).1.2.14. General method J: One-pot Miyaura borylation and Suzuki coupling1) B2Pin2R-j X - ► R-j R22)R2- X

[0366] To a stirred solution of the halide substrate (1 eq.) and bis(pinacolato)diboron (CAS# 73183-34-3; 1.3 to 2 eq.) in 1,4-dioxane is added AcOK (3 eq.). The mixture is degassed with nitrogen for 5 min. cataCXium Pd G3 (0.1 eq.) is then added and the reaction is stirred at 110 °C to 150 °C for 30 min to 2 h under microwave irradiation. Then halide substrate (1.0 to 1.1 eq.), water, CS2CO3 or K3PO4 (3 eq.) are added. The mixture is degassed with nitrogen for 5 min. Pd(dppf)C12'DCM (0.1 eq.) is potentially added and the reaction is stirred at 80 °C to 120 °C for 30 min to 1 h under microwave irradiation. The reaction mixture is fdtered over celite®, evaporated and purified either by column chromatography on silica gel or by preparative HPLC.1.2.14.1. Illustrative synthesis of Cpd-71

[0367] In a sealed tube, to Int-70 (1 eq., 150 mg, 0.2 mmol) in 1,4-dioxane (1.606 mb) was added bis(pinacolato)diboron (2 eq., 100.6mg, 0.4 mmol) and AcOK (3 eq., 58.3 mg, 0.59 mmol). The resulting mixture was degassed with N2 and cataCXium A Pd G3 (0.1 eq., 14.42 mg, 0.02 mmol) was added. The resulting mixture was heated at 150 °C using one single mode microwave (Anton Paar) with a power output ranging from Oto 850 W for 30 min. After cooling down to rt, 3-iodo-l-(3-methyloxetan-3-yl)-lH-pyrazole (CAS# 2468058-13-9; 57.52 mg, 0.22 mmol, 1.1 eq.), Cs2CO3(193.55 mg, 0.59 mmol, 3.0 eq.), Pd(dppf)C12-DCM (16.17 mg, 0.02 mmol, 0.1 eq.) and water (0.24 mL) were added, the mixture was refded with N2 flux then heated at 120 °C for 30 min. The mixture was filtered over celite and then concentrated under reduced pressure. The crude was purified by column chromatography on silica gel (eluting with DCM / MeOH from 100 / 0 to 96 / 4) then via by preparative HPLC (eluting with aq. NH4HCO3 0.2% (pH=7.9) / ACN from 90 / 10 to 30 / 70). The residue was taken-up in ACN, extended with water and freeze-dried to afford Cpd-71 (58 mg, 0.101 mmol, 51%).1.2.15. Gen er al meth od K: MesylationR"NHIR2Ao o

[0368] To a solution of amine (1 eq), TEA (1.5 to 10 eq.) and potentially DMAP (0.1 eq.) in DCM and / or THF is added MsCl (1.3 to 10 eq.) and the reaction mixture is stirred at RT to 60 °C for 1 h to 16 h. The reaction mixture is quenched with water and extracted with DCM. The organic layers are combined, dried over MgSCE, filtered and evaporated to dryness. Alternatively, the reaction mixture is evaporated to dryness. The residue is purified either by column chromatography on silica gel or by preparative HPLC to afford the desired compound.1.2.15.1. Illustrative synthesis of Int-13

[0369] To a stirred solution of 3-(3-bromophenyl)-lH-pyrazole (CAS# 149739-65-1; 200 mg, 0.9 mmol, 1 eq.) and TEA (187 pL, 1.34 mmol, 1.5 eq.) in DCM (4.00 mL) was added methanesulfonyl chloride (CAS# 124-63-0; 133.501 mg, 90.2 pL, 1.17 mmol, 1.3 eq.) at RT for 16 h. The solvent was evaporated to dryness. The crude was purified by column chromatography on silica gel (eluting with Heptane / EtOAc from 100 / 0 to 40 / 60) to afford Int-13 as a regioisomer mixture (35 / 65).1.2.16. General method L: Boc removal with TFAR,'NHR2R2

[0370] To a solution of carbamate (1 eq.) in DCM is added TFA (20 to 50 eq.) at RT. The reaction mixture is stirred at RT for 2 to 72 h. The crude is evaporated to dryness to give the desired amine as TFA salt(s). Potentially, the residue is partitioned between sat aq. NaHCOs or aq. K2CO3 and DCM. The organic layer is evaporated to dryness to give the desired amine as free base.1.2.16.1. Illustrative synthesis of Cpd-6o

[0371] The reaction was performed in a round bottom flask with anhydrous solvent. To a stirred solution of Cpd-7 (34 mg, 0.054 mmol, 1.0 eq.) in DCM (2.0 mL) was added TFA (0.0802 mL, 1.08 mmol, 20.0 eq.). The reaction mixture was stirred at RT for 72 h. Toluene was added (3 mL) and the reaction mixture was evaporated to dryness. DCM was added to the reaction mixture and the pH was adjusted to 9 by addition of a saturated NaHCOs aq. solution. The mixture was fdtered over chromabond® fdter and the organic layer was evaporated to dryness to afford Cpd-6 (24 mg, 0.045 mmol, 84%).1.2.17. General method L2: Boc removal with HClR,'NHR2

[0372] To a solution of carbamate (1 eq.) in dichloromethane, HC1 4M in dioxane (10 eq.) was added dropwise. The reaction mixture was stirred at rt for 2.5 h until a white precipitate appeared. The reaction mixture was triturated in Et2O. The precipitate was fdtered, rinced twice with Et2O then dried under vacuo to give the amine as hydrochloride salt.

[0373] A flask was charged with tert-butyl N-({4-[4-methoxy-3-(l-methyl-lH-pyrazol-3-yl)phenyl]pyridin-2-yl}methyl)carbamate (1 eq., 523 mg, 1.33 mmol) and dichloromethane (13.075 mL) then HC1 4M in dioxane (10 eq., 3.31 mL, 13.26 mmol) was added dropwise. The reaction mixture was stirred at rt for 2.5 h until a white precipitate appeared. The reaction mixture was triturated in Et2O. The precipitate was fdtered, rinsed twice with Et2O then dried under vacuo to give l-{4-[4-methoxy-3-(l-methyl-lH-pyrazol-3-yl)phenyl]pyridin-2-yl}methanamine hydrochloride (438.6 mg, 1.33 mmol, 100%) as a pale yellow powder.1.3. Preparation of the compounds of the invention1.4. Int-5Raney Ni, Boc2O, NEt3H2THF, rt, 5 dlnt-4 lnt-5

[0374] Raney Ni (287 mg, 3.32 mmol, 0.6 eq.) was added to a solution of Int-4 (1.44 g, 5.53 mmol, 1.0 eq.), BOC2O (16.9 g, 16.6 mL, 16.6 mmol, 3.00 eq.) and TEA (2.31 mL, 16.6 mmol, 3.0 eq.) in THF (50 mL) under nitrogen. The reaction mixture was then purged with hydrogen for 10 min and stirred at rt for 5 d. the reaction mixture was fdtered over celite and concentrated. Purified by normal phase chromatography (Biotage 50 g, from 0 to 100% of EtOAc in heptane 10 CV) to afford Int-5.1.5. Int-6Int-6

[0375] HC1 (4 mol / L) in 1,4-dioxane (1.7 g, 1.59 mL, 6.4 mmol, 20 eq.) was added to a solution of Int-5 (0.116 g, 0.32 mmol, 1 eq.) in 1,4- dioxane (2 mL). The reaction mixture was stirred at rt for Ih. After full conversion monitored by HPLC / MS, solvent was evaporated and the crude product was co-evaporated with 1,4-dioxane to dryness and to Int-6 (0.154 g, 0.32 mmol, 85% pure, 100%) which was used as such in the next step.1.6. Int-11O

[0376] Under N2, to a stirred solution of triethyl phosphonoacetate (CAS 867-13-0; 2.16 g, 1.91 mL, 9.65 mmol, 1.5 eq.) in THF (20 mL) at 0 °C, NaH (2 eq., 0.51 g, 12.87 mmol) was added portionwise and the reaction mixture was stirred at 0 °C for 30 min. 4-bromo-2-iodobenzaldehyde (1261470-87-4; 2.0 g, 6.43 mmol, 1.0 eq.) in THF (5 mL) was added slowly and the reaction mixture was stirred at 0 °C for 2 h. Water was added, the reaction mixture was extracted twice with EtOAc, the organic layers were combined, washed with brine, dried (MgSO4) and evaporated in vacuum till dryness. The crude was suspended in heptane, the suspension was stirred at RT for 1 h, the solid was filtered off, washed with heptane and dried (50 °C, vacuum) to afford Int-11 (1.1 g, 2.89 mmol, 45%) as E isomer.1.7. Int-12Int-11 Int-12

[0377] A round botom flask was charged with a magnetic stirring bar, Int-11 (100 mg, 0.26 mmol, 1.0 eq.), l-methyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (1.1 eq., 60.072 mg, 0.29 mmol), potassium carbonate (3 eq., 394 pL, 0.79 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.1 eq., 30.33 mg, 0.026 mmol). The vial was capped then set under inert atmosphere via 3 iterations of a cycle vacuum / N2. toluene (2792.56 microL) and ethanol (714.95 microL) were added to the vial through the septum. The reaction mixture was degassed by bubbling N2 for 5 min then heated to 90 °C for 2 h. The reaction mixture was cooled-down to rt and diluted with water (30 mL) and DCM (50 mL) and the layers were separated. The aq. one was extracted with DCM (2 x 50 mL) and the combined organic extracts were washed with water, brine, dried over MgSCL, filtered and concentrated under reduced pressure. This crude was purified by normal phase preparative LC (Stationnary phase: regular SiOH, 50 pm, Interchim, 40 g, liquid loading (DCM), mobile phase gradient Heptane / EtOAc 100 / 0 to 50 / 50, 12 CV). The fractions containing product were concentrated under vacuum to afford Int-12.1.8. Int-1452864-55-8 Int-14

[0378] Ethyl 2-(2-bromo-4-chloro-phenyl)acetate (10.7 g, 38.6 mmol, 1 eq.) in toluene (50 mL, 473 mmol, 12.3 eq.) was added dropwise to a stirred solution of diethyl carbonate (18.2 g, 18.7 mL, 154 mmol, 4 eq.) and sodium hydride (60 mass%) in mineral oil (3.08 g, 77.1 mmol, 2 eq.) and the mixture was heated to 80 °C for 16 h. After full conversion, monitored by UPLC / MS, the mixture was cooled to rt, quenched with water and extracted with EtOAc. The combined org. phases were washed with brine, dried over Na2SC>4 and evaporated to dryness. Purified by normal phase chromatography (Interchim 120 g, 0 to 30% EtOAc in heptane, 15 CV) to afford diethyl 2-(2-bromo-4-chloro-phenyl)propanedioate (11.7 g, 33.5 mmol, 87%) as a light-yellowish oil which was used as such in the next step.1.9. Int-16lnt-15 Int-16

[0379] To a mixture of lnt-15 (0.53 g, 1.51 mmol, 1.0 eq.) in anhydrous THF (3.0 mL) at 0 °C was added dropwise a solution of LiAlFL (1.0 M) in THF (1.5 mL, 1.51 mmol, 1.0 eq.). The mixture was kept at 0 °Cfor 2 h then a solution of LiAlIL (1.0 M) in THF (1.5 mL, 1.51 mmol, 1 eq.) was added to the reaction mixture and the mixture was stirred at RT for 16 h. At 0 °C, water and EtOAc was added to the reaction mixture. The mixture was fdtered, and the layers were separated. Then, the aq. layer was extracted with EtOAc (3x). The combined organic layers were washed brine, dried with Na2SO4, filtered and evaporated to dryness. The crude was purified by column chromatography on silica gel (eluting with Heptane / EtOAc from 100 / 0 to 0 / 100 then DCM / MeOH from 100 / 0 to 100 / 10) to afford Int-16.1.10. Int-20Int-19

[0380] BINAP (0.042 g, 0.067 mmol, 0.10 eq.), Pd2(dba)3(0.042 g, 0.067 mmol, 0.10 eq.) and NaOt-Bu (0.087 g, 0.88 mmol, 1.3 eq.) were added to a solution of Int-19 (0.18 g, 0.67 mmol, 1.0 eq.) and 1-methylpiperazine (0.076 mL, 0.67 mmol, 1.0 eq.) in PhMe (1.5 mL). The mixture was flushed with nitrogen and was heated to 100 °C for 16 h. After 16 h, NaOt-Bu (0.13 g, 1.3 mmol, 2.0 eq.), Pd2(dba)3(0.012 g, 0.013 mmol, 0.020 eq.) and BINAP (0.021 g, 0.034 mmol, 0.050 eq.) were added and the reaction mixture was stirred at 100 °C for 16 h.. After 40 h, (2-Dicyclohexylphosphino-2',4',6'-triisopropyl-l,l'-biphenyl)[2-(2'-amino-l,l'-biphenyl)]palladium(II) methanesulfonate (0.029 g, 0.034 mmol, 0.050 eq.) was added to the N2-purged solution. The reaction mixture was stirred at 100 °C for 16 h.Then, the reaction mixture was filtered on Celite® and purified by column chromatography on silica gel (eluting with Heptane / EtOAc from 100 / 0 to 0 / 100 then with DCM / MeOH 100 / 0 to 90 / 10) to afford Int-20.1.11. Int-23Int-23

[0381] NBS (716 mg, 4.02 mmol, 1.0 eq.) and benzoyl peroxide (201 mg, 0.804 mmol, 0.2 eq.) were added to a stirred solution of methyl 4-methyl-3-methylsulfonyl-benzoate (CAS# 906816-32-8; 918 mg, 4.02 mmol, 1.0 eq.) in CCL (13 mL) and the reaction mixture was heated at 75 °C for 16 h. The mixture was cooled to rt, washed with water and brine, dried with Na2SC>4, and was evaporated to dryness to afford Int-23.1.12. Int-24lnt-23 Int-24

[0382] t-BuOK (1 mol / L) in THF (3.47 mL, 3.47 mmol, 2.0 eq.) was added to a stirred solution of lnt-23 (0.53 g, 1.74 mmol, 1.00 eq.) in MeOH (30 mL) and the reaction mixture was stirred at rt for 1 h. Then the reaction mixture was concentrated, and the residue was dissolved in EtOAc / Water. The layers were separated, and the aq. layer was extracted with EtOAc (2x). The combined organic layers were washed with brine, dried with Na2SO4, filtered, and evaporated to dryness to afford Int-24.1.13. Int-29lnt-29

[0383] NaBEL (0.091 g, 2.42 mmol, 1.10 eq.) was added to a solution of 6-bromoisochroman-4-one (CAS# 676134-70-6; 0.5 g, 2.20 mmol, 1.00 eq.) in MeOH (10 mL) at 0 °C and the reaction mixture was stirred at RT for 1 h. then sat. NaHCOs and water were added and the aq. layer was extracted with EtOAc (3x). The combined organic layers were washed with sat. NaHCOs, brine, dried with Na2SO4, filtered and evaporated to dryness to afford 6-bromoisochroman-4-ol (0.472 g, 2.06 mmol, 93%) as a colorless oil. PBr, 1 M in DCM (0.80 mL, 0.79 mmol, 0.50 eq.) was added dropwise to a solution of 6-bromoisochroman-4-ol (CAS# 676134-70-6; 366 mg, 1.59 mmol, 1.0 eq.) in anhydrous DCM (5 mL) at 0 °C and the reaction mixture was stirred at rt for 2h. then sat. NaHCOs was added to reach pH=6. Then, water was added and the aq. layer was extracted with DCM (3x). The combined organic layers were washed with brine, dried over Na2SC>4, filtered and evaporated to dryness to afford lnt-29.1.14. Int-35lnt-35

[0384] A mixture of 3-(methylsulfamoyl)benzoic acid (300 mg, 1.39 mmol, 1.0 eq.), acetyl chloride (CAS #75-36-5 ; 164.13 mg, 149.21 pL, 2.091 mmol, 1.5 eq.) and TEA (426.3 pL, 3.067 mmol, (2.2 eq.) in THF (6853.06 pL) was stirred at RT for 16 h. The reaction mixture was quenched with an aq. solutionof HC1 IM and extracted twice with EtOAc. The combined organic layers were washed with brine (3x), dried over MgSCE, fdtered and concentrated in vacuo to afford Int-35 (140 mg, 0.54 mmol, 39%).1.15. Int-36

[0385] A solution of methyl 3-(chlorosulfonyl)benzoate (CAS# 63555-50-0; 400 mg, 1.705 mmol, 1.0 eq.), (2-methoxyethyl)(methyl)amine (CAS# 38256-93-8; 227.93 mg, 277.96 pL, 2.56 mmol, 1.5 eq.) and DIPEA (2.5 eq., 550.808 mg, 742.3 pL, 4.26 mmol) in DCM (6.0 mL) was stirred at rt for 1 h.Water was added and the DCM layer was fdtered through a Chromabond® fdter then concentrated in vacuo. The residue was purified by column chromatography on silica gel (eluting with Heptane / EtOAc from 100 / 0 to 50 / 50). Fractions containing product were combined and evaporated to dryness to afford Int-36 (420 mg, 1.46 mmol, 86%).1.16. Int-42O ii

[0386] To a solution of Int-40 (100 mg, 0.36 mmol, 1.0 eq.) and TEA (72.501 mg, 0.1 mL, 0.72 mmol, 2.0 eq.) in DCM (3.58 mL) at 0 °C was added MsCl (1.4 eq., 57.44 mg, 0.039 mL, 0.502 mmol) dropwise. The mixture was stirred at 0 °C during 1 h. The mixture was quenched with water and extracted with DCM (3 times). The combined organic layers were dried under chromabond and the solvent was removed under vacuum (with a cold bath). This residue was disolved in THF (3.58 mL) and dimethylamine 2 M in THF (15 eq., 2.69 mL, 5.37 mmol) was added at room temperature. The mixture was stirred at this temperature for 1 h. The mixture was quenched with water and extracted with DCM (3 times). The combined organic layers were dried under chromabond and the solvent was removed under vacuum to afford Int-42 (95 mg, 0.31 mmol, 87%).1.17. Int-43

[0387] In a sealed bomb were added Int-42 (95 mg, 0.31 mmol, 1.0 eq.) and TEA (0.26 mL, 1.86 mmol, 6.0 eq.) in MeOH (3.0 mL) then [l,T-bis(diphenylphosphino)ferrocene]dichloropalladium(ii) complex with dichloromethane (25.33 mg, 0.031 mmol, 0.1 eq.). The sealed bomb was fdled with CO (5 bar). Themixture was heated at 120 °C for 18 h. The reaction mixture was cooled to room temperature, fitered on celite, and concentrated to dryness under vacuum. This crude was purified by column chromatography on silica gel (eluting with Heptane / EtOAc from 70 / 30 to 0 / 100) to afford Int-43 (83 mg, 0.29 mmol, 93%). 1.18. Cpd-5Cpd-6 Cpd-5

[0388] To a stirred solution of Cpd-6 (54 mg, 0.12 mmol, 1.0 eq.) and formaldehyde 37 wt.% in H2O (36 pL, 0.48 mmol, 4 eq.) in DCE (2 mL) and MeOH (0.5 mL) was added AcOH (7 pL, 0.12 mmol, 1 eq.). The reaction mixture was stirred at RT for 10 min and then NaBH(OAc)s (25 mg, 0.12 mmol, 1 eq.) was added. The reaction mixture was stirred at RT for 30 min. The crude was evaporated to dryness and the residue was purified by column chromatography on a Biotage® Sfar KP -Amino D chromatography cartridge (eluting with DCM to DCM / MeOH 99 / 1) to afford Cpd-5 (15 mg, 0.028 mmol, 73%).1.19. Cpd-46O nlnt-36 lnt-6 Cpd-46

[0389] At 0 °C, to a solution of lnt-36 (80 mg, 0.28 mmol, 1 eq.) and Int-6 (92 mg, 0.306 mmol, 1.1 eq.) in dry THF (1.83 mL) was added dropwise LiHMDS (1 M) in THF (1.25 mL, 1.25 mmol, 4.5 eq.), then the mixture was stirred at RT for 1 h. The reaction was quenched with water and extracted twice with EtOAc. The combined organic layers were dried over anhydrous MgSCL, filtered and concentrated under reduced pressure. The crude was purified by column chromatography on silica gel (eluting with DCM / MeOH from 100 / 0 to 96 / 4) then by preparative HPLC (eluting with aq. NH4HCO3 0.2% / ACN from 100 / 0 to 40 / 60) to afford Cpd-46 (30 mg, 0.058 mmol, 21%).Cpd-70

[0390] Under N2, to a stirred solution of Cpd-11 (50.0 mg, 0.11 mmol, 1.0 eq.) in anhydrous DMF (1.0 mL) was added t-BuOK (0.17 mL, 0.17 mmol, 1.5 eq.). The reaction was stirred at room temperature for 5 minthen l,3,2-dioxathiolane,2,2-dioxide (CAS 1072-53-3; 1.5 eq., 20.85 mg, 0.17 mmol) was added. After 18 h, l,3,2-dioxathiolane,2,2-dioxide (20.85 mg, 0.17 mmol, 1.5 eq.) and t-BuOK (0.17 mL, 0.17 mmol,1.5 eq.) were added to the mixture and stirred at room temperature for 24 h. The mixture was quenched with HC1 cone (0.3 mL) and the mixture was stirred 2h at room temperature. NaHCCh saturated solution was added until pH=7 and the mixture was extracted with ethyl acetate. The organic an aqueuous layers were finally combined (Expected compound is present in each layer) and concentrated under reduce pressure. The crude was purified on on a 6g Star C 18 column (Biotage), silica deposit, eluted with a gradient 0 to 100% [ACN / 0.1% NH4OH] in [H2O / 0.1%NH4OH] (10CV). The product fraction was evaporated to dryness then was dissolved in DMSO (2 mL) and a new purification was performed on Reverse Phase Buchi C850 Puriflash on C18 AQ IOOA 250x20, F = 25mL / min, Gradient 5 to 100% [ACN / 0.1% HCOOH] in [H2O / 0.1%HCOOH] (6CV). The product fraction was evaporated to dryness to afford Cpd-70 (6 mg, 0.011 mmol, 9%).1.21. Cpd-75Cpd-75

[0391] To a mixture of Int-83 (1 eq., 54 mg, 0.092 mmol) in MeOH (2 mL) was added Si-Propyl sulfonic acid (43 eq., 491 mg, 3.99 mmol) at rt. The resulting mixture was stirred at rt for 16 h. The mixture was filtered over frit and washed with MeOH. The filtrate was discarded and the solid on the frit was washed with 7N NH3 in MeOH. The filtrate was evaporated to dryness to give Cpd-75 (38 mg, 0.076 mmol, 83%).1.22. Int-76Int-76

[0392] To a solution of Int-77 (1 eq., 506 mg, 1.33 mmol) in EtOH (9.75 mL) was added portionwise NaBEL (2.5 eq., 125.8 mg, 3.33 mmol) and the mixture was stirred at rt for 20 h. The reaction mixture was concentrated to dryness then water and EtOAc were added. The layers were separated then the aq. layer was extracted once again with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by column chromatography on silica gel (eluting with Heptane / EtOAc from 90 / 10 to 20 / 80) to give Int-76 (120 mg, 0.405 mmol, 30%).1.23. Int-77

[0393] A mixture of 3-iodo-lH-pyrazole (CAS# 4522-35-4; 1 eq., 859.3 mg, 4.43 mmol), 1,3-diethyl 2-bromo-2-ethylpropanedioate (CAS# 29237-78-3; 1.2 eq., 1420 mg, 5.32 mmol) and K2CO3 (1 eq., 612.3 mg, 4.43 mmol) in DMF (8.59 mL) was stirred at 80 °C for 4 h. The reaction mixture was stirred at 80 °C for 20 h. After cooling down to rt, the reaction mixture was quenched with water and diluted with EtOAc. The layers were separated and the aq. layer was extracted twice with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by column chromatography on silica gel (Heptane / EtOAc from 100:0 to 50:50) to afford Int-77 (556 mg, 1.46 mmol, 33%).Table II. Intermediates use md towards the compounds of the invention.SM = Starting Material, Mtd = Method, MS Mes’d = Measured mass, NA = not measuredMSInt# Str Ouc ZI / = ture Name SM Mtd MW Mes’d N-((4-bromopyridin-2- CAS#\k C / / O 'Kc / ' ' yl)methyl) -4-methyl - 51522-22-6 [M+H]+Int-1 3- + Al 383.2 383.1(methylsulfonyl)benza CAS# 385.1 mide 865156-50-9CAS#4-(3- 591-18-4 [M+H]+Int-3 JOL bromophenyl)picolino + Bl 259.1 258.9 nitrile CAS#903513-60-0Int-34-(3-(l -methyl- 1H- CAS#pyrazol-3- [M+H]+Int-4 1^1 1897698-89-3 Bl 260.3H ] f N- yl)phenyl)picolinonitri 261.1+leCAS#1020174-04-2MS Int# Structure Name SM Mtd MW Mes’d tert-butyl ((4-(3-(l- CDiInt-50methyl - IH-pyrazol-3 - [M+H] u JL JI+N Int-4 Ex 364.40Hb H * y r 1= / >- yl)phenyl)85yridine-2- 365.2 yl)methyl)carbamate° -Z\(4-(3-(l -methyl- 1H- pyrazol-3- Int-5 [M+H]+Int-6 H2N^YY^yNvyl)phenyl)85yridine-2- Ex 264.3265.1 HCI N^1yl)methanaminehydrochloride salt4-methyl-3- (methylsulfonyl) -N - Int-1((4-(4,4,5,5-tetraethyl- + [M+H]+Int-7 „ 0 0 0-\ / — 12 486.4l,3,2-dioxaborolan-2- CAS# 487.2 yl)85yridine-2- 2247367-07-1 yl)methyl)benzamideCAS#3 -bromo -1 -((3- 14521-80-3methyloxetan-3 - Int-8Br— + H 231.1 - yl)mcthyl)-IH- CAS#pyrazole78385-26-9CAS#14521-80-3 [M+H]+3 -bromo - 1 -(oxetan-3 - Int-9 + H 217.1 217.0 ylmethyl) - 1 H-pyrazolcCAS# 219.0 1374014-30-8CAS#1261470-87-4Int-01~ J ethyl-3-(4-bromo-2- + Ex. 381.0 - 11 iodophenyl)acrylate£T CAS#867-13-0Int-11° 1 ethyl-3 -(4-bromo-2-( 1 - Int- +rcA° methyl- lH-pyrazol-3 - Ex 335.2 - 12 CAS#BrJ^ y yl)phenyl)acrylate1020174-04-2MS Int# Structure Name SM Mtd MW Mes’d O CAS#3 -(3 -bromophenyl) - 1 - 124-63-0 [M+H]+Int- JL M o (methylsulfonyl)- 1H- + K 301.2 301.0 13U / N'® o_pyrazole CAS# 302.9 b Qi 149739-65-1CAS#O^OEt 52864-55-8Int- diethyl 2-(2-bromo-4- Ex. 349.6+ - 14 chlorophenyl)malonate 1CAS#ora °"105-58-8O^OEt Int-14diethyl 2-(4-chloro-2- Int- + 350.8( 1 -methyl- IH-pyrazol- Bl - 15 JLJCJN° m CAS# 03 -yl)phenyl)malonate1020174-04-2JDH 2-(4-chloro-2-(l- Int- % methyl - lH-pyrazol-3 - 266.7 [M+H]+ZI Int-15 Ex.16 yl)phenyl)propane -1,3- 3 267.0 ilN__diolX3 -(5 -chloro-2-(oxetan- Int- / O ' 248.7 [M+H]+3 -yl)phenyl) - 1 -methyl - Int-16 C17 1 249.0IH-pyrazoleN-((4-(3- bromophenyl)pyridin- Int-7Int- [M+H]+2-yl)methyl)-4- +18 Bl 459.4 459.0 methyl-3- CAS#461.0 (methylsulfonyl)benza 591-18-4mideCAS#3-(2-bromo-5- 148836-41-3 [M+H]+Int- 271.6chlorophenyl)-l- + Bl 27 19CIJOC^ 0.9XLn-_4methyl - 1 H-py razole CAS# 272.91020174-04-2MS Int# Structure Name SM Mtd MW Mes’d on / O / -, l-(4-chloro-2-(l- ° / o < / «.Int- x\ "O / \ "O / _ _ methyl- lH-pyrazol-3 - 290.8 [M+H]+Int-19 Ex20CUIAJA 12N yl)phenyl)-4- 0 291.1° 2= N— methylpiperazine2o=' o o 4-methyl-3- i(methylsulfonyl) -N - Int-23((4-(3-(4, 4,5,5- + [M+H]+Int- tetraethyl-1,3,2- 12 562.521 CAS# 563.4 dioxaborolan-2- 2247367-07-1yl)phenyl)87yridine-2- yl)methyl)benzamideN-((4-bromopyridin-2- CAS#yl)methyl)-2,3- 2771132-16-0 [M+H]+dihydro-5H- Int- ° <-° n+ Al 411.2 411.1 22 < XXXQ benzo[e] [l,4]oxathiepiCAS# 413.1 ne-8-carboxamide 1,1- 865156-50-9dioxideCAS#methyl 4- i 906816-32-8o' (bromomethyl)-3- Ex. Int- + - 307.223 (methylsulfonyl)benzoCAS#ate128-08-5methyl 4- (methoxymethyl) -3 - [M+H]+Int- Int-23 Ex. 258.324 259.1 (methylsulfonyl)benzo Xu ate4-(methoxymethyl) -3 - [M-H]- Int- Int-24 D2 244.3 (methylsulfonyl)benzo25 243.0 ic acidCAS#(5-bromo-2- 69321-55-7 No Int- + methylphenyl)(methox Hl 247.2 ionizati jQT 26on ymethyl)sulfane CAS#13057-17-5MS Int# Structure Name SM Mtd MW Mes’d 4-bromo-2- No Int- 1 o ((methoxymethyl)sulfo Int-26 Ex 279.2 ionizati 27 \nyl)- 1 -methylbenzene on 3- XInt- tn ((methoxymethyl)sulfo [M-H]- Int-27 Ex. 244.328 nyl)-4-methylbenzoic 242.9 acidCAS#Br 676134-70-6Int- 4,6- Ex.Br^^ / L + 292.0 - 29 TX?° dibromoisochromaneCAS#7789-60-8CNInt- 4-cyanoisochromane- CAS# [M-H]'HO2C^^ A I Ex. 203.2 31 o 6-carboxylic acid 2682047-65-8 201.9MJo7V-((4-(4, 4,5,5- tetraethyl-1,3,2- J> / / Cl / ' dioxaborolan-2- 1 o Int-22yl)88yridine-2- Int- + [M+H]+yl)methyl)-2,3- 12 514.432 CAS# 515.3 di hydro -5H- 2247367-07-1benzo [e] [ 1 ,4] oxathiepine-8-carboxamide 1,1- dioxideJV-((4-bromopyridin-2- Int-28yl)methyl)-3- + [M+H]+Int- ((methoxymethyl)sulfo CAS# Al 413.3 413.1 33 / ° XXSO nyl)-4- 865156-50-9 415.2 methylbenzamideMS Int# Structure Name SM Mtd MW\ Mes’d o 3- ((methoxymethyl)sulfoz — Int 33°?co nyl)-4-methyl-JV-((4- Int- + [M+H]+(4, 4, 5, 5 -tetraethyl - 12 516.534 CAS# 517.2 co \ l,3,2-dioxaborolan-2- 2247367-07-1yl)89yridine-2- yl)methyl)benzamide3-(JV-acetyl-A- Int- 0 o O 0 CAS# [M+H]+methylsulfamoyl)benz Ex. 257.335 N1kJ OH 35623-11-1 258.1 oic acidmethyl 3-(N-(2- methoxy ethyl) -N- CAS#methylsulfamoyl)benz 63555-50-0Int- [M+H]+oatemethyl 3-(N-(2- + Ex. 287.336 288.2 methoxy ethyl) -N- CAS#methylsulfamoyl)benz 38256-93-8oateCAS#2-((5-bromo-2- 69321-55-7 No Int- methylphenyl)thio)eth + Hl 247.1 ionizati 39Ho^sxyBran-l-ol CAS# on 540-51-2Br2-((5-bromo-2- No Int- methylphenyl)sulfonyl Int-39 K 279.1 ionisati 40^4 )ethan-l-ol on X)HO^OH3-((2- No Int- hydroxyethyl)sulfonyl) Int-40 G 244.3 ionisati 41-4-methylbenzoic acid onSDHMS Int# Structure Name SM Mtd MW Mes’d Br2-((5-bromo-2- Int-40Int- methylphenyl)sulfonyl + 306.2Ex - 42^4 )-N,N -dimethylethan- CAS# 21 -amine 124-40-31methyl 3-((2- Int- (dimethylamino)ethyl) Ex. 285.3 [M+H]+Int-4243 sulfonyl)-4- 6 286.2^ 4 methylbenzoate13-((2- CO2H (dimethylamino)ethyl)Int- 271.3 [M+H]+sulfonyl)-4- Int-43 DI44 3 272.2 ffi O- methylbenzoic acid1 0 olithium salt0ZT CAS#rac-(R)-N-((4- (O=865156-50-9N o bromopyridin-2- [M+H]+Int- x'i / s0 +Z^ O ■ yl)methyl)-4-cyano-4- A2 386.3 386.2 49 CAS# o^yra8' methylisochromane-6- 388.22677883-72-4carboxamiderac-(R)-4-cyano-4- methyl-N-((4-(4, 4,5,5- Int-49tetraethyl-1,3,2- Int- + [M+H]+dioxaborolan-2- 12 489.450 CAS# 490.3 yl)pyridin-2- 2247367-07-1 yl)methyl)isochromane-6-carboxamideMS Int# Structure Name SM Mtd MW Mes’d rac-(R)-N-((4-(3- bromo-4- Int-50methoxyphenyl)pyridi [M+H]+Int- +n-2-yl)methyl)-4- Bl 492.4 492.1 51 CAS#cyano-4- 494.1182056-39-9methylisochromane-6- carboxamiderac-(R) -4-cyano-N - ((4-(4-methoxy-3- (4, 4, 5, 5 -tetramethyl - Int- l,3,2-dioxaborolan-2- [M+H]+Int-51 II 539.452 yl)phenyl)pyridin-2- 540.3 yl)methyl)-4- methylisochromane-6- carboxamide% CAS#2248309-39-7Int- o-yo methyl 4 -methyl -3- +Ex 206.161 (oxetan-3 -yl)benzoate CAS#JU090347-66-3BrInt- 4,6- CAS#Ex 289.963 dibromoisochromane 676134-68-2EtO2C^CO2Et diethyl 2-(6- Int- bromoisochroman-4- Int-63 Ex 370.064yl)malonateuQ>HCKU^UDH 2-(6- Int- bromoisochroman-4- Int-64 Ex 286.065yl)propane - 1 , 3 -diol•CQMS Int# Structure Name SM Mtd MW Mes’dInt- 6-bromo-4-(oxetan-3- Int-65 C 268.066 yl)isochromaneN-((4-(3-bromo-4- methoxyphenyl)pyridin-2-yl)methyl) -2,3- CAS# [M+H]+Int- I? rr°" dihydro-5H- 182056-39-9 Bl 517.4 517.1 70 Qyro-0* benzo[e] [l,4]oxathiepi + 519.1 ne-8-carboxamide 1,1- Int-32dioxideN-((4-(3-bromo-4- o tno —-y °~~^methoxyphenyl)pyridi[M+H]+Int- 1 n-2-yl)methyl)-3- ozo 2 $ r ii Int-34 Bl 519.4 519.1 71 ((methoxymethyl)sulfoJU ZIHU 521.1 nyl)-4- i methylbenzamidexol / 'xN-((4-(4-methoxy-3- (4, 4, 5, 5 -tetramethyl - l,3,2-dioxaborolan-2- Int- yl)phenyl)pyridin-2- [M+H]+Int-71 II 566.572 yl)methyl)-3- 567.3((methoxymethyl)sulfonyl)-4- methylbenzamideMS Int# Structure Name SM Mtd MW Mes’d N-((4-(4-methoxy-3- i C (4, 4, 5, 5 -tetramethyl - l,3,2-dioxaborolan-2- yl)phenyl)pyridin-2- Int- [M+H]+yl)methyl)-2,3- Int-70 13 564.574 565.4 dihydro-5H- benzo[e] [l,4]oxathiepine-8-carboxamide 1,1- dioxidel\ ^N r~OInt- 1 -(3 -ethyloxetan-3 -yl)- [M+H]+— Int-76 C 278.175 3 -iodo - IH-pyrazole 279.0^OH 2-ethyl-2-(3-iodo-lH- Int- I^N / Q fflO- [M+H]+pyrazol - 1 -yl)propan Int-77 Ex 296.176 X' N-7 — v e - 297.1 \ O 1,3 -diol$ HZI CAS#diethyl 2-ethyl-2-(3- 4522-35-4Int- [M+H]+iodo- IH-pyrazol- 1 - + Ex 380.277 381.0 yl)malonate CAS#29237-78-3(4-(4-methoxy-3 -( 1 - (3 -methyloxetan-3 -yl)- 1Int- ■5TFA l^jT0lH-pyrazol-3- [M+H]+Int-79 L 350.478 H2N^Y^r ^ TN'N-U yl)phenyl)pyridin-2- 351.3L-0yl)methanamine TFAsalttert-butyl ((4-(4- CAS#methoxy-3-(l-(3- Int- 1 2468058-13-9 [M+H] 1 ° rr°+methyloxetan-3 -yl) - Bl 450.579 H Y j YHn + 451.4L-o lH-pyrazol-3- Int-80yl)phenyl)pyridin-2- yl)methyl)carbamateMS Int# Structure Name SM Mtd MW Mes’d (tert-butyl ((4-(4- IZc methoxy-3-(4,4,5,5- Z z= IZInt- w tetraethyl-1,3,2- [M+H]+Int-81 12 496.580 o dioxaborolan-2- 497.4OW O —- vVJo yl)phenyl)pyridin-2- ° O“ yl)methyl)carbamatetert-butyl ((4-(3- CAS#1 bromo-4- [M+H]+Int- 182056-39-9i ° rr°"4 u JL JI methoxyphenyl)pyridi Bl 393.3 393.3 81 "" X) N Ti — Br +HM n-2- 395.3Int-82yl)methyl)carbamatetert-butyl ((4-(4, 4,5,5 - tetraethyl-1,3,2- Int- CAS# [M+H]+dioxaborolan-2- 12 390.382 1060813-12-8 391.3CD O •— yl)pyridin-2- yl)methyl)carbamatep N-((4-(4-methoxy-3- ZI( 1 -(tetrahydro-2H- opyran-2-yl)-lH- pyrazol-5- Int-70Int- yl)phenyl)pyridin-2- + [M+H]+Bl 588.783 yl)methyl)-2,3- CAS# 589.4 dihydro-5H- 903550-26-5benzo[e] [l,4]oxathiepine-8-carboxamide 1,1- dioxide(4-(4-methoxy-3 -( 1 - i (3 -methyloxetan-3 -yl)- Int- [M+H]+lH-pyrazol-3- Int-79 L 350.284 351.3'== / O yl)phenyl)pyridin-2- yl)methanamineMS Int# Structure Name SM Mtd MW Mes’d (4-(4-methoxy-3 -( 1 - 1^x^O methyl- lH-pyrazol-3 - Int- [M+H]+yl)phenyl)pyridin-2- Int-86 L2 294.285 H2N^V^ YNV 295.1 yl)methanamineH-CIhydrochloridetert-butyl ((4-(4- Int-801 methoxy-3 -(1 -methyl - Int- + [M+H]+lH-pyrazol-3- B3 394.586 O N Ti r5^ \i _ C 395.4 ^xk 1 H H N AS#N^l yl)phenyl)pyridin-2- 151049-87-5yl)methyl)carbamate2-(4-(2- OH (aminomethyl)pyridin- Int- 4-yl)-2-(l -methyl- 1H- [M+H]+^X / O Int-88 L2 324.287 pyrazol-3- 325.2 H2N / VY^ / YN'N'H-CIN--A yl)phenoxy)ethan- 1 -olhydrochloridetert-butyl ((4-(4-(2- OH Int-89hydroxy ethoxy) -3 -( 1 - Int- + [M+H]+methyl- lH-pyrazol-3 - B3 424.588 ° rr°CAS# 425.3 O I N H T IiI ^*7 \ , i _ yl)phenyl)pyridin-2- ^xk N^lN1020174-04-2 yl)methyl)carbamatetert-butyl ((4-(3- OH Int-82bromo-4-(2- [M+H]+Int- +hydroxyethoxy)phenyl Bl 423.3 423.1- 89 X ° L rr II ° CAS#O N Br )pyridin-2- 425.1 x[xHM 866929-98-8yl)methyl)carbamateTable III. Illustrative compounds of the invention.SM = Starting Material, Mtd = Method, MS Mes’d = Measured mass / OxMSCpd# Structure Name SM Mtd MW Mes’d «: IZ4-methyl-N-((4-(3-(l- Int-23o methyl- lH-pyrazol-3 - o O + [M+H] Cpd- yl)phenyl)pyridine-2- 460.CAS# Bl + 1\ yl)methyl)-3- 5' z 1020174 461.1 (methylsulfonyl)benza6 -04-2mideN-((4-(3-(l-methyl- lH-pyrazol-3- Int-22yl)phenyl)pyridine-2- + [M+H] Cpd- %0 Al yl)methyl)-2,3- 488. +CAS# Bl 62 ay-sxrV- dihydro-5H- 1020174 489.3 benzo [e] [ 1 ,4] oxathiepi-04-2ne-8-carboxamide 1,1- dioxide4-methyl-N-((4-(3-(l- ( 1 -methylpiperidin-4- Cpd-6yl)-lH-pyrazol-3- [M+H] Cpd- + 543. + yl)phenyl)pyridine-2- Ex 75 CAS#yl)methyl)-3- 544.450-00-0 (methylsulfonyl)benzamide4-methyl-3- (methylsulfonyl) -N - [M+H] Cpd- ,0 ? r^il ((4-(3-(l-(piperidin-4- ^st JU JU C L 529.pd-7 + 6 yl)-lH-pyrazol-3- 7530.4 yl)phenyl)pyridine-2- yl)methyl)benzamideMS Cpd# Structure Name SM Mtd MW Mes’d \% / / tert-butyl 4-(3-(3-(2- ((4-methyl-3- Int-21IZ (methylsulfonyl)benza+ [M+H] Cpd- mido)methyl)pyridine 629.s n po CAS# Bl 8 + 7 -4-yl)phenyl)-lH- 1211876o 630.5 pyrazol-1- -26-4i c z yl)piperidine-l- 1carboxylate3-(N,N- CAS#dimethylsulfamoyl)- 7326- [M+H] Cpd- N-((4-(3-(l-methyl- X 73-0 Al 475. + 8 z 11 z lH-pyrazol-3- 6p zp = = + 476.1 yl)phenyl)pyridine-2- pzInt-6o O yl)methyl)benzamide4-(methoxymethyl)- Qp pZI N-((4-(3-(l-methyl- zx ZIlH-pyrazol-3- Int-25 [M+H] Cpd- 5 % yl)phenyl)pyridine-2- + Al 490. + 9 x Wzz - - p° ' 6 \ / \O ' yl)methyl)-3- Int-6 491.1(methylsulfonyl)benzamide3-(N,N- CAS#dimethylsulfamoyl)-4- 926248- [M+H] Cpd- methyl-N-((4-(3-(l- 01-3 Al 489. + 10 methyl- lH-pyrazol-3 - 6+ 490.2 yl)phenyl)pyridine-2- Int-6 yl)methyl)benzamideN-((4-(3-(lH-pyrazol- 3- Int-23yl)phenyl) 97 yridine- + [M+H] Cpd- 2-yl)methyl)-4- CAS# Bl 446. + 11 5methyl-3- 844501- 447.1 (methylsulfonyl)benza 71-9mideMS Cpd# Structure Name SM Mtd MW Mes’d (R)-4-cyano-4-methyl- Int-6N-((4-(3-(l-methyl- +Cpd- lH-pyrazol-3- [M+H]Nv A nbCAS# Al+12 r 1 ^ ®T N H 7 Hi K NI— 463.5yl)phenyl)98yridine-2- 464.32677883- yl)methyl)isochromane72-4-6-carboxamide(S)-4-cyano-4-methyl- CAS#N-((4-(3-(l-methyl- 2677883- Cpd- ,N lH-pyrazol-3- X. / ' n L il [M+H]71-3 Al+r^MTi N 7| T5^ \ 463.513 1 H N|— yl)phenyl)98yridine-2- 464.2+yl)methyl)isochromaneInt-6-6-carboxamide3- ((methoxymethyl)sulfonyl)-4-methyl-N-((4- Int-28Cpd- Os zO ? n il [M+H](3 -(1 -methyl -lH- + Al+490.614 ]| 1 H H 7 I N 491.1 pyrazol-3- Int-6yl)phenyl)98yridine-2- yl)methyl)benzamide4-methyl-N-((4-(3-(l- ((3 -methyloxetan-3 - yl)methyl)- IH-pyrazol- Int-8Cpd- [M+H]+A y° <%y^ £N^j^yA A:J^N >N_ / \ 3-yl)phenyl)98yridine- + Bl 530.615 531.22-yl)methyl)-3- Int-21 (methylsulfonyl)benzamide4-methyl-3- (methylsulfonyl) -N - Cpd- ((4-(3-(l-(oxetan-3- Int-21 [M+H] i-° A n+Bl 516.616 ylmethyl)- IH-pyrazol- + 517.23-yl)phenyl)98yridine- Int-92-yl)methyl)benzamideMS Cpd# Structure Name SM Mtd MW Mes’d 4-methyl-3- Int-23) (methylsulfonyl) -N - n %: +Cpd- ((4-(3 -( 1 -(oxetan-3 -yl)- Bl [M+H]+CAS#Z=502.6 17 \ lH-pyrazol-3- 503.2o) K 2924752- yl)phenyl)pyridine-2- o O 26-9z / yl)methyl)benzamide\ 1i H CZ / ' z 4-methyl-3- ' z Int-23(methylsulfonyl) -N - +Cpd- ((4-(3-(l-phenyl-lH- [M+H]CAS# Bl+522.618 pyrazol-3- 524.31002334- yl)phenyl)pyridine-2- 13-5yl)methyl)benzamideCAS#p100523- W 4-methyl-N-((2’-(l- 96-4methyl- lH-pyrazol-3 - +Cpd- yl)-[4,4’-bipyridin]-2- [M+H]Int-7 B+461.519 yl)methyl)-3- + 462.2 (methylsulfonyl)benzaCAS#mide1020174- 04-24-cyano-N-((4-(3-( 1 - methyl- lH-pyrazol-3 - Int-31Cpd- [M+H] yl)phenyl)pyridine-2- + Al+449.520 450.1 yl)methyl)isochromane Int-6-6-carboxamideN-((4-(3-(l,5- Int-23dimethyl- IH-pyrazol- +Cpd- V S A 3 -yl)phenyl)pyridin-2- [M+H]+CAS# Bl2 Y 474.6 1 ^ yl)methyl)-4-methyl-3- 475.42243322- (methylsulfonyl)benza62-3mideMS Cpd# Structure Name SM Mtd MW Mes’d 4-methyl-N-((4-(3-(l- methyl- lH-pyrazol-3 - yl)-4-(oxetan-3- Int-17Cpd- r~° [M+H])ph nyl pyr ++yl e ) idin-2- Bl 516.622 / YAAY H N »^ ]1\ A / N- 517.2 yl)methyl)-3- Int-7 (methylsulfonyl)benzamideN-((4-(3-(l-(2- methoxy ethyl) - 1 H- Int-21pyrazol-3- +Cpd- 0 0 rf^<-01 [M+H] yl)phenyl)pyridin-2- CAS# Bl+523 °'^Qi 04.6505.5 yl)methyl)-4-methyl-3- 1512429- izUZ(methylsulfonyl)benza 29-6O mideo 4-methyl-N-((4-(3-(l- / zZI methyl- lH-pyrazol-3 - yl)-4-(4- Int-7Cpd- / 0 ' i methylpiperazin- 1 - [M+H]+? — Bl+°zA nrNx>558.7 25 yl)phenyl)pyridin-2- 559.3Int-20yl)methyl)-3- (methylsulfonyl)benzamide3-(isopropylsulfonyl)- CAS#N-((4-(3-(l-methyl- 20884- Cpd- Os ,o 9 [* || [M+H] \XzXvvYM lH-pyrazol-3- 64-4 Al+426 T II T T T ,N" 74.6HNII-A '= / 475.2 yl)phenyl)pyridin-2- +yl)methyl)benzamide Int-63-(isopropylsulfonyl)- CAS#4-methyl-N-((4-(3-(l- 1152497- Cpd- [M+H] methyl- lH-pyrazol-3 - 12-5 Al+488.627 489.2 yl)phenyl)pyridin-2- +yl)methyl)benzamide Int-6MS Cpd# Structure Name SM Mtd MW Mes’d / / O OxIZ WO \x, « —o= / < / N-((4-(3-(l-methyl- z CAS#A lH-pyrazol-3- M) IZco= 35623- Cpd- IZ iz yl)phenyl)pyridin-2- [M+H]11-1 Al+28 oZZ z= 461.5z= yl)methyl)-3-(N- 462.2 *w +o methylsulfamoyl)benzao Int-6oi C mideHi C' z N-((4-(4-methoxy-3- 6 1 1( 1 -methyl- IH-pyrazol- Int-7Cpd- 3 -yl)phenyl)pyridin-2- + [M+H]Bl+490.629 Y i H YY f N- yl)methyl)-4-methyl-3- CAS# 491.4(methylsulfonyl)benza 1360444- mide 97-8N-((4-(3-(l-methyl- CAS#lH-pyrazol-3- 5345-27- [M+H]+yl)phenyl)pyridin-2- Cpd- ox zo 9 1* 117 Al 446.5 447.1 YY H ii Y r / n" 30 yl)methyl)-3- +(methylsulfonyl)benzaInt-6mideN-((4-(3-(l-methyl- CAS#lH-pyrazol-3- 1521806- yl)phenyl)pyridin-2- Cpd- [M+H]+48-3 Al 435.531 yl)methyl)-l- 436.1+(methylsulfonyl)- 1H- Int-6pyrrole -3 -carboxamide4-methyl-3- (methylsulfonyl) -N - Int-21+ ((4-(3 -( 1 -(tetrahydro - Cpd- [M+H]+2H-pyran-4-yl)- 1H- Bl CAS# 530.632 531.5 pyrazol-3- 1227954- yl)phenyl)pyridin-2- 60-0yl)methyl)benzamideMS Cpd# Structure Name SM Mtd MW Mes’d / ex,C / K \ N-((2'-(l -methyl- 1H- pyrazol-3-yl)-[4,4'- A TZ Int-32bipyridin]-2- / Z= +Cpd- O yl)methyl)-2,3- [M+H]CAS# Bl+489.633 dihydro-5H- 490.2< z= 2378820- benzo [e] [ 1 ,4] oxathiepi33-6^ OzX | ne-8-carboxamide 1,1- dioxide4-methyl-N-((4-(3-(l- (3 -methyloxetan-3 -yl)- Int-21lH-pyrazol-3- +Cpd- [M+H] yl)phenyl)pyridin-2- CAS Bl+# 516.634 517.7z yl)methyl)-3- 2468058- pz(methylsulfonyl)benza 13-9mideo / zN-((4-(3 -( 1 -(2-amino- zx 2-oxoethyl)-lH- Int-21pyrazol-3- +Cpd- s ° [M+H] _ .o < yl)phenyl)pyridin-2-+CAS# Bl 503.635 504.4 yl)methyl)-4-methyl-3- 1233525- (methylsulfonyl)benza 74-0mideN-((4-(4-methoxy-3- ( 1 -methyl- IH-pyrazol- Int-323 -yl)phenyl)pyridin-2- +Cpd- O o 0 yl)methyl)-2,3- [M+H]+CAS# Bl 518.636 dihydro-5H- 519.41360444- benzo [e] [ 1 ,4] oxathiepi97-8ne-8-carboxamide 1,1- dioxideMS Cpd# Structure Name SM Mtd MW Mes’d ethyl (E)-3-(2-(l- methyl- lH-pyrazol-3 - 0 Int-7Cpd- yl)-4-(2-((4-methyl-3- [M+H]+ Bl+558.737 T 1 H » Y \ N- (methylsulfonyl)benza 559.3Int-12 mido)methyl)pyridin- 4-yl)phenyl)acrylate(E)-3-(2-(l-methyl-lH- pyrazol-3-yl)-4-(2-((4- 0 methyl-3- Cpd- 0,0 0 f=!^Y^A'OH [M+H](methylsulfonyl)benza Cpd-37 DI+530.638YT H « T i ,N" 531.3 mido)methyl)pyridin- 1 4-yl)phenyl)acrylicYYfacidzp w = 4-chloro -N-((4-(3 -( 1 - CAS#O o methyl- lH-pyrazol-3 - / z51522- Cpd- °s z° 9 ZI \Y~ \ n yl)phenyl)pyridin-2- / z[M+H]07-7 Al+4839 YY ZI H « Y \ ,N" 0.9CIYU M yl)methyl)-3- 481.1+W 'X(methylsulfonyl)benzas> °'\ / oW' Int-6o \' mideN-((4-(4-methoxy-3- ( 1 -methyl- IH-pyrazol- Int-343 -yl)phenyl)pyridin-2- +Cpd- [M+H]+yl)methyl)-3- CAS# Bl 520.640 521.2((methoxymethyl)sulfo 1360444- nyl)-4- 97-8methylbenzamideN-((4-(3 -( 1 -(3 -amino- 3 -oxopropyl) -1H- pyrazol-3- Cpd-11Cpd- + [M+H] yl)phenyl)pyridin-2-+CAS# H 517.641 518.5 yl)methyl)-4-methyl-3- 5875-24- 1(methylsulfonyl)benzamide formic acid saltMS Cpd# Structure Name SM Mtd MWMes’d °? « \ 4-methyl-3- A (methylsulfonyl) -N - IZ((4-(3-(l-Z=\ Int-7Cpd- w (methylsulfonyl)- 1H- [M+H]+ Bl+524.642 pyrazol-3- O 526.3Int-13i r yl)phenyl)pyridin-2- ' zyl)methyl)benzamideformic acid saltN-((4-(3-(l-(2- (dimethylamino)-2- oxoethyl)- IH-pyrazol- Cpd-11Cpd- o 9 9x / + [M+H]JA\ 1 3 -yl)phenyl)pyridin-2- H+z CAS# 531.643 XJ ” NJ X / Nyl)methyl)-4-methy 5468-77- 532.3 pzl-3- 9vJ* (methylsulfonyl)benzamide / zZI N-((4-(3-(l- (cyanomethyl) - 1 H- sZWpyrazol-3- Cpd-11Cpd- z- Y V i A / / / [M+H])ph nyl ++° yl e )pyridin-2- H44 YY H H 4 f N-7485.6 AAA t= / 486.1 yl)methyl)-4-methyl-3- CAS# (methylsulfonyl)benza 590-17-0mide3-(N-acetyl-N- methylsulfamoyl) -N - Int-6Cpd- ((4-(3-(l-methyl-lH- [M+H]+ Al+503.645 pyrazol-3- 504.3Int-35yl)phenyl)pyridin-2- yl)methyl)benzamideMS Cpd# Structure Name SM Mtd MW Mes’d / I' oIZO o'z 3-(N-(2- t toomethoxy ethyl) -N - Aiz methylsulfamoyl) -N - Int-36Cpd- % IZ IZ [M+H]z ( 4 ( - l m t y - H ++Z= ( - 3 ( - e h l l - Ex 46 / ZZ==\ 519.6O O 520.3 w pyrazol-3- Int-6O O yl)phenyl)pyridin-2- (C ri c r'' z z yl)methyl)benzamide' 1 z 1 1 3-((2- methoxyethyl)sulfonyl) CAS#Cpd- -N-((4-(3-(l-methyl- 1094294- Al [M+H]+490.648 lH-pyrazol-3- 44-6 491.31z 1z yl)phenyl)pyridin-2- +yl)methyl)benzamide Int-6O 3-((2- O CAS#O / z / zmethoxyethyl)sulfonyl)ZI 1094238- Cpd- ZI -4-methyl-N-((4-(3-(l- [M+H]30-8 Al+504.649 methyl- lH-pyrazol-3 - 505.3; owb ' +' Z ZOTz— yl)phenyl)pyridin-2- Int-6O o\ / yl)methyl)benzamide3-((2- hydroxyethyl)sulfonyl) CAS#Cpd- -N-((4-(3-(l-methyl- 7180-11- [M+H]Al+476.650 lH-pyrazol-3- 2 477.1 yl)phenyl)pyridin-2- +yl)methyl)benzamide Int-64-methyl-N-((4-(3-(l- methyl- lH-pyrazol-3 - CAS#Cpd- yl)phenyl)pyridin-2- 90610- [M+H]+Al 475.651 yl)methyl)-3-(N- 74-5 476.3 methylsulfamoyl)benza +mide Int-6MS Cpd# Structure Name SM Mtd MW Mes’d I X N O>f 1o. N-((4-(3-(l-(2- b' °\1J hydroxy ethyl) - 1 H- Ao=TZ z Cpd 11zz- pyrazol-3- Cpd- A / Z=xz +w [M+H]+Z z= yl)phenyl)pyridin-2- H 490.652 0 CAS#O 491.2 O yl)methyl)-4-methyl-3- O 540-51-2O' z (methylsulfonyl)benzai C' z z O mide1 1 X3-((2- hydroxyethyl)sulfonyl)Int-6Cpd- -4-methyl-N-((4-(3-(l- [M+H]+ Al+490.653 methyl- lH-pyrazol-3 - 491.2Int-41yl)phenyl)pyridin-2- yl)methyl)benzamide3-((2- (dimethylamino)ethyl)sulfonyl) -4-methyl -N - Int-44Cpd- q. a 9 p ll [M+H]((4-(3-(l-methyl-lH- + Al+517.6541 HN^l U / 518.3 pyrazol-3- Int-6yl)phenyl)pyridin-2- yl)methyl)benzamide(R)-4-cyano-N-((4-(4- methoxy-3-(l-(3- CAS#methyloxetan-3 -yl)- 2468058- Cpd- lH-pyrazol-3- [M+H]+55 Z^^XLN r° 13-9 Bl 549.2 Cusyl)phenyl)pyridin-2- 550.3XT t^ +yl)methyl)-4- Int-52methylisochromane-6- carboxamidel-methyl-N-((4-(3-(l- methyl- lH-pyrazol-3 - CAS#Cpd- yl)phenyl)pyridin-2- 1515029- [M+H]+Al 450.258 yl)methyl)-5- 32-9 451.1 sulfamoyl- IH-pyrrole- +3 -carboxamide Int-6MS Cpd# Structure Name SM Mtd MW Mes’d / 1 „O Oc=noc=p=Q=l-methyl-N-((4-(3-(l- Int-6z—W \-S methyl- lH-pyrazol-3 - 4 20= +Cpd- IZ TZ yl)phenyl)pyridin-2- [M+H]+A CAS# Al 59 iz 449.2yl)methyl)-5- 450.2 o wZ z= 1541588- O (methylsulfonyl)- 1H- 74-2O O pyrrole -3 -carboxamidei c' zzZ' 1 z1 1 l-methyl-N-((4-(3-(l- CAS#methyl- lH-pyrazol-3 - 1935943- Cpd- yl)phenyl)pyridin-2- [M+H]+85-3 Al 449.265 yl)methyl)-4- 450.2+(methylsulfonyl)- 1H- Int-6pyrrole-2 -carboxamide3-(N-(2- methoxy ethyl) -N - Int-6methylsulfamoyl)-4- +Cpd- [M+H]+methyl-N-((4-(3-(l- CAS# Al 533.266 534.3 methyl- lH-pyrazol-3 - 1183830- yl)phenyl)pyridin-2- 59-2yl)methyl)benzamide3 -(N -acetylsulfamoyl) - Int-6N-((4-(3-(l-methyl- +Cpd- H o o [M+H]+lH-pyrazol-3- CAS# Al67 o o T V B YY X / N" 489.5'’xiZ 490.1 yl)phenyl)pyridin-2- 28011- yl)methyl)benzamide 76-93-(N,N- diethylsulfamoyl) -N - Int-6Cpd- ((4-(3-(l-methyl-lH- + [M+H]+QNY55 A Al 503.6 68 o r II H H Y T ,N-pyrazol-3- CAS# 504.N'Yl== / 2 yl)phenyl)pyridin-2- 1576-46- yl)methyl)benzamide 1MS Cpd# Structure Name SM Mtd MW Mes’d N-((4-(3-(l-methyl- lH-pyrazol-3- Int-6Cpd- yl)phenyl)pyridin-2- + [M+H]+Al 501.669 yl)methyl)-3- CAS# 502.2(pyrrolidin-1- 7326-79- 6 ylsulfonyl)benzamide2-(3-(3-(2-((4-methyl- 3- CAS# (methylsulfonyl)benza 1072-53- Cpd- x. ,P H A [M-H]- o YY H mido)methyl)pyridin- 3 ExJMH j i ,I ^ >N-\ „A N l 570.6 70 = / X-0,sxo, ' 569.30OH 4-y +l)phenyl)-lH- pyrazol- 1 -yl)ethyl Cpd-11 p _ O1zz hydrogen sulfateN-((4-(4-methoxy-3- CAS#vP( 1 -(3 -methyloxetan-3 - 73183- o / zp yl)-lH-pyrazol-3- 34-3 ZIZI+ yl)phenyl)pyridin-2- [M+H]+Cpd- O n 0x OTh I yl)methyl)-2,3- CAS# J 574.7> °' 71 568.4 o o°' \ dihydro-5H- 2468058- 13-9 benzo [e] [ 1 ,4] oxathiepi+ ne-8-carboxamide 1,1- Int-70 dioxideN-((4-(4-methoxy-3- ( 1 -(3 -methyloxetan-3 - CAS#yl)-lH-pyrazol-3- 2468058- yl)phenyl)pyridin-2- [M+H]+Cpd- 13-9 Bl 576.772 yl)methyl)-3- 577.4+((methoxymethyl)sulfoInt-72nyl)-4- methylbenzamideMS Cpd# Structure Name SM Mtd MW Mes’d N-((4-(4-methoxy-3- Int-70(4-methyl-l-(3- +A methyloxetan-3 -yl)- CAS#o lH-pyrazol-3- w 73183- Cpd- yl)phenyl)pyridin-2- [M+H]+34-3 J 588.773 Yv yl)methyl)-2,3- 589.4' zn +dihydro-5H- CAS#d _ _ benzo [e] [ 1 ,4] oxathiepi3034997- ne-8-carboxamide 1,1- 23-1dioxide3-((2- hydroxyethyl)sulfonyl)-N-((4-(4-methoxy-3- Int-41Cpd- ( 1 -(3 -methyloxetan-3 - [M+H]++ A2 576.774 yl)-lH-pyrazol-3- 577.3Int-78yl)phenyl)pyridin-2- yl)methyl)-4- methylbenzamideN-((4-(4-methoxy-3- (lH-pyrazol-5- yl)phenyl)pyridin-2- Cpd- yl)methyl)-2,3- Ex [M+H]+Int-83 504.675 dihydro-5H- 505.3 c5y x / Y>benzo [e] [ 1 ,4] oxathiepine-8-carboxamide 1,1- dioxideMS Cpd# Structure Name SM Mtd MW Mes’d N-((4-(4-methoxy-3- ( 1 -(methylsulfonyl)- lH-pyrazol-3- Cdp-75yl)phenyl)pyridin-2- Cpd- X + [M+H]+yl)methyl)-2,3- K 582.776 N-NOCAS# 583.3 dihydro-5H- 124-63-0benzo [e] [ 1 ,4] oxathiepine-8-carboxamide 1,1- dioxideN-((4-(3-(l-(3- ethyloxetan-3 -yl)- 1H- pyrazol-3-yl)-4- methoxyphenyl)pyridin Int-74Cpd- f'Y0'' [M+H]+-2-yl)methyl)-2,3- + Bl 588.777 589.4 dihydro-5H- Int-75benzo [e] [ 1 ,4] oxathiepine-8-carboxamide 1,1- dioxide(R) -4, 9 -difluoro -N-((4- (4-methoxy-3-(l-(3- methyloxetan-3 -yl)- Int-78lH-pyrazol-3- +Cpd- yl)phenyl)pyridin-2- [M+H]+CAS# A3 610.678 yl)methyl)-3,4- 611.33008582- dihydro-2H- 46-2benzo [b] [ 1 ,4] oxathiepine-7-carboxamide 5,5- dioxideIllMSCpd# Structure Name SM Mtd MW Mes’d r k° (R)-9-chloro-4-fluoro- N-((4-(4-methoxy-3- Azz ( 1 -(3 -methyloxetan-3 - Int-78yl)-lH-pyrazol-3- + [M+H] Cpd- o yl)phenyl)pyridin-2-+CAS# A3 627.1 627.3 79 yl)methyl)-3,4- Cl 3008582- 629.3 dihydro-2H- 64-4benzo [b] [ 1 ,4] oxathiepine-7-carboxamide 5,5- dioxideN-((4-(4-methoxy-3- Int-70( 1 -(tetrahydro -2H- +pyran-4-yl)-lH- CAS#pyrazol-5- 73183- Cpd- yl)phenyl)pyridin-2- [M+H]+34-3 J 588.780 yl)methyl)-2,3- 589.4+dihydro-5H- CAS#benzo [e] [ 1 ,4] oxathiepi1650546- ne-8-carboxamide 1,1- 67-0dioxideN-((4-(4-methoxy-3- Int-70( 1 -(tetrahydro -2H- +pyran-4-yl)-lH- CAS#pyrazol-3- 73183- Cpd- 0 o 0 yl)phenyl)pyridin-2- [M+H]+34-3 J 588.781 dy'axroct^° yl)methyl)-2,3- 589.4+dihydro-5H- CAS#benzo [e] [ 1 ,4] oxathiepi1540221- ne-8-carboxamide 1,1- 68-8dioxideMS Cpd# Structure Name SM Mtd MW Mes’d (R) -2, 6 -difluoro -N-((4- y(s° V= / soW ■"~ (4-methoxy-3 -( 1 - °=o / =z zz IZ zz methyl- lH-pyrazol-3 - Int-85yl)phenyl)pyridin-2- +Cpd- o o o yl)methyl)-2,3- CAS# A2 554.6 555.3 82o dihydro-5H- 3008582- O r'' z z11 benzo [e] [ 1 ,4] oxathiepi 33-7' z1 ne-8-carboxamide 1,1- dioxide(R)-9-chloro-4-fluoro- N-((4-(4-methoxy-3- ( 1 -methyl- IH-pyrazol- Int-853 -yl)phenyl)pyridin-2- +Cpd- yl)methyl)-3,4- CAS# A2 571.0 571.1 83dihydro-2H- 3008582- benzo [b] [ 1 ,4] oxathiepi 64-4ne-7-carboxamide 5,5- dioxide(R) -4, 9 -difluoro -N-((4- (4-methoxy-3 -( 1 - methyl- lH-pyrazol-3 - Int-85yl)phenyl)pyridin-2- +Cpd- yl)methyl)-3,4- CAS# A2 554.6 555.1 84dihydro-2H- 3008582- benzo [b] [ 1 ,4] oxathiepi 46-2ne-7-carboxamide 5,5- dioxideMS Cpd# Structure Name SM Mtd MW Mes’d (R) -2, 6 -difluoro -N-((4- (4-methoxy-3-(l-(3- methyloxetan-3 -yl)- Int-84lH-pyrazol-3- +Cpd- fY0" yl)phenyl)pyridin-2- CAS# A2 610. 611.2 85 r‘ N- / -J6yl)methyl)-2,3- 3008582- dihydro-5H- 33-7benzo [e] [ 1 ,4] oxathiepine-8-carboxamide 1,1- dioxide3 -chloro -5- ((difluoromethyl)sulfoInt-84nyl)-N-((4-(4- +Cpd- n methoxy-3-(l-(3- CAS# A2 603.0 603.1 86 methyloxetan-3 -yl)- 2592405- lH-pyrazol-3- 50-8yl)phenyl)pyridin-2- yl)methyl)benzamide3 -chloro -5- ((difluoromethyl)sulfo Int-85nyl)-N-((4-(4- +Cpd- methoxy-3 -( 1 -methyl- CAS# A2 547.1 87 n Lj X 547.0lH-pyrazol-3- 2592405- yl)phenyl)pyridin-2- 50-8yl)methyl)benzamideMS Cpd# Structure Name SM Mtd MW Mes’d (R)-9-chloro-4-fluoro- N-((4-(4-(2- hydroxy ethoxy) -3 -( 1 - Int-87methyl- lH-pyrazol-3 - +Cpd- yl)phenyl)pyridin-2- CAS# A2 601.0 601.3 88 yl)methyl)-3,4- Cl 3008582- dihydro-2H- 64-4benzo [b] [ 1 ,4] oxathiepine-7-carboxamide 5,5- dioxide3x= compound not synthetized according a general method, procedure has been described.Table IV. NMR data of illustrative compounds of the invention.Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable)’H NMR (400 MHz, CD3OD) 5 8.59 - 8.52 (m, 2H), 8.14 - 8.06 (m, 2H), 7.83 (m, 1H), Cpd-1 7.77 - 7.72 (m, 1H), 7.68 - 7.63 (m, 2H), 7.61 (d, 1H), 7.57 - 7.47 (m, 2H), 6.68 (d, 1H), 4.77 (s, 2H), 3.94 (s, 3H), 3.16 (s, 3H), 2.75 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.48 (t, 1H), 8.60 (d, 1H), 8.49 (d, 1H), 8.21 (dd, 1H), 8.12 (t, 1H), 7.87 (dt, 1H), 7.76 (d, 1H), 7.73 - 7.68 (m, 2H), 7.65 (dt, 2H), 7.54 (t, 1H), Cpd-26.79 (d, 1H), 4.96 (s, 2H), 4.69 (d, 2H), 4.25 - 4.18 (m, 2H), 3.89 (s, 3H), 3.69 - 3.62 (m, 2H).’H NMR (400 MHz, DMSO-J6) 59.37 (t, 1H), 8.63 - 8.57 (m, 1H), 8.45 (d, 1H), 8.15 (dd, 1H), 8.11 (t, 1H), 7.87 (dd, 2H), 7.72 - 7.62 (m, 3H), 7.59 (d, 1H), 7.54 (t, 1H), 6.81 Cpd-5(d, 1H), 4.68 (d, 2H), 4.16 (dq, 1H), 3.25 (s, 3H), 2.86 (d, 2H), 2.70 (s, 3H), 2.22 (s, 3H), 2.11 - 1.94 (m, 6H).’H NMR (400 MHz, DMSO-J6) 59.37 (t, 1H), 8.60 (d, 1H), 8.45 (d, 1H), 8.15 (dd, 1H), 8.11 (t, 1H), 7.88 (d, 1H), 7.84 (d, 1H), 7.69 (d, 1H), 7.68 - 7.62 (m, 2H), 7.59 (d, 1H), Cpd-67.53 (t, 1H), 6.80 (d, 1H), 4.68 (d, 2H), 4.29 - 4.18 (m, 1H), 3.25 (s, 3H), 3.05 (d, 2H), 2.70 (s, 3H), 2.60 (t, 2H), 1.98 (d, 2H), 1.83 (td, 2H).’H NMR (400 MHz, DMSO-J6) 59.36 (t, 1H), 8.60 (d, 1H), 8.45 (d, 1H), 8.15 (dd, 1H), 8.11 (s, 1H), 7.91 - 7.85 (m, 2H), 7.69 (s, 1H), 7.65 (d, 2H), 7.59 (d, 1H), 7.54 (t, 1H), Cpd-76.82 (d, 1H), 4.68 (d, 2H), 4.39 (d, 1H), 4.07 (d, 2H), 3.25 (s, 3H), 2.91 (s, 2H), 2.70 (s, 3H), 2.05 (d, 2H), 1.89 - 1.79 (m, 2H), 1.43 (s, 9H).Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable)’H NMR (400 MHz, DMSO-J6): 59.49 (t, 1H), 8.61 (dd, 1H), 8.32 - 8.23 (m, 2H), 8.12 Cpd-8 (t, 1H), 7.90 (m, 2H), 7.83 - 7.74 (m, 2H), 7.74 - 7.69 (m, 1H), 7.66 (dt, 2H), 7.54 (t, 1H), 6.80 (d, 1H), 4.70 (d, 2H), 3.90 (s, 3H), 2.63 (s, 6H).’H NMR (400 MHz, DMSO-J6): 59.44 (t, 1H), 8.61 (dd, 1H), 8.48 (d, 1H), 8.26 (dd, 1H), 8.12 (t, 1H), 7.87 (dt, 1H), 7.82 (d, 1H), 7.76 (d, 1H), 7.72 (dd, 1H), 7.69 - 7.62 (m, 2H), Cpd-97.54 (t, 1H), 6.80 (d, 1H), 4.88 (s, 2H), 4.70 (d, 2H), 3.90 (s, 3H), 3.41 (s, 3H), 3.29 (s, 3H).’H NMR (400 MHz, DMSO-J6): 59.39 (t, 1H), 8.64 - 8.58 (m, 1H), 8.32 (d, 1H), 8.15 - Cpd- 8.09 (m, 2H), 7.87 (dt, 1H), 7.76 (d, 1H), 7.70 (d, 1H), 7.68 - 7.62 (m, 2H), 7.59 (d, 1H), 107.54 (t, 1H), 6.79 (d, 1H), 4.68 (d, 2H), 3.90 (s, 3H), 2.73 (s, 5H), 2.61 (s, 3H). ’H NMR (400 MHz, DMSO-J6) 5 12.95 (s, 1H), 9.37 (t, 1H), 8.62 (d, 1H), 8.46 (d, 1H), CPd- 8.19 - 8.12 (m, 2H), 7.90 (d, 1H), 7.82 - 7.70 (m, 2H), 7.70 - 7.64 (m, 2H), 7.63 - 7.52 11(m, 2H), 6.83 (d, 1H), 4.69 (d, 2H), 3.26 (s, 3H), 2.70 (s, 3H).’H NMR (400 MHz, DMSO-J6): 59.27 (t, 1H), 8.61 (d, 1H), 8.16 (d, 1H), 8.12 (d, 1H), Cpd- 7.89 (m, 2H), 7.77 (d, 1H), 7.70 (d, 1H), 7.65 (dt, 2H), 7.54 (t, 1H), 7.28 (d, 1H), 6.80 (d, 12 1H), 4.90 (d, 1H), 4.82 (d, 1H), 4.69 (d, 2H), 4.21 (d, 1H), 3.90 (s, 2H), 3.85 (d, 1H), 1.68 (s, 3H).’H NMR (400 MHz, DMSO-J6): 59.27 (t, 1H), 8.61 (d, 1H), 8.14 (d, 2H), 7.94 - 7.83 (m, Cpd- 2H), 7.76 (d, 1H), 7.70 (s, 1H), 7.68 - 7.61 (m, 2H), 7.53 (t, 1H), 7.27 (d, 1H), 6.79 (d, 13 1H), 4.93 - 4.78 (m, 2H), 4.69 (d, 2H), 4.21 (d, 1H), 3.90 (s, 3H), 3.85 (d, 1H), 1.68 (s, 3H).’H NMR (400 MHz, DMSO-J6): 59.39 (t, 1H), 8.60 (d, 1H), 8.44 (d, 1H), 8.18 (dd, 1H), Cpd- 8.12 (t, 1H), 7.87 (dt, 1H), 7.76 (d, 1H), 7.70 (d, 1H), 7.68 - 7.62 (m, 2H), 7.60 (d, 1H), 14 7.53 (t, 1H), 6.80 (d, 1H), 4.86 (s, 2H), 4.68 (d, 2H), 3.89 (s, 3H), 3.49 (s, 3H), 2.68 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.38 (t, 1H), 8.70 - 8.53 (m, 1H), 8.49 - 8.42 (m, 1H), Cpd- 8.19 - 8.08 (m, 2H), 7.88 (dt, 1H), 7.84 (d, 1H), 7.83 - 7.51 (m, 6H), 6.86 - 6.79 (m, 1H), 15 4.68 (d, 2H), 4.64 (d, 2H), 4.38 (s, 2H), 4.24 (d, 2H), 3.26 (s, 3H), 2.71 (s, 3H), 1.16 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.41 (s, 1H), 8.61 (d, 1H), 8.46 (d, 1H), 8.16 (dd, 1H), Cpd- 8.11 (t, 1H), 7.90 - 7.86 (m, 1H), 7.85 (d, 1H), 7.70 (d, 1H), 7.69 - 7.64 (m, 2H), 7.60 (d, 16 1H), 7.55 (t, 1H), 6.82 (d, 1H), 4.76 - 4.60 (m, 4H), 4.54 - 4.39 (m, 4H), 3.50 - 3.40 (m, 1H), 3.26 (s, 3H), 2.71 (s, 3H).Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable) ’H NMR (400 MHz, DMSO-J6) 59.39 (t, 1H), 8.62 (d, 1H), 8.46 (d, 1H), 8.19 - 8.12 (m, Cpd- 2H), 7.99 (d, 1H), 7.98 - 7.91 (m, 1H), 7.74 - 7.65 (m, 3H), 7.63 - 7.53 (m, 2H), 6.90 (d, 171H), 5.63 (p, 1H), 4.98 - 4.90 (m, 4H), 4.69 (d, 2H), 3.25 (s, 3H), 2.70 (s, 3H). ’H NMR (400 MHz, DMSO-J6) 59.39 (t, 1H), 8.62 (dd, 2H), 8.47 (d, 1H), 8.28 (d, 1H), Cpd- 8.17 (dd, 1H), 8.04 (dd, 1H), 7.97 - 7.90 (m, 2H), 7.78 - 7.68 (m, 3H), 7.67 - 7.49 (m, 184H), 7.35 (t, 1H), 7.18 (d, 1H), 4.71 (d, 2H), 3.25 (s, 3H), 2.70 (s, 3H).’H NMR (400 MHz, DMSO-J6): 59.40 (t, 1H), 8.69 (t, 2H), 8.45 (d, 1H), 8.21 - 8.12 (m, Cpd- 2H), 7.80 (dd, 2H), 7.74 (dd, 1H), 7.66 (dd, 1H), 7.60 (d, 1H), 6.86 (d, 1H), 4.70 (d, 2H), 193.93 (s, 3H), 3.25 (s, 3H), 2.70 (s, 3H).’H NMR (400 MHz, DMSO-J6): 59.23 (t, 1H), 8.61 (dd, 1H), 8.12 (t, 1H), 7.99 (d, 1H), Cpd- 7.94 _ 7.84 (m, 2H), 7.76 (d, 1H), 7.71 - 7.61 (m, 3H), 7.53 (t, 1H), 7.28 (d, 1H), 6.80 (d, 20 1H), 4.89 (d, 1H), 4.77 (d, 1H), 4.68 (d, 2H), 4.46 (t, 1H), 4.21 (dd, 1H), 4.02 (dd, 1H), 3.90 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.36 (t, 1H), 8.59 (d, 1H), 8.45 (d, 1H), 8.15 (dd, 1H), Cpd- 7.71 - 7.57 (m, 6H), 7.54 (t, 1H), 7.48 (dt, 1H), 4.67 (d, 2H), 3.79 (s, 3H), 3.25 (s, 3H), 212.70 (s, 3H), 2.36 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.39 (t, 1H), 8.59 (d, 1H), 8.45 (d, 1H), 8.15 (dd, 1H), Cpd- 7.99 (d, J = 2.1 Hz, 1H), 7.70 (d, J = 2.2 Hz, 1H), 7.68 - 7.56 (m, 4H), 7.31 (d, J = 7.9 Hz, 22 1H), 6.49 (d, J = 2.3 Hz, 1H), 5.43 - 5.37 (m, 1H), 5.02 (q, J = 1.7 Hz, 2H), 4.67 (d, J = 5.7 Hz, 2H), 3.96 (s, 2H), 3.87 (s, 3H), 3.25 (s, 3H), 2.70 (s, 3H) ppm.’H NMR (400 MHz, DMSO-J6) 59.38 (t, 1H), 8.61 (d, 1H), 8.46 (d, 1H), 8.16 (dd, 1H), Cpd- 8.12 (t, 1H), 7.88 (dt, 1H), 7.79 (d, 1H), 7.73 - 7.63 (m, 3H), 7.63 - 7.51 (m, 2H), 6.80 (d, 231H), 4.69 (d, 2H), 4.31 (t, 2H), 3.72 (t, 2H), 3.26 (s, 3H), 3.24 (s, 3H), 2.71 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.38 (t, 1H), 8.54 (d, 1H), 8.45 (d, 1H), 8.15 (dd, 1H), Cpd- 7.99 (d, 1H), 7.74 (d, 1H), 7.69 - 7.57 (m, 3H), 7.55 (dd, 1H), 7.20 (d, 1H), 6.90 (d, 1H), 25 4.65 (d, 2H), 3.88 (d, 3H), 3.25 (s, 3H), 2.86 (t, 4H), 2.70 (s, 3H), 2.46 - 2.35 (m, 4H), 2.21 (s, 3H)’H NMR (400 MHz, DMSO-J6) 59.49 (t, 1H), 8.61 (d, 1H), 8.40 (d, 1H), 8.31 (dt, 1H), Cpd- 8.13 (d, 1H), 8.03 (dt, 1H), 7.88 (dt, 1H), 7.84 - 7.75 (m, 2H), 7.73 (d, 1H), 7.66 (dt, 2H), 267.54 (t, 1H), 6.80 (d, 1H), 4.71 (d, 2H), 3.90 (s, 3H), 3.48 (m, 1H), 1.17 (d, 6H). ’H NMR (400 MHz, DMSO-J6) 59.42 (t, 1H), 8.61 (d, 1H), 8.41 (d, 1H), 8.17 (dd, 1H), Cpd- 8.12 (d, 1H), 7.87 (dt, 1H), 7.76 (d, 1H), 7.71 (d, 1H), 7.69 - 7.58 (m, 3H), 7.54 (t, 1H), 276.80 (d, 1H), 4.68 (d, 2H), 3.90 (s, 3H), 3.50 (m, 1H), 2.68 (s, 3H), 1.17 (d, 6H).Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable)’H NMR (400 MHz, DMSO-J6) 59.42 (t, 1H), 8.61 (d, 1H), 8.33 (t, 1H), 8.20 (dt, 1H), Cpd- 8.12 (t, 1H), 7.94 (dt, 1H), 7.87 (dt, 1H), 7.79 - 7.69 (m, 3H), 7.66 (dt, 2H), 7.54 (t, 1H), 286.80 (d, 1H), 4.69 (d, 2H), 3.89 (s, 3H), 2.42 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.38 (t, 1H), 8.55 (dd, 1H), 8.45 (d, 1H), 8.23 (d, 1H), Cpd- 8.15 (dd, 1H), 7.72 (d, 1H), 7.69 (dd, 1H), 7.64 - 7.54 (m, 3H), 7.23 (d, 1H), 6.73 (d, 1H), 294.66 (d, 2H), 3.91 (s, 3H), 3.88 (s, 3H), 3.25 (s, 3H), 2.70 (s, 3H).’H NMR (400 MHz, DMSO-t / 6) 59.44 (t, 1H), 8.61 (d, 1H), 8.47 (t, 1H), 8.27 (dt, 1H), Cpd- 8.15 - 8.06 (m, 2H), 7.87 (dt, 1H), 7.83 - 7.74 (m, 2H), 7.73 (d, 1H), 7.70 - 7.63 (m, 2H), 307.54 (t, 1H), 6.80 (d, 1H), 4.70 (d, 2H), 3.90 (s, 3H), 3.26 (s, 3H).’H NMR (400 MHz, DMSO-J6) 58.87 (t, 1H), 8.60 (d, 1H), 8.16 - 8.09 (m, 1H), 7.91 - Cpd- 7.84 (m, 2H), 7.76 (d, 1H), 7.71 - 7.61 (m, 3H), 7.54 (t, 1H), 7.30 (dd, 1H), 6.84 - 6.77 31(m, 2H), 4.61 (d, 2H), 3.90 (s, 3H), 3.55 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.37 (t, 1H), 8.61 (d, 1H), 8.45 (d, 1H), 8.15 (dd, 1H), Cpd- 8.12 (d, 1H), 7.92 - 7.85 (m, 2H), 7.72 - 7.62 (m, 3H), 7.59 (d, 1H), 7.54 (t, 1H), 6.82 (d, 32 1H), 4.68 (d, 2H), 4.52 - 4.40 (m, 1H), 4.02 - 3.93 (m, 2H), 3.54 - 3.43 (m, 2H), 3.25 (s, 3H), 2.70 (s, 3H), 2.05 - 1.91 (m, 4H).1H NMR (400 MHz, DMSO-J6) 59.52 (t, 1H), 8.69 (td, 2H), 8.48 (d, 1H), 8.24 - 8.17 (m, Cpd- 2H), 7.82 - 7.78 (m, 2H), 7.74 (dd, 1H), 7.71 (d, 1H), 7.67 (dd, 1H), 6.85 (d, 1H), 4.96 (s, 332H), 4.71 (d, 2H), 4.24 - 4.17 (m, 2H), 3.93 (s, 3H), 3.70 - 3.62 (m, 2H).’HNMR (400 MHz, CD3OD) 5 8.60 - 8.52 (m, 2H), 8.18 (t, 1H), 8.11 (dd, 1H), 7.90 (dt, Cpd- 1H), 7.83 - 7.74 (m, 2H), 7.72 - 7.63 (m, 2H), 7.59 - 7.49 (m, 2H), 6.77 (d, 1H), 5.18 (d, 342H), 4.78 (s, 2H), 4.72 - 4.66 (m, 2H), 3.17 (s, 3H), 2.76 (s, 3H), 1.93 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.38 (t, 1H), 8.61 (d, 1H), 8.46 (d, 1H), 8.19 - 8.09 (m, Cpd- 2H), 7.89 (dt, 1H), 7.78 (d, 1H), 7.74 - 7.70 (m, 1H), 7.68 - 7.64 (m, 2H), 7.62 - 7.50 (m, 353H), 7.28 (s, 1H), 6.84 (d, 1H), 4.83 (s, 2H), 4.69 (d, 2H), 3.26 (s, 3H), 2.70 (s, 3H).’H NMR (400 MHz, DMSO-J6) 58.66 (t, 1H), 7.72 (dd, 1H), 7.66 (d, 1H), 7.43 - 7.35 Cpd- (m, 2H), 6.91 - 6.83 (m, 3H), 6.82 - 6.77 (m, 1H), 6.74 (dd, 1H), 6.40 (d, 1H), 5.90 (d, 361H), 4.13 (s, 2H), 3.84 (d, 2H), 3.42 - 3.35 (m, 2H), 3.06 (d, 6H), 2.85 - 2.78 (m, 2H) ’H NMR (400 MHz, CDCI3) 5 8.63 (d, 1H), 8.50 (d, 1H), 8.19 (d, 1H), 8.10 (dd, 1H), 7.93 Cpd- (d, 1H), 7.79 (d, 1H), 7.69 (t, 1H), 7.64 (dd, 1H), 7.59 (s, 1H), 7.53 - 7.50 (m, 1H), 7.48 - 37 7.44 (m, 2H), 6.48 (d, 1H), 6.43 (d, 1H), 4.83 (d, 2H), 4.26 (q, 2H), 4.01 (s, 3H), 3.12 (s, 3H), 2.78 (s, 3H), 1.34 (t, 3H).’H NMR (500 MHz, DMSO-J6) 59.51 (t, 1H), 8.78 (d, 1H), 8.46 (d, 1H), 8.23 - 8.15 (m, Cpd- 2H), 8.14 - 8.09 (m, 2H), 8.08 - 8.03 (m, 2H), 7.94 - 7.88 (m, 1H), 7.87 (d, 1H), 7.62 (d, 381H), 6.59 (d, 1H), 6.57 (d, 1H), 4.82 (d, 2H), 3.94 (s, 3H), 3.26 (s, 3H), 2.71 (s, 3H).Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable) ’H NMR (500 MHz, DMSO-J6) 59.45 (t, 1H), 8.53 (d, 1H), 8.50 (d, 1H), 8.19 (dd, 1H), Cpd- 8.05 (s, 1H), 7.85 - 7.77 (m, 2H), 7.69 (d, 1H), 7.66 - 7.62 (m, 1H), 7.62 - 7.56 (m, 2H), 397.47 (t, 1H), 6.73 (d, 1H), 4.62 (d, 2H), 3.83 (s, 3H), 3.33 (s, 3H).’H NMR (400 MHz, CDC13) 5 8.56 (d, 1H), 8.48 (d, 1H), 8.25 (d, 1H), 8.09 (dd, 1H), 7.81 Cpd- - 7.72 (m, 1H), 7.63 - 7.55 (m, 2H), 7.54 - 7.48 (m, 1H), 7.45 (d, 1H), 7.42 (d, 1H), 7.07 40 (d, 1H), 6.80 (d, 1H), 4.82 (d, 2H), 4.60 (s, 2H), 3.99 (s, 3H), 3.96 (s, 3H), 3.66 (s, 3H), 2.76 (s, 3H)’H NMR (400 MHz, DMSO-J6) 59.37 (q, 1H), 8.61 (d, 1H), 8.46 (d, 1H), 8.24 (s, 1H), Cpd- 8.19 - 8.09 (m, 2H), 7.88 (dt, 1H), 7.74 (d, 1H), 7.73 - 7.68 (m, 1H), 7.68 - 7.48 (m, 5H), 41 7.42 (s, 1H), 6.92 (s, 1H), 6.78 (d, 1H), 4.69 (d, 2H), 4.36 (t, 2H), 3.25 (s, 3H), 2.69 (d, 5H).’H NMR (400 MHz, DMSO-J6) 59.37 (t, 1H), 8.62 (dd, 1H), 8.45 (d, 1H), 8.39 (d, 1H), Cpd- 8.25 (t, 1H), 8.18 - 8.11 (m, 2H), 8.02 (dt, 1H), 7.81 (ddd, 1H), 7.77 - 7.55 (m, 4H), 7.26 42(d, 1H), 4.69 (d, 2H), 3.61 (s, 3H), 3.25 (s, 3H), 2.69 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.36 (t, 1H), 8.60 (dd, 1H), 8.45 (d, 1H), 8.14 (dd, 1H), Cpd- 8.11 (t, 1H), 7.87 (dt, 1H), 7.71 (dd, 2H), 7.67 - 7.63 (m, 2H), 7.60 - 7.52 (m, 2H), 6.83 43(d, 1H), 5.18 (s, 2H), 4.68 (d, 2H), 3.25 (s, 3H), 3.05 (s, 3H), 2.86 (s, 3H), 2.70 (s, 3H). ’H NMR (400 MHz, DMSO-J6) 59.37 (t, 1H), 8.61 (d, 1H), 8.45 (d, 1H), 8.18 - 8.10 (m, Cpd- 2H), 7.96 - 7.90 (m, 2H), 7.72 - 7.65 (m, 3H), 7.61 - 7.57 (m, 2H), 6.95 (d, 1H), 5.55 (s, 442H), 4.68 (d, 2H), 3.25 (s, 3H), 2.70 (s, 3H).’H NMR (500 MHz, DMSO-J6) 59.47 (t, 1H), 8.61 (d, 1H), 8.45 - 8.41 (m, 1H), 8.30 - Cpd- 8.24 (m, 1H), 8.14 - 8.08 (m, 2H), 7.90 - 7.84 (m, 1H), 7.80 - 7.71 (m, 3H), 7.69 - 7.63 45 (m, 2H), 7.57 - 7.50 (m, 1H), 6.79 (d, 1H), 4.70 (d, 2H), 3.90 (s, 3H), 3.33 (s, 3H), 2.24 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.49 (t, 1H), 8.60 (d, 1H), 8.32 (t, 1H), 8.27 - 8.20 (m, Cpd- 1H), 8.15 - 8.09 (m, 1H), 7.98 - 7.91 (m, 1H), 7.91 - 7.84 (m, 1H), 7.80 - 7.69 (m, 3H), 46 7.69 - 7.62 (m, 2H), 7.57 - 7.49 (m, 1H), 6.80 (d, 1H), 4.69 (d, 2H), 3.89 (s, 3H), 3.42 (t, 2H), 3.20 - 3.13 (m, 5H), 2.73 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.45 (t, 1H), 8.61 (d, 1H), 8.44 (t, 1H), 8.26 (dt, 1H), Cpd- 8.12 (t, 1H), 8.05 (dt, 1H), 7.87 (dt, 1H), 7.80 - 7.74 (m, 2H), 7.74 - 7.71 (m, 1H), 7.69 - 48 7.62 (m, 2H), 7.53 (t, 1H), 6.80 (d, 1H), 4.70 (d, 2H), 3.89 (s, 3H), 3.67 - 3.58 (m, 4H), 3.04 (s, 3H).’H NMR (500 MHz, CDCI3) 5 8.62 (d, 1H), 8.47 (d, 1H), 8.11 - 8.07 (m, 2H), 7.87 - 7.83 Cpd- (m, 1H), 7.73 - 7.66 (m, 1H), 7.61 - 7.49 (m, 4H), 7.46 - 7.40 (m, 2H), 6.60 (d, 1H), 4.84 49(d, 2H), 3.98 (s, 3H), 3.75 (t, 2H), 3.45 (t, 2H), 3.20 (s, 3H), 2.76 (s, 3H).Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable) ’HNMR (400 MHz, CDC13) 5 8.62 (d, 1H), 8.46 (t, 1H), 8.21 (dt, 1H), 8.11 - 8.07 (m, Cpd- 2H), 7.94 - 7.89 (m, 1H), 7.85 (dt, 1H), 7.70 (t, 1H), 7.61 (d, 1H), 7.59 - 7.49 (m, 3H), 50 7.42 (d, 1H), 6.61 (d, 1H), 4.85 (d, 2H), 4.04 (s, 2H), 3.98 (s, 3H), 3.42 - 3.37 (m, 2H), 2.99 - 2.87 (m, 1H).’H NMR (400 MHz, DMSO-J6) 59.35 (t, 1H), 8.60 (dd, 1H), 8.35 (d, 1H), 8.11 (t, 1H), Cpd- 8.08 (dd, 1H), 7.87 (dt, 1H), 7.76 (d, 1H), 7.71 - 7.68 (m, 1H), 7.67 - 7.62 (m, 2H), 7.60 - 517.49 (m, 3H), 6.79 (d, 1H), 4.67 (d, 2H), 3.89 (s, 3H), 2.61 (s, 3H), 2.42 (s, 3H). ’H NMR (400 MHz, DMSO-J6) 59.36 (q, 1H), 8.60 (dd, 1H), 8.45 (dd, 1H), 8.15 (dd, J = Cpd- 7.9, 2.0 Hz, 1H), 8.12 (t, 1H), 7.88 (dt, 1H), 7.77 (d, 1H), 7.71 - 7.62 (m, 3H), 7.61 - 7.51 52 (m, 2H), 6.79 (d, 1H), 4.91 (t, 1H), 4.67 (t, 2H), 4.19 (t, 2H), 3.77 (q, 2H), 3.25 (s, 3H), 2.70 (s, 3H).’H NMR (500 MHz, CDCI3) 5 8.62 (d, 1H), 8.51 (d, 1H), 8.11 - 8.07 (m, 2H), 7.85 (dt, Cpd- 1H), 7.82 - 7.78 (m, 1H), 7.62 - 7.59 (m, 1H), 7.58 - 7.49 (m, 3H), 7.46 (d, 1H), 7.42 (d, 53 1H), 6.60 (d, 1H), 4.84 (d, 2H), 4.09 - 4.04 (m, 2H), 3.98 (s, 3H), 3.44 - 3.39 (m, 2H), 2.93 - 2.87 (m, 1H), 2.76 (s, 3H).’H NMR (500 MHz, DMSO-J6) 59.37 (t, 1H), 8.60 (d, 1H), 8.43 (d, 1H), 8.14 (dd, 1H), Cpd- 8.11 (t, 1H), 7.88 - 7.85 (m, 1H), 7.75 (d, 1H), 7.70 - 7.68 (m, 1H), 7.66 - 7.63 (m, 2H), 54 7.58 (d, 1H), 7.53 (t, 1H), 6.79 (d, 1H), 4.68 (d, 2H), 3.89 (s, 3H), 3.51 - 3.42 (m, 2H), 2.69 (s, 3H), 2.57 - 2.53 (m, 2H), 2.01 (s, 6H)’H NMR (400 MHz, DMSO-J6) 59.30 (t, 1H), 8.56 (d, 1H), 8.22 (d, 1H), 8.15 (d, 1H), Cpd- 7.96 (d, 1H), 7.91 (dd, 1H), 7.73 (dd, 1H), 7.62 (d, 1H), 7.60 (dd, 1H), 7.26 (t, 2H), 6.80 55 (d, 1H), 5.01 (dd, 2H), 4.93 - 4.78 (m, 2H), 4.66 (d, 2H), 4.57 (dd, 2H), 4.21 (d, 1H), 3.92 (s, 3H), 3.85 (d, 1H), 1.84 (s, 3H), 1.67 (s, 3H).’H NMR (400 MHz, DMSO-J6) 58.81 (t, 1H), 8.58 (dd, 1H), 8.13 (t, 1H), 7.89 (dt, 1H), Cpd- 7.77 (d, 1H), 7.72 - 7.63 (m, 3H), 7.58 - 7.50 (m, 2H), 7.34 (d, 1H), 7.18 (s, 2H), 6.83 (d, 581H), 4.63 (d, 2H), 3.91 (s, 3H), 3.68 (s, 3H) ppm.’H NMR (400 MHz, DMSO-J6) 58.77 (t, 1H), 8.62 - 8.56 (m, 1H), 8.10 (t, 1H), 7.87 (dt, Cpd- 1H), 7.77 (d, 1H), 7.72 (d, 1H), 7.63 (m, 3H), 7.54 (t, 1H), 7.36 (d, 1H), 6.80 (d, 1H), 4.58 59(d, 2H), 3.91 (s, 3H), 3.87 (s, 3H), 3.27 (s, 3H) ppm.Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable) ’HNMR (400 MHz, DMSO-J6) 58.98 (t, 1H), 8.59 (dd, 1H), 8.12 (t, 1H), 7.87 (dt, 1H), Cpd- 7.76 (d, 1H), 7.66 (m, 3H), 7.54 (t, 1H), 7.31 (d, 1H), 6.80 (d, 1H), 4.59 (d, 2H), 3.90 (s, 656H), 3.10 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.39 (t, 1H), 8.61 (dd, 1H), 8.34 (d, 1H), 8.15 - 8.07 Cpd- (m, 2H), 7.91 - 7.84 (m, 1H), 7.77 (d, 1H), 7.73 - 7.69 (m, 1H), 7.69 - 7.63 (m, 2H), 7.61 66 - 7.50 (m, 2H), 6.80 (d, 1H), 4.68 (d, 2H), 3.90 (s, 3H), 3.43 (t, 2H), 3.31 (t, 2H), 3.17 (s, 3H), 2.81 (s, 3H), 2.59 (s, 3H).’H NMR (400 MHz, DMSO-J6) 5 12.21 (s, 1H), 9.46 (t, 1H), 8.61 (d, 1H), 8.43 (s, 1H), Cpd- 8.25 (d, 1H), 8.13 (s, 1H), 8.07 (d, 1H), 7.88 (d, 1H), 7.79 - 7.71 (m, 3H), 7.70 - 7.64 (m, 672H), 7.54 (t, 1H), 6.81 (s, 1H), 4.70 (d, 2H), 3.90 (s, 3H), 1.92 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.50 (t, 1H), 8.61 (d, 1H), 8.35 (t, 1H), 8.22 (dt, 1H), Cpd- 8.13 (t, 1H), 7.97 (dt, 1H), 7.88 (dt, 1H), 7.79 - 7.70 (m, 3H), 7.69 - 7.62 (m, 2H), 7.54 (t, 681H), 6.80 (d, 1H), 4.71 (d, 2H), 3.90 (s, 3H), 3.18 (q, 4H), 1.03 (t, 6H).’H NMR (400 MHz, DMSO-J6) 59.51 (t, 1H), 8.61 (d, 1H), 8.34 (d, 1H), 8.26 (d, 1H), Cpd- 8.13 (t, 1H), 7.99 (d, 1H), 7.88 (d, 1H), 7.81 - 7.70 (m, 3H), 7.70 - 7.63 (m, 2H), 7.54 (t, 691H), 6.80 (d, 1H), 4.70 (d, 2H), 3.90 (s, 3H), 3.21 - 3.13 (m, 4H), 1.68 - 1.57 (m, 4H). ’H NMR (400 MHz, DMSO-J6) 59.51 (t, 1H), 8.82 (d, 1H), 8.46 (d, 1H), 8.32 - 8.26 (m, Cpd- 2H), 8.24 - 8.18 (m, 1H), 8.15 (dd, 1H), 8.01 (dt, 1H), 7.88 - 7.79 (m, 2H), 7.68 - 7.59 70(m, 2H), 6.85 (d, 1H), 4.86 (d, 2H), 4.37 (t, 2H), 4.11 (t, 2H), 3.26 (s, 3H), 2.71 (s, 3H). ’H NMR (400 MHz, DMSO-J6) 59.52 (t, 1H), 8.56 (d, 1H), 8.49 (d, 1H), 8.26 - 8.19 (m, Cpd- 2H), 7.96 (d, 1H), 7.74 (dd, 1H), 7.70 (d, 1H), 7.63 (d, 1H), 7.60 (dd, 1H), 7.25 (d, 1H), 71 6.80 (d, 1H), 5.01 (d, 2H), 4.96 (s, 2H), 4.67 (d, 2H), 4.57 (d, 2H), 4.25 - 4.18 (m, 2H), 3.92 (s, 3H), 3.69 - 3.62 (m, 2H), 1.83 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.43 (t, 1H), 8.56 (d, 1H), 8.44 (d, 1H), 8.22 (d, 1H), Cpd- 8.19 (dd, 1H), 7.96 (d, 1H), 7.73 (dd, 1H), 7.65 - 7.57 (m, 3H), 7.25 (d, 1H), 6.80 (d, 1H), 72 5.02 (d, 2H), 4.86 (s, 2H), 4.66 (d, 2H), 4.58 (d, 2H), 3.92 (s, 3H), 3.48 (s, 3H), 2.69 (s, 3H), 1.83 (s, 3H).’H NMR (500 MHz, DMSO-J6) 59.43 (t, 1H), 8.53 (d, 1H), 8.47 (d, 1H), 8.20 (dd, 1H), Cpd- 7.81 (dd, 1H), 7.71 (s, 1H), 7.68 (d, 1H), 7.65 (d, 1H), 7.64 (d, 1H), 7.59 (dd, 1H), 7.24 (d, 73 1H), 4.99 (d, 2H), 4.96 (s, 2H), 4.66 (d, 2H), 4.55 (d, 2H), 4.22 (dd, 2H), 3.84 (s, 3H), 3.67 - 3.61 (m, 2H), 1.93 (s, 3H), 1.82 (s, 3H).’H NMR (500 MHz, DMSO-J6) 59.39 (t, 1H), 8.56 (d, 1H), 8.42 (d, 1H), 8.23 (d, 1H), Cpd- 8.15 (dd, 1H), 7.96 (d, 1H), 7.73 (dd, 1H), 7.63 (d, 1H), 7.60 (dd, 1H), 7.57 (d, 1H), 7.25 74 (d, 1H), 6.80 (d, 1H), 5.03 (d, 2H), 4.84 (s, 1H), 4.66 (d, 2H), 4.59 (d, 2H), 3.92 (s, 3H), 3.75 - 3.67 (m, 2H), 3.49 (t, 2H), 2.68 (s, 3H), 1.84 (s, 3H).Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable) ’H NMR (400 MHz, DMSO-J6) 5 12.95 (s, 1H), 9.50 (t, 1H), 8.57 (d, 1H), 8.48 (d, 1H), Cpd- 8.27 - 8.17 (m, 2H), 7.80 - 7.61 (m, 5H), 7.27 (d, 1H), 6.79 (d, 1H), 4.97 (s, 2H), 4.28 - 754.19 (m, 2H), 3.94 (s, 3H), 3.73 - 3.59 (m, 2H).’H NMR (400 MHz, DMSO-J6) 59.51 (t, 1H), 8.58 (d, 1H), 8.48 (d, 1H), 8.34 (d, 1H), Cpd- 8.26 - 8.18 (m, 2H), 7.86 (dd, 1H), 7.71 (d, 1H), 7.67 (s, 1H), 7.65 - 7.61 (m, 1H), 7.34 76 (d, 1H), 7.04 (d, 1H), 4.97 (s, 2H), 4.68 (d, 2H), 4.28 - 4.16 (m, 2H), 3.95 (s, 3H), 3.71 - 3.65 (m, 2H), 3.60 (s, 3H).’H NMR (400 MHz, DMSO-J6) 59.52 (t, 1H), 8.56 (d, 1H), 8.49 (d, 1H), 8.25 - 8.18 (m, Cpd- 2H), 7.95 (d, 1H), 7.75 - 7.69 (m, 2H), 7.61 (s, 1H), 7.59 (dd, 1H), 7.25 (d, 1H), 6.82 (d, 77 1H), 4.99 - 4.91 (m, 4H), 4.67 (d, 2H), 4.63 (d, 2H), 4.26 - 4.17 (m, 2H), 3.92 (s, 3H), 3.69 - 3.63 (m, 2H), 2.16 (q, 2H), 0.66 (t, 3H).’H NMR (400 MHz, DMSO-J6) 59.55 (t, 1H), 8.56 (d, 1H), 8.32 - 8.30 (m, 1H), 8.28 (dd, 1H), 8.23 (d, 1H), 7.97 (d, 1H), 7.75 (dd, 1H), 7.64 (d, 1H), 7.60 (dd, 1H), 7.25 (d, 1H), 6.80 (d, 1H), 6.34 - 6.19 (m, 1H), 5.03 (d, 2H), 4.66 (d , 2H), 4.63 - 4.60 (m, 1H), Cpd- 4.58 (dd, 2H), 4.14 (t, 1H), 3.92 (s, 3H), 2.90 - 2.69 (m, 1H), 2.63 - 2.54 (m, 1H), 1.85 (s, 783H).19F NMR (471 MHZ, DMSO-J6) 5 -127.53 (s, IF), -186.82 (s, IF).OR: -35,573 ° (589 nm, c 0,15 w / v %, DMF, 20°C)’H NMR (500 MHz, DMSO-J6) 59.51 (t, 1H), 8.56 (d, 1H), 8.48 (d, 1H), 8.41 (d, 1H), 8.23 (d, 1H), 7.95 (d, 1H), 7.74 (dd, 1H), 7.64 (s, 1H), 7.59 (d, 1H), 7.25 (d, 1H), 6.81 (d, Cpd- 1H), 6.21 (dd, 1H), 5.04 (d, 2H), 4.66 (d, 2H), 4.59 (d, 3H), 4.09 (t, 1H), 3.93 (s, 3H), 2.82 79 (dt, 1H), 2.58 (d, 1H), 1.85 (s, 3H).19F NMR (471 MHZ, DMSO-J6) 5 -127.53 (s, IF), -186.82 (s, IF).OR: -35,573 ° (589 nm, c 0,15 w / v %, DMF, 20°C)’H NMR (500 MHz, DMSO-J6) 59.38 (t, 1H), 8.54 (d, 1H), 8.46 (d, 1H), 8.18 (dd, 1H), Cpd- 7.89 (dd, 1H), 7.70 - 7.66 (m, 2H), 7.63 (d, 1H), 7.61 (dd, 1H), 7.54 (d, 1H), 7.32 (d, 1H), 80 6.26 (d, 1H), 4.96 (s, 2H), 4.65 (d, 2H), 4.25 - 4.19 (m, 2H), 4.00 (tt, 1H), 3.88 (dd, 2H), 3.84 (s, 3H), 3.64 (dd, 2H), 3.30 (dd, 2H), 2.08 (qd, 2H), 1.74 - 1.67 (m, 2H). ’H NMR (500 MHz, DMSO-J6) 59.43 (t, 1H), 8.56 (d, 1H), 8.49 (d, 1H), 8.25 - 8.18 (m, Cpd- 2H), 7.83 (d, 1H), 7.73 - 7.65 (m, 2H), 7.63 (d, 1H), 7.57 (dd, 1H), 7.24 (d, 1H), 6.75 (d, 81 1H), 4.96 (s, 2H), 4.67 (d, 2H), 4.50 - 4.40 (m, 1H), 4.25 - 4.19 (m, 2H), 3.97 (m, 2H), 3.92 (s, 3H), 3.67 - 3.61 (m, 2H), 3.49 (td, 2H), 2.07 - 1.95 (m, 4H).Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable)’H NMR (500 MHz, DMSO-t / 6) 59.59 (t, 1H), 8.56 (d, 1H), 8.44 (d, 1H), 8.24 (d, 1H), 8.22 (dd, 1H), 7.71 (td, 2H), 7.66 (d, 1H), 7.58 (dd, 1H), 7.23 (d, 1H), 6.73 (d, 1H), 6.26 - 6.09 (m, 1H), 5.23 (d, 1H), 4.89 (dd, 1H), 4.68 (d, 2H), 4.51 - 4.33 (m, 2H), 3.92 (s, 3H), Cpd- 3.88 (s, 3H).8219F {1H} NMR (471 MHz, DMSO-t / 6) 5 -114.90, -191.43.[a]D20°c: -39,661 ° (589 nm, c 0,23 w / v %, DMF , 20°C)SFC: Stationary phase: Chiralpak IH-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 55 / 45, rt = 1.03, ee = 100%’H NMR (500 MHz, DMSO-t / 6) 59.53 (t, 1H), 8.55 (d, 1H), 8.48 (t, 1H), 8.43 - 8.39 (m, 1H), 8.26 - 8.21 (m, 1H), 7.76 - 7.69 (m, 2H), 7.64 (s, 1H), 7.57 (d, 1H), 7.23 (d, 1H), 6.75 - 6.71 (m, 1H), 6.23 (dd, 1H), 4.66 (d, 2H), 4.63 - 4.56 (m, 1H), 4.09 (t, 1H), 3.92 (s, Cpd- 3H), 3.89 (s, 3H), 2.81 (dt, 1H), 2.62 - 2.54 (m, 1H).8319F {1H} NMR (471 MHz, DMSO-t / 6) 5 -186.67[a]D20°c: -41,7970(589 nm, c 0,19 w / v %, DMF , 20°C)SFC: Chiralpak IH-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 55 / 45, rt = 1.25, ee = 100%’H NMR (500 MHz, DMSO-t / 6) 59.50 (t, 1H), 8.55 (d, 1H), 8.31 (s, 1H), 8.27 (dd, 1H), 8.24 (d, 1H), 7.73 - 7.67 (m, 2H), 7.63 (s, 1H), 7.57 (dd, 1H), 7.23 (d, 1H), 6.74 (d, 1H), 6.24 (ddd, 1H), 4.66 (d, 2H), 4.59 (dt, 1H), 4.15 (t, 1H), 3.92 (s, 3H), 3.89 (s, 3H), 2.80 Cpd- (dt, 1H), 2.61 - 2.55 (m, 1H).8419F {1H} NMR (471 MHz, DMSO-t / 6) 5 -127.57, -186.87.[a]D20°c: -36,3640(589 nm, c 0,2 w / v %, DMF , 20°C)SFC: Chiralpak IH-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 55 / 45, rt = 0.99, ee = 100%’H NMR (400 MHz, CDCI3) 5 8.58 (d, 1H), 8.42 (s, 1H), 8.33 - 8.26 (m, 1H), 8.01 (d, 2H), 7.64 - 7.49 (m, 4H), 7.08 (d, 1H), 6.91 - 6.84 (m, 1H), 5.40 (d, 1H), 5.37 - 5.26 (m, 3H), 4.95 (d, 1H), 4.83 (d, 2H), 4.69 (d, 2H), 4.52 - 4.41 (m, 2H), 3.97 (s, 3H), 2.01 (s, Cpd- 4H).8519F {1H} NMR (471 MHz, DMSO-t / 6) 5 -113.76, -190.50.[a]D20°c: -31.8180(589 nm, c 0,13 w / v %, DMF, 20°C)SFC: Chiralpak IH-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 55 / 45 ; rt = 1.20 min, ee = 100%Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable)’H NMR (400 MHz, DMSO-t / 6) 59.67 (t, J= 5.8 Hz, 1H), 8.56 (d, J = 5.3 Hz, 1H), 8.54 (t, J = 1.8 Hz, 1H), 8.45 (t, J= 1.6 Hz, 1H), 8.23 (d, J = 2.5 Hz, 1H), 8.20 (t, J = 1.8 Hz, Cpd- 1H), 7.96 (d, J = 2.4 Hz, 1H), 7.75 (dd, J = 8.7, 2.5 Hz, 1H), 7.67 (d, J = 1.8 Hz, 1H), 7.60 86(dd, J = 5.3, 1.8 Hz, 1H), 7.25 (d, J = 8.7 Hz, 1H), 6.80 (d, J= 2.4 Hz, 1H), 5.03 (d, J= 6.3 Hz, 2H), 4.68 (d, J = 5.7 Hz, 2H), 4.58 (d, J = 6.3 Hz, 2H), 3.92 (s, 3H), 1.84 (s, 3H). ’H NMR (400 MHz, DMSO-t / 6) 59.67 (t, 1H), 8.56 (d, 1H), 8.54 (t, 1H), 8.45 (t, 1H), Cpd- 8.24 (d, 1H), 8.20 (t, 1H), 7.72 (dd, 2H), 7.67 (d, 1H), 7.58 (dd, 1H), 7.43 (t, 1H), 7.23 (d, 87 1H), 6.74 (d, 1H), 4.68 (d, 2H), 3.92 (s, 3H), 3.89 (s, 3H).19F {1H} NMR (471 MHz, DMSO-t / 6) 5 -124.18.’H NMR (500 MHz, DMSO-t / 6) 59.54 (t, 1H), 8.55 (d, 1H), 8.49 (d, 1H), 8.42 (d, 1H), 8.28 (d, 1H), 7.71 (d, 1H), 7.68 (dd, 1H), 7.65 (s, 1H), 7.57 (dd, 1H), 7.22 (d, 1H), 6.95 (d, 1H), 6.24 (ddd, 1H), 4.94 (s, 1H), 4.66 (d, 2H), 4.60 (dt, 1H), 4.15 (t, 2H), 4.09 (t, 1H), Cpd- 3.89 (s, 3H), 3.85 - 3.79 (m, 2H), 2.91 - 2.74 (m, 1H), 2.63 - 2.54 (m, 1H).8819F {1H} NMR (471 MHz, DMSO-t / 6) 5 -186.70SFC: Chiralpak IH-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 55 / 45 ; rt = 1.31 min, ee = 99.3%[a]D20°c: -40,20(589 nm, c 0,17 w / v %, DMF , 20°C)BIOLOGICAL EXAMPLESExample 2. In vitro assays2.1. Biochemical assays2.1.1. ADP-Glo™ SMARCA2 / 4 Assays2.1.1.1. Overview

[0394] The ADP-Glo™ assay is a luminescent technology assay which measures the ADP formed from a helicase reaction. In this specific study, the helicase reactions consisted of the metabolism of ATP to ADP using pCMV-dR8.91 plasmid as a substrate by SWI / SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2 (635-1331, N-ter FLAG, Active Motif, Cat# 81439) or SMARCA4 (658-1328, N-ter FLAG, Active Motif, Cat# 81440). In a second step the ATPase reactions are terminated, and all the remaining ATP is depleted. In a final step the ADP is converted into ATP and this newly synthesized ATP is measured by using a luciferase / luciferin reaction. The generated light is measured using an EnVision plate reader, wherein the luminescent signal obtained positively correlates with the helicase activity.2.1.1.2. Protocol with compound pre-incubation

[0395] The test compounds were prepared as a 10-point dilution series with 1 / 5 dilution steps in 100% DMSO starting from 2 mM highest concentration, diluted 1 / 20 in water and 1 pL was transferred to the assay plates (Revvity Inc., Cat# 6007290).

[0396] The enzyme-substrate mixture was prepared by adding the enzyme and the substrate to the assay buffer (final concentration 25 mM Hepes pH7.5, 0.25 mM EGTA, 5% glycerol, 0.005% Tween 20, 5 mM MgCl2and 1 mM DTT).

[0397] 2 pL enzyme-substrate mixture was added to the assay plates, resulting in a final enzyme concentration of 0.625 nM (SMARCA2) and 1.25 nM (SMARCA4) and a final substrate concentration of 2 nM (SMARCA2 assay) and 1 nM (SMARCA4 assay).

[0398] The reaction was started by adding 2 pL of ATP (diluted in the assay buffer, (final concentration 10 pM)) on the assay plates. Plates were centrifuged for a few seconds at 300xg, followed by an incubation at RT for 120 min.

[0399] The reactions were stopped, and the unconsumed ATP was depleted by adding 5 pL ADP-Glo Reagent (Promega, Cat# V912B) to the reaction. The plates were centrifuged for a few seconds at 300 xg and incubated at RT for 40 min (ATP depletion).

[0400] The ADP was converted to ATP and luciferase and luciferin was introduced to detect ATP by adding 10 pL Kinase Detection Reagent (Promega, Cat# V913B + V914B) to the reaction. The plates were centrifuged for a few seconds at 300xg and incubated at RT for 30 min (ADP detection).

[0401] Luminescence was measured on an EnVision plate reader (Revvity Inc.).2.1.1.3. Assay variant with high ATP concentration

[0402] Besides the standard ADP-Glo™ assay, an assay variant with high ATP concentration was developed, this to mimic the ATP concentration in the intra-cellular environment. In this high ATP variant, an ATP concentration of 1 mM and an enzyme concentration of 7.5 nM was used. The incubation time with luciferin and luciferase (ADP detection step) was increased to 60 min.Table V. Conditions for human SMARCA helicase ADP-Glo™ assaysEnzyme, Substrate, Incubation ATP Assay buffer[Enzyme] [Substrate] time25 mM Hepes10 pM ATP (or 1 pH7.5, 0.25 mMSMARCA2 (Active pCMV-dR8.91mM ATP for EGTA, 5%Motif, Cat# 81439), plasmid (Gentaur,high ATP assay) glycerol, 0.005% 120 min 0.625 nM (7.5 nM for Cat# PVT2323), 2(Promega, Cat# Tween 20, 5 mMhigh ATP assay) nMV915B) MgCl2and 1 mMDTTEnzyme, Substrate, Incubation ATP Assay buffer[Enzyme] [Substrate] time25 mM Hepes10 pM ATP (or 1 pH7.5, 0.25 mMSMARCA4 (Active pCMV-dR8.91mM ATP for EGTA, 5%Motif, Cat# 81440), plasmid (Gentaur,high ATP assay) glycerol, 0.005% 120 min 1.25 nM (7.5 nM for Cat# PVT2323), 1(Promega, Cat# Tween 20, 5 mMhigh ATP assay) nMV915B) MgCE and 1 mMDTT2.1.1.4. Data analysis and Results

[0403] Raw data were generated following the read-out performed on the EnVision plate reader, plotted to generate concentration response curves to calculate percentage inhibition (PIN) and IC50 for each SMARCA homologue.Table VI. SMARCA2 & SMARCA4 ADP-Glo™ assay ICso of illustrative compounds of the invention.* > 500 - 20000 nM** > 100 - 500 nM*** > 50 - 100 nM**** 0.01 - 50 nMNA not measuredCpd SMARCA2 SMARCA4Cpd- 17 * * * * **Cpd- 18 * * * * **Cpd- 19 * * * * *Cpd-20 ** *Cpd-21 * * * *Cpd-22 ** *Cpd-23 * * * * **Cpd-25 * *Cpd-26 * * * *Cpd-27 * * * *Cpd-28 ** *Cpd-29 * * * * * * * *Cpd-30 ** *Cpd SMARCA2 SMARCA4 Cpd-31 ** * Cpd-32 * * * * * * * Cpd-33 * * * * ** Cpd-34 * * * * * * * Cpd-35 * * * * Cpd-36 * * * * * * * * Cpd-37 * * * * * Cpd-38 * * * * * Cpd-39 * * * * ** Cpd-40 * * * * * * * * Cpd-41 * * * * * Cpd-42 * * * * ** Cpd-43 ** N / A Cpd-44 * * * * ** Cpd-45 * * * * * Cpd-46 ** * Cpd-48 * * * * * Cpd-49 * * * * * Cpd-50 * * * * * Cpd-51 * * * * ** Cpd-52 * * * * ** Cpd-53 * * * * * * * * Cpd-54 ** * Cpd-55 * * * * * * * * Cpd-66 * N / A Cpd-67 * N / A Cpd-68 * N / A Cpd-69 * * Cpd-70 * * Cpd-71 * * * * * * * * Cpd-72 * * * * * * * * Cpd-73 * * * * * Cpd-74 * * * * * * * * Cpd-75 * * * * **Cpd SMARCA2 SMARCA4Cpd-76 * * * * * * * *Cpd-77 * * * * * * * *Cpd-78 * * * * * * * *Cpd-79 * * * * * * * *Cpd-80 ** *Cpd-81 * * * * * * * *Cpd-82 * * * * * * * *Cpd-83 * * * * * * * *Cpd-84 * * * * * * * *Cpd-85 * * * * * * * *Cpd-86 * * * * * * * *Cpd-87 * * * * * * * *1.1. Cellular assays2.1.2. KRT80-Based Target Engagement Assay2.1.2.1. Overview

[0404] Keratin, type II cytoskeletal 80 (KRT80) is a gene that is transcriptionally regulated downstream of SMARCA2 and is known to be a biomarker for SMARCA2 inhibition in SMARCA4 deficient cells, such as A549. The KRT80 mRNA transcription assay aims at measuring the reduction of KRT80 gene expression levels in A549 cells upon treatment with possible SMARCA2 inhibitors using quantitative Polymerase Chain Reaction (qPCR) as a readout. For normalization purposes, glucuronidase beta (B2M) mRNA levels are measured within the same cDNA sample.2.1.2.2. Protocols

[0001] The test compounds are prepared as a 10-point 1 / 5 dilution series in 100% DMSO starting from 10 mM.

[0002] A549 cells (ATCC, Cat# CCL-185) are seeded (7000 cells in 45 pL per well) in DMEM assay medium supplemented with 2% heat-inactivated fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (P / S) in 384-well cell plates. The plates are briefly centrifuged at 300xg and stored at RT for 15-30 min to allow cells to distribute evenly in the wells.

[0003] Compounds and controls are diluted 1 / 10 in assay medium and 5 pL transferred to the cell plates. The plates containing cells and compounds are briefly centrifuged at 300xg and incubated at 37 °C, 5% CO2 for 15-18 h.

[0004] The supernatant is then removed, and the cells washed once with cold PBS (4 °C) using a Blue®Washer device (BlueCatBio GmbH).

[0005] Then the cells are lysed by adding 25 pL of Cells-to-Ct lysis buffer (Thermo Fisher Scientific Inc., Cat# 4391851C). The plates are incubated on an orbital shaker for 5 min. 2.5 pL of Cells-to-Ct STOP solution is added on top of the lysis buffer and the plates incubated 2 min on the orbital shaker.

[0006] Plates are put on ice if the RT-PCR is performed the same day. If the RT-PCR is performed later, plates are sealed with an aluminum seal and kept at -80 °C and later thawed on an orbital shaker (30 min at 500 rpm) and put on ice until the RT-PCR.

[0007] A PCR plate is filled with 20 pL of reverse transcription mix containing 50% Fast Advanced reverse transcription buffer, 5% Fast Advanced reverse transcription enzyme mix (Thermo Fisher Scientific Inc., Cat# A39110), and 20% nuclease-free water (Qiagen GmbH, Cat# 129117).

[0008] 5 pL of the cell lysate is added on top of the reverse transcription mix in the PCR plate and the plate is sealed.

[0009] RT-PCR is performed in a thermal cycler to generate cDNA: samples are incubated for 30 min at 37 °C, 5 min at 95 °C followed by cooling to 4 °C. Sample plates are then kept on ice or frozen at -20 °C for later use.

[0010] A PCR plate is filled with 6 pL of a mix (60% of the total reaction volume) containing 50% of TaqMAN Fast Universal PCR Master Mix (Thermo Fisher Scientific Inc., Cat# 4444557), 1.7% of TaqMAN KRT80 gene expression assay (Thermo Fisher Scientific Inc., Cat# 4351368) (250 nM final), 1.7% of TaqMAN B2M expression assay (Thermo Fisher Scientific Inc., Cat# 4448491) (250 nM final) and 6.6% of nuclease-free water (Qiagen GmbH, Cat# 129117).

[0011] With a liquid handler, 4 pL of the cDNA (40% of the total reaction volume) is added on top of the qPCR mix. The PCR plate is sealed, briefly centrifuged, and the qPCR is performed using the following program: 20 s at 95 °C, 40 cycles of 1 s at 95 °C and 20 s at 60 °C.

[0012] Raw data are generated by the ViiA7 Real-Time PCR System and the cycle threshold (Ct) calculations are done by the ViiATM 7 software (Thermo Fisher Scientific Inc.) for both genes, KRT80 and B2M. These data are imported into the Phaedra software (Open Analytics NV) for automated calculation of Delta Ct (DCt) and Normalized Relative Quantities (NRQ) . Based on the control wells, data are converted to percentage of inhibition (PIN) and concentration-response curves generated. From those curves, IC50 values were determined, all using Phaedra.2.1.3. SMARCA2 / 4 Selectivity Assay (HT1080 SMARCA2 / 4 KO Cells, Multiplexed qPCR KRT802.1.3.1. Overview

[0013] Keratin, type II cytoskeletal 80 (KRT80) is a gene transcriptionally regulated downstream of both SMARCA2 and SMARCA4. Its expression is reduced upon inhibition of either target and therefore serves as a pharmacodynamic biomarker for SMARCA2 / 4 inhibition. The SMARCA2 / 4 selectivity assay usesHT1080 SMARCA2 knockout (KO) cells to assess SMARCA4 inhibition, and HT1080 SMARCA4 KO cells to assess SMARCA2 inhibition, enabling the evaluation of compound selectivity. Quantitative Polymerase Chain Reaction (qPCR) is used to detect changes in KRT80 mRNA expression. TATA-Box Binding Protein (TBP) is measured in the same lysate as a housekeeping gene using a multiplexed readout.2.1.3.2. ProtocolsTest compounds are prepared as a 10-point 1 / 5 dilution series in 100% DMSO, starting from a 2 mM top concentration (final assay concentration: 6.67 pM @ 0.33% DMSO).HT1080 SMARCA2 KO and SMARCA4 KO cells are seeded separately (10,000 cells in 45 pL per well) in EMEM assay medium supplemented with 2% heat -inactivated fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (P / S) in 384-well cell plates. Plates are briefly centrifuged at 1000 RPM and left at room temperature (RT) for 30-45 min to allow even cell distribution.Compounds and controls are diluted 1 / 30 in assay medium and 5 pL is transferred to the assay plates (duplicates per cell line on separate plates). Plates are briefly centrifuged again and incubated at 37 °C, 5% CO2 for 15-18 hours.After incubation, supernatants are removed, and cells are washed once with cold PBS (4 °C) using a Blue®Washer device (BlueCatBio GmbH).Cells are lysed by adding 25 pL of Cells-to-Ct lysis buffer (Thermo Fisher Scientific Inc.) followed by 5 min incubation on an orbital shaker. 2.5 pL of Cells-to-Ct STOP solution is added and plates are incubated another 2 min on the shaker.Plates are placed on ice if RT-PCR is performed the same day. For delayed analysis, plates are sealed and stored at -80 °C. Prior to reverse transcription, plates are thawed on an orbital shaker (30 min at 500 rpm) and kept on ice.A PCR plate is prepared with 18 pL of reverse transcription mix per well containing 70% Fast Advanced RT buffer, 7% Fast Advanced RT enzyme mix (Thermo Fisher Scientific Inc.), and 23% nuclease-free water (Qiagen GmbH).7 pL of lysate is added to the PCR plate, which is then sealed. RT-PCR is performed with the following program: 60 min at 37 °C, 5 min at 95 °C, followed by cooling to 4 °C. The cDNA is stored on ice or at -20 °C until qPCR analysis.A new PCR plate is filled with 6 pL of qPCR mix containing 83.3% TaqMAN Fast Advanced Master Mix (Thermo Fisher Scientific Inc.), 2.6% TaqMAN KRT80 gene expression assay (Thermo Fisher Scientific Inc., Cat# Hs01372365_ml), 2.6% TaqMAN TBP expression assay (Thermo Fisher Scientific Inc., Cat# Hs00427620_ml), and 11.1% nuclease-free water (Qiagen GmbH).With a liquid handler, 4 pL of cDNA is added to the qPCR mix. The PCR plate is sealed, briefly centrifuged, and stored at 4 °C if not immediately run. qPCR is performed using the following program: 20 s at 95 °C, followed by 40 cycles of 1 s at 95 °C and 20 s at 60 °C.Raw data are generated using the ViiA7 or QuantStudio Real-Time PCR systems. Ct values for both genes (KRT80 and TBP) are calculated by their respective software. Data are then imported into Phaedra software (Open Analytics NV) for automated calculation of Delta Ct (ACt), Normalized Relative Quantities (NRQ) and scaled NRQ. Based on the control wells, data are converted to Percentage of Inhibition (PIN) and concentration-response curves are generated. From those curves, IC50 values are determined, all using Phaedra software.

[0014] 2.1.4. Cell Death Based Ph en otypic Assay2.1.4.1. Overview

[0015] SK-MEL-5 (ATCC, Cat# HTB-70) is a SMARCA4 mutant melanoma cell line which is highly dependent on SMARCA2 to grow. The SK-MEL-5 proliferation assay aims at measuring the effect of possible SMARCA2 inhibitors on the proliferation of the SK-MEL-5 cells by using an ATPlite™ readout (Revvity, Inc.). ATP is a marker for cell viability because it is present in all metabolically active cells. SMARCA2 inhibitors are able to decrease SK-MEL-5 cell proliferation and thus the amount of ATP, which results in a decrease in ATPlite™ luminescent signal.2.1.4.2. Protocols

[0016] The test compounds were prepared as 8-point serial dilutions with 1 / 4 dilution steps in 100% DMSO starting from 10 mM highest concentration (final highest concentration 30 pM) in 384 well plates.

[0017] Four days prior to the start of the assay, SK-MEL-5 cells were thawed and seeded in T175 flasks, 2.0 xlO6cells per flask, in 25 mL culture medium (EMEM containing 10% heat inactivated Fetal Bovine Serum (FBS) and 1% Penicillin - Streptomycin (P / S)). After 24 h incubation at 37 °C, 5% CO2, the medium was refreshed, and the cells were further incubated in an incubator at 37 °C and 5% CO2 for 72 h

[0018] SK-MEL-5 cells were harvested using 0.25% Trypsin-EDTA and counted. 2000 cells were seeded in only the inner wells of a 384 well cell plate, in 70 pL assay medium (EMEM containing 2% heat inactivated FBS and 1% P / S) per well. The outer wells were filled with 70 pL of phosphate -buffered saline. The plates were briefly centrifuged at 300 xg and stored at RT for 15-30 min to allow cells to distribute evenly in the wells.

[0019] Compounds and controls were diluted 1 / 22 in assay medium and 5 pL was transferred to the cell plates. The plates with cells and compound were briefly centrifuged at 300 xg and incubated at 37 °C, 5% CO2 for 96 h.

[0020] After 96 h incubation, the plates were centrifuged for 1 min at 300 xg and 50 pL supernatant was removed from the wells. 25 pL ATPlite™ reagent (Revvity, Cat# 6016739) was added to the wells containing cells and compounds. The plates were briefly centrifuged at 300 xg and were incubated at RT for 10 min.

[0021] Readout of the luminescent signal was performed on a plate reader, e.g., EnVision (Revvity, Inc.).

[0022] Raw data were generated by the plate reader (e.g., EnVision). These raw data were imported into the Phaedra software (Open Analytics NV) for automated calculation of results based on the control wells and the creation of the concentration response curves from which IC50 values were derived.2.1.4.3. Results & Outcome

[0023] The data obtained when subjecting illustrative compounds of the invention are described in the table below.Table VII. SK-MEL-5 cell death assay results of illustrative compounds of the invention.* > 1000 - 20000 nM** > 500 - 1000 nM*** > 100 - 500 nM**** 0.01 - 100 nMCpd SK-MEL-5Cpd-1 *Cpd-2 *Cpd-8 *Cpd-9 *Cpd- 10 *Cpd- 12 **Cpd-14 **Cpd- 16 *Cpd- 17 **Cpd- 18 **Cpd- 19 *Cpd-20 *Cpd-21 *Cpd-22 *Cpd-23 *Cpd-25 *Cpd-26 *Cpd-27 *Cpd-28 *Cpd-29 * * *Cpd-30 *Cpd SK-MEL-5 Cpd-31 * Cpd-32 ** Cpd-33 * Cpd-34 ** Cpd-35 * Cpd-36 * * * Cpd-37 * Cpd-39 * Cpd-40 * * * Cpd-41 * Cpd-42 ** Cpd-43 * Cpd-44 * Cpd-45 * Cpd-46 * Cpd-48 * Cpd-49 * Cpd-50 * Cpd-51 * Cpd-52 * Cpd-53 * Cpd-54 * Cpd-55 * * * * Cpd-66 * Cpd-68 * Cpd-69 * Cpd-71 * * * * Cpd-72 * * * * Cpd-73 * Cpd-74 * * * Cpd-75 * Cpd-76 * * * Cpd-77 * * * * Cpd-78 * * * *Cpd SK-MEL-5Cpd-79 * * * *Cpd-80 **Cpd-81 * * * *Cpd-82 * * * *Cpd-83 * * * *Cpd-84 * * * *Cpd-85 * * * *Cpd-86 * * *Cpd-87 * * *Cpd-88 * * * *Example 3. Pharmacokinetic, ADME and Toxicity Assays3.1. Thermodynamic solubility

[0024] The thermodynamic solubility is determined in Fasted State Simulated Gastric Fluid (FaSSGF, pH 1.6), Fed State Simulated Intestine Fluid (FeSSIF v2, pH 5.8), Fasted State Simulated Intestine Fluid (FaSSIF v2, pH 6.5) and phosphate buffer (pH7.4).

[0025] Approximately 1 mg of each compound is weighed into a 12 m clear glass screw cap vial and 1 m of medium is added (final concentration about 1 mg / mL). The sample is placed in a thermodynamic water bath at 37 °C and 120 rpm of orbital shaking for 24 h.

[0026] For HPLC / DAD analysis the sample is filtered through a 0.2 pm PTFE filter mounted onto syringe and then analysed neat and accurately diluted 10 and 100 times.

[0027] The same batch of test compound is used as a standard, assigning the purity of 100%, in order to prepare the calibration curve. Test compound stock solution is prepared at a concentration of 1 mg / mL in DMSO and diluted to cover the calibration range from 0.0001 - 0.1 mg / mL.

[0028] The samples are analysed on HPLC system with a flow rate of 0.5 mL / min. Solvent A is 10 mM ammonium carbonate at pH 10 and solvent B is acetonitrile. The sample is going through a XB ridge Cl 8 2.7 pM (2.1 x 50 mm) column, from Waters. The solvent gradient has a total run time of 12 min and ranges from 10% B to 90% B.

[0029] Peak areas are analysed and are plotted against the standard curve to obtain the solubility of the compound.

[0030] Solubility values are reported in pM or pg / mL.3.2. Aqueous Solubility

[0031] This protocol describes determination of kinetic solubility by turbidimetry.

[0032] Turbidimetric solubility allows rapid determination of solubility using small amounts of compound. Briefly, compound’s DMSO solutions (prepared at specific concentrations) are spiked into aqueous buffer and turbidity is measured using VIS spectrophotometry at 620 nm. Sulfaphenazole and a-naphtoflavone are used as assay controls.

[0033] 10 mM DMSO stock solution is diluted in DMSO (in 96-well V-bottom polypropylene microplates) to a concentration of 1 mM.

[0034] 3 pL of compound ’s / control’s dilution in DMSO in triplicates are added to appropriate wells containing 297 pL of 100 mM PBS solution to the final concentration of 10 pM (1% DMSO; Table 3.; done in 96-well flat bottom microplates)

[0035] The plate is incubated by gently shaking (200-300 rpm) for 45 min at 37 °C and left at RT (without shaking) for 15 min (total incubation time = 1 h).

[0036] The plate absorbance at 620 nm is read on a Microplate reader (Tecan, Infinite F500 or Spark).

[0037] Calculation of solubility range data and resulting curves is made by Excel tools software.

[0038] The absorbance is proportionally increased with concentration of insoluble particles. Compound / control samples are compared to a solvent control in aqueous buffer (DMSO 1% final concentration), where significant increase of sample absorbance is considered when its absorbance is 3-fold standard deviation of average DMSO absorbance.

[0039] Results are accepted depending on solubility values obtained for assay controls:a-naphtoflavone: <10 pMsulfaphenazole: >10 pM

[0040] Results are expressed as an average of three replicas (<10 pM or >10 pM) for one concentration set-up.3.3. Plasma Protein Binding (Equilibrium Dialysis)

[0041] The binding of the test compound to plasma proteins is tested by equilibrium dialysis using a Teflon unit from HTDialysis, performed on a Freedom EVO liquid handling unit.

[0042] Prior to the start of the experiment, dialysis membranes (Dialysis membranes MW cut-off 12-14kDa - HTDialysis - Cat# 1101) are soaked in deionised water for 60 min, transferred and left overnight in 20% ethanol. On the day of experiment, compound and control stock solutions are diluted, spiked into plasma in order to achieve a final concentration of 5 pM (0.5% DMSO).

[0043] Immediately after assembly of the Teflon unit, a volume of 100 pL of plasma (spiked with compound / control) is placed on one side of the well and 100 pL of blank PPB buffer (60 mM Na2HPO4, 14 mM KH2PO4, 70 mM NaCl) is added to the other side, respectively, with each compound assayed in duplicate. The test compound is incubated for 4 h at 37 °C with gentle shaking. Thereafter, an aliquot is taken from each side of the well and matrix matched (mix of equal volumes of spiked plasma with blank PPB buffer and samples from buffer compartment with blank plasma). In order to estimate the recovery an aliquot is also taken at t=0 min from spiked plasma solutions and matrix matched as described above.

[0044] Matrix matched samples are further mixed with six volumes of STOP solution (acetonitrile: methanol, 2: 1 v / v with an internal standard (IS)). After brief mixing and centrifugation (at 4500 rpm for 30 min, at +4°C), the supernatant is transferred into new plates and analysed and quantified by LC-MS / MS.

[0045] The percentage bound (PPB) is determined using the following equation:

[0046] PPB = [(Cplasma-Cbuffer) / Cplasma]*100

[0047] Cplasma = Peak area of the compound in the plasma / Peak area of the IS in the plasma

[0048] Cbuffer = Peak area of the compound in the buffer / Peak area of the IS in the buffer

[0049] The recovery is a control, it allows to be sure that the compound has not a non-specific binding to the plates or it is not stable in the plasma in these conditions.

[0050] % recovery = [(Buffer+Plasma) / Recovery]* 100

[0051] Buffer = (ratio of the peak area of the compound / peak area of IS) in Buffer compartment after 4 h

[0052] Plasma = (ratio of the peak area of the compound / peak area of IS) in Plasma compartment after 4 h

[0053] Recovery = ratio at TO of the peak area of the compound in the well recovery / peak area of the IS in the well recovery3.4. Aldehyde oxidase stability

[0054] An in vitro metabolic stability in human and rat liver S9 (human: 20-donor pool, mixed gender (Coming, Cat# 452961) and rat: pooled, male Sprague -Dawley (Coming, Cat# 452591)) is done in order to investigate the test compound as substrate of aldehyde oxidase. A 10 mM DMSO stock solution of the test compound is first diluted in DMSO (40 fold) to obtain a 250 pM working solution. Incubation mixtures are prepared by adding liver S9 suspension (final protein concentration of 2 mg / mL) to 50 mM potassium phosphate buffer, pH 7.4. Hydralazine (Sigma, Cat# H1753) (selective inhibitor of aldehyde oxidase; final concentration of 100 pM) or miliQ water are added for incubations with and without addition of selective inhibitor, respectively. After pre-warming for 5 min at 37 °C, the reaction is initiated by addition of test compound to the incubation mixture (final concentration in the incubation mixture of 1 pM, 0.4%DMSO). After 0, 3, 6, 12, 18 and 30 min of incubation, the reaction (aliquot of 100 pL) is terminated with 300 pL of acetonitrile: methanol (2: 1) mixture with 1% acetic acid and the analytical internal standard. Samples are mixed, centrifuged and the supernatant analysed by LC-MS / MS (Table 2 and Table 3). Phthalazine (Aldrich, Cat# P38706) is included as a positive control.

[0055] S9 stability, expressed as the percentage of remaining parent compound, is calculated from the peak area ratio of compound and internal standard following different incubation times compared to the same ratio at the t=0 min (100%). The half-life (tl / 2) is calculated in GraphPadPrism software from % remaining vs. time regression using non-linear regression fit (one phase exponential decay) with following constrain parameters: Span=100, Plateau=0, K=no constraint).

[0056] In vitro intrinsic clearance (CLint) is calculated from the half-life value using following equation: CLint[pL / min / mg] = (ln2 / tI / 2)*(mL per incubation / mg S9 protein)3.5. Liver microsomal stability

[0057] The test compound is diluted from DMSO stock solution to obtain a final concentration of 1 pM in the final incubation mix (final DMSO 0.03%). A NADPH generating system (Cofactor solution) is prepared by adding to a 50 mM PBS pH 7.4 buffer, NADP (Sigma, N0505), G6P (Sigma, G6526), MgCLxOILO (Sigma, M2670) and G6P DH (Sigma, G637) to obtain in the final incubation mix NADP at 0.5 mM , G6P at 5 mM , MgC12.6H2O at 0.5 mM and G6P DH at 1.5 U / mL. Liver microsomes (Coming; Discovery Life Sciences) solution is prepared from 20 mg / mL stock concentration to obtain a final concentration in the incubation mix of 0.5 mg / mL.

[0058] Test compounds are incubated at 37 °C with and without cofactors and reaction is started by adding cofactors or buffer (for negative control) to incubation mix. Time points are taken at 0, 10, 25 and 40 min. At the desired incubation time point, a STOP solution (acetonitrile: methanol, 2:1 v / v) is added at a ratio 3: 1 to the incubation mix. Samples are then centrifuged (at 4500 rpm, at 4 °C, for 30 min). The supernatant is then analyzed using a LC-MS / MS method.

[0059] Metabolic stability, expressed as the percentage of remaining parent compound, is calculated from the ratio of peak area of the remaining compound and peak area of the internal standard after different time of incubation compared to the same ratio at the t=0 min (100%):

[0060] % remaining = (peak area ratios of test compound vs IS at appointed time) / (peak area ratios of test compound vs IS at 0 min) x 100

[0061] The half-life (ti / 2) is calculated in GraphPad Prism software from % remaining vs. time regression using non-linear regression fit (one phase exponential decay with following constrain parameters: Span=100, Plateau=0, K=no constraint).

[0062] In vitro intrinsic clearance (CLmt) is calculated from half-life using following equation:

[0063] CLmt = [pL / min / mg] = 0.693 / ti / 2 / min ' (mL of incubation / mg protein) x 10003.6. Hepatocyte stability

[0064] The test compound is diluted from DMSO stock solution to obtain a final concentration of 1 pM in the final incubation mix. The test compound is incubated in dog, monkey, human, mouse and rat hepatocytes (BioIVT, mouse Cat. No. M005052, rat Cat. No. M00005, dog, Cat. No. M00205, monkey Cat. No. M00305, human Cat. No. X008001) (final concentration: 0.5x106 cells / mL), resuspended in Krebs-Henseleit modified buffer for 3 h (except in human - 90 min) at 37 °C. Aliquots are taken at different time points and the reaction is terminated by addition of 3 volumes of STOP solution (acetonitrile: methanol = 2:1 with an internal standard). Aliquots were then centrifuged (at 4500 rpm, at 4 °C, for 30 min). The supernatant is then analysed using a LC-MS / MS method.

[0065] Metabolic stability, expressed as the percentage of remaining parent compound, is calculated from the ratio of peak area of the remaining compound and peak area of the internal standard after different time of incubation compared to the same ratio at the t=0 min (100%).

[0066] The half-life (t 1 / 2) is calculated in GraphPadPrism software from % remaining vs. time regression using non-linear regression fit (one phase exponential decay) with following constrain parameters: Span=100, Plateau=0, K=no constraint)

[0067] In vitro intrinsic clearance (CLint) is calculated from half-life using the following equation:

[0068] CLint[pL / min / 106cells] = (ln2 / tl / 2)*(mL per incubation / #cells per incubation)3.7. Caco2 Permeability

[0069] Bi-directional Caco-2 assays are performed as described below. Cells are seeded at 1 x 105 cells / cm2 in 96-well HTS Transwell plates (Coming). Permeability assays are performed with the cells at days 21-25 post-seeding.

[0070] This assay is performed in both the apical (A) to basolateral (B) A-B or B-A direction. Compounds and the references (propranolol, labetalol, ranitidine, colchicine) are prepared at 10 pM in HBSS-MES (pH 6.5) or HBSS-HEPES (pH 7.4) with a final DMSO concentration of 1 % (v / v). The working solution is then centrifuged and the supernatant is added to the donor side.

[0071] The assay plate is incubated at 37 °C for 60 min or 40 min for the A-B or B-A assay, respectively. Samples are aliquoted from the donor side at time zero and the end point, and from the receiver side at the end point.

[0072] In addition, Lucifer yellow (LY), a membrane integrity marker, is co-incubated with the test compound at the start of the experiment to assess integrity of the cell layers. As LY cannot freely permeate lipophilic barriers, a high Papp of the Lucifer yellow (measured by fluorescence) indicates poor formation of the cell monolayer.

[0073] Moreover, the Transepithelial electrical resistance (TEER) of each Multiscreen™ well is also evaluated prior to the initiation of the assay so as to evaluate monolayer integrity.

[0074] Reference compounds namely, Propranolol (highly permeable), Labetalol (moderately permeable), Ranitidine (poorly permeable), and Colchicine (P -glycoprotein substrate) are included in this assay. Samples are analysed by LC / MS-MS.

[0075] Apparent permeability (Papp) values are calculated from the relationship:

[0076] Papp = [compound] acceptor final ' Vacceptor / ([COmpOUnd] donor initial ' Vd onor ) / Tine Vd onor / surface area ' 60 ' IO-6cm / s

[0077] V = chamber volume

[0078] Tine = incubation time.

[0079] Surface area = 0.33cm2

[0080] The Efflux ratios, as an indication of active efflux from the apical cell surface, are calculated using the ratio of Papp B>A / Papp A>B.

[0081] The following assay acceptance criteria are used: If at least 3 out of 4 control molecules are in these ranges determined by the historical data, the assay is validated.

[0082] Lucifer yellow permeability: <0.5 10-6 cm / s

[0083] Colchicine: Papp (A>B) value < 1 (xlO-6 cm / s) with Efflux ratio >4

[0084] Labetalol: Papp (A>B) value < 6 (xlO-6 cm / s)

[0085] Propranolol: Papp (A>B) value < 25 (xlO-6 cm / s)

[0086] Ranitidine: Papp (A>B) value < 2 (xlO-6 cm / s)3.8. MDCKII-MDR1 Permeability

[0087] MDCKII-MDR1 cells are Madin-Darby canine kidney epithelial cells, over-expressing human multi -drug resistance (MDR1) gene, coding for P -glycoprotein (P-gp). Cells are obtained from Netherlands Cancer Institute and used after a 3-4 day cell culture in 24-well Millicell cell culture insert plates (Millipore, PSRP010R5). Bi-directional MDCKII-MDR1 permeability assay is performed as described below.

[0088] 3x105 cells / mL (1.2x105 cells / well) are seeded in plating medium consisting of DMEM + 1% Glutamax-100 + 1% Antibiotic / Antimycotic + 10% FBS (Biowest, S1810). Cells are left in CO2 incubator for 3-4 days. The medium is changed 24 h after seeding and on the day of experiment.

[0089] Test and reference compounds (amprenavir and propranolol) are prepared in Dulbecco’s phosphate buffer saline (D-PBS, pH7.4) and added to either the apical (400 pL) or basolateral (800 pL) chambers of the Millicell cell culture insert plates assembly at a final concentration of 10 pM (0.5 pM in case of amprenavir) with a final DMSO concentration of 1%

[0090] 100 pM Lucifer Yellow (Sigma) is added to the all-donor buffer solutions, in order to assess integrity of the cell monolayers by monitoring Lucifer Yellow permeation. Lucifer yellow is a fluorescent marker for the paracellular pathway, and it is used as an internal control in every monolayer to verify tight junction integrity during the assay.

[0091] After a 1 h incubation at 37 °C while shaking at an orbital shaker at 150 rpm, 75 pL aliquots are taken from both apical (A) and basal (B) chambers and added to 225 pL acetonitrile: water solution (2:1) containing analytical internal standard (10 ng / mL warfarin) in a 96 well plate. Aliquoting is also performed at the beginning of the experiment from donor solutions to obtain initial (Co) concentration.

[0092] Concentration of compound in the samples is measured by high performance liquid-chromatography / mass spectroscopy (LC-MS / MS).

[0093] Lucifer yellow is measured with a Fluoroscan Ascent FL Thermo Scientific (Ex 485 nm and Em 530 nm) in a 96 well plate containing 150 pL of liquid from all receiver wells (basolateral or apical side).

[0094] The apparent permeability coefficient (Papp) is calculated according to the following equation: Papp = (dQ / dT)*(l / C0)*(l / A)

[0095] where dQ / dT = permeability rate

[0096] CO = initial concentration in donor compartment

[0097] A = surface area of the cell monolayer (0.11 cm2)

[0098] ‘ ‘Concentration” is the ratio between compound and internal standard peak areas.

[0099] The Papp value has a dimension of a rate (xlO-6 cm / sec).

[0100] Permeability values are classified as follows: low permeability: <2xl0-6cm / sec, moderate permeability: 2-10x 10'6cm / sec, high permeability: >10* 10'6cm / sec.

[0101] The Efflux ratio, as an indication of active efflux from the apical cell surface, is calculated using following equation: Efflux ratio = Papp (B2A) / Papp (A2B).

[0102] A compound is considered to be a possible P-gp substrate when the efflux ratio is > 2.

[0103] Mass balance (MB) is calculated from equation: MB = (Md+Mr) / Mo, where Md = mass of drug in donor compartment at time 60 min, Mr = mass of drug in receiver compartment at time 60 min, Mo = mass of drug in donor compartment at time 0 min, Mass of drug = Analyte / IS ratio * volume of compartment (75 pL or 250 pL).

[0104] Mass balance results should be evaluated as follows: Mass balance between 80-120%: acceptable, Mass balance between 50-80% and 120-135% should be interpreted with caution, Mass balance <50% and >135% should be discarded.

[0105] Results are accepted based on obtained data: Lucifer yellow: all Papp values should be <3x10-6 cm / sec, Amprenavir: low permeability (PappA2B <2x10-6 cm / sec), efflux ratio >2, Diclofenac: high permeability (PappA2B >10x10-6 cm / sec), efflux ratio <23.9. Pharmacokinetic study in rodents3.9.1. Animals

[0106] Wistar-Han rats (male, 200-225g) are obtained from Janvier (France).

[0107] CD-I Mice (male, 25 -30g) are obtained from Janvier (France).

[0108] Animals are acclimatized for at least 7 days before treatment and are kept on a 12 h light / dark cycle (0700 - 1900). Temperature is maintained at approximately 22 °C, and food and water are provided ad libitum.3.9.2. Pharmacokinetic study

[0109] Compounds are formulated in DMSO / 10% hydroxylpropyl -[3-cyclodextrine (5 / 95) for the intravenous route and in a suitable solution for the oral route. Test compounds are orally dosed as a single oesophageal gavage at 5 mg / kg under a dosing volume of 10 mL / kg (group of 3 animals) and intravenously dosed as a bolus via the caudal vein at 0.5 mg / kg under a dosing volume of 5 mL / kg. (groups of 2 animals). Blood samples are collected at the retro-orbital sinus with EDTA as anti -coagulant at the following time points: 0.05, 1, 3, 6 and 24 h (intravenous route), and 0.25, 1, 3, 6, and 24 h (oral route). Whole blood samples are centrifuged at 5000 rpm for 10 min and the resulting plasma samples are stored at -20 °C pending analysis.3.9.3. Quantification of compound levels in plasma

[0110] Plasma concentrations of each test compound are determined by an LC-MS / MS method in which the mass spectrometer is operated in positive or negative electrospray mode.3.9.4. Determination of pharmacokinetic parameters[oni] Pharmacokinetic parameters are calculated for each individual animal and for each analyte by noncompartmental analysis.3.10. Liability for QT prolongation

[0112] Potential for QT prolongation is assessed in the hERG manual patch clamp assay.3.10.1. Manual patch clamp assay

[0113] Single CHO cells are used for recording hERG currents at near physiological temperature (34-35 °C) using the whole-cell patch-clamp technique with an Axopatch 700A amplifier / pClamp software (Molecular Devices, Sunnyvale CA).

[0114] Electrodes (5-7 MQ resistance) are prepared from GC150-10 glass capillary tubes (Harvard Apparatus, Cambridge, UK) and filled with intracellular solution (in mM: KC1 120; Na2ATP 4; HEPES 10; EGTA 10; MgCl21.75; CaCl25.374, pH 7.2 adjusted with KOH).

[0115] The patch-clamp recording chamber is perfused with control extracellular solution (in mM: NaCl 145; KC14; MgC12 1; HEPES, 10; glucose 10; CaCl22 at pH 7.4 adjusted with NaOH).

[0116] With the formation of a gigaohm seal, the cell membrane is ruptured to establish the whole -cell configuration. The minimum acceptable seal resistance is 1 gigaohm, and access resistance no greater than 20pF.

[0117] The cell membrane is then voltage-clamped at a holding potential of -80 mV and depolarised to +20 mV for 2 sec followed by a negative pulse at -40 mV for 1.6 sec, before returning to -80 mV at a frequency of 0.1 Hz.

[0118] Once the hERG current is stable, the perfusion is switched to extracellular solution containing test compounds starting from the lowest concentration. Each concentration on the 4pt concentration-response curve is tested for 4 min to achieve steady state.3.10.2. Automated patch clamp

[0119] Electrophysiological recordings are made from a Chinese Hamster Ovary cell line stably expressing the full-length ion channel. Single cell ionic currents are measured in whole-cell configuration at RT (21-23 °C) using a QPatch II (Sophion Bioscience).

[0120] The internal solution for hERG contains (mM): 120 KC1, 20 KF, 10EGTA, 10 HEPES and is buffered to pH 7.3.

[0121] The external solution (HEPES -buffered saline, HBPS) contains (mM): 138 NaCl, 4.5 KC1, 1.8 CaCl2, 1.0 MgCl2, 10 HEPES, 10 glucose, buffered to pH 7.4.

[0122] Cells are clamped at a holding potential of -80 mV before a step to +20 mV for 500 ms, and then -40 mV for 500 ms. The test pulse is applied every 10 seconds. Currents are measured from the -40 mV step and referenced to the holding current.

[0123] Compounds are incubated for 120 seconds to allow stabilization of the parameters. Concentration -response curves are generated by cumulative addition of compound with concentrations low to high.FINAL REMARKS

[0124] It will be appreciated by those skilled in the art that the foregoing descriptions are exemplary and explanatory in nature, and intended to illustrate the invention and its preferred embodiments. Through routine experimentation, an artisan will recognize apparent modifications and variations that may be made without departing from the spirit of the invention. All such modifications coming within the scope of the appended claims are intended to be included therein. Thus, the invention is intended to be defined not by the above description, but by the following claims and their equivalents.

[0125] All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication are specifically and individually indicated to be incorporated by reference herein as though fully set forth.

[0126] It should be understood that factors such as the differential cell penetration capacity of the various compounds can contribute to discrepancies between the activity of the compounds in the in vitro biochemical and cellular assays.

[0127] At least some of the chemical names of compound of the invention as given and set forth in this application, may have been generated on an automated basis by use of a commercially available chemical naming software program, and have not been independently verified. Representative programs performing this function include the Lexichem naming tool sold by OpenEye Scientific Software, Inc. and the Autonom Software tool sold by MDL, Inc. In the instance where the indicated chemical name and the depicted structure differ, the depicted structure will control.REFERENCESBundgaard H. 1985. Design of prodrugs, Elsevier.Clark K et al. 2012. Phosphorylation of CRTC3 by the salt -inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc. Natl. Acad. Sci. U. S. A. 109, 16986— 16991.Ehrenhbfer-Wblfer K et al. 2019. SMARCA2 -deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines. Sci. Rep. 9, 11661.Kadoch C et al. 2013. Proteomic and bioinformatic analysis of mammalian SWI / SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592-601.Ozanne J, Prescott AR, Clark K. 2015. The clinically approved drugs dasatinib and bosutinib induce antiinflammatory macrophages by inhibiting the salt -inducible kinases. Biochem. J. 465, 271-279. Remington JP, Gennaro AR. 1985. Remington ’s Pharmaceutical Sciences, Mack.Stahl PH, Wermuth CG. 2011. Pharmaceutical Salts: Properties, Selection, and Use, 2nd Revised Edition Wiley,Sundberg TB et al. 2014. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc. Natl. Acad. Sci. U. S. A. Ill, 12468-12473.Wilson BG et al. 2014. Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation. Mol. Cell. Biol. 34, 1136-1144.Wuts PGM, Greene TW. 2006. Greene ’s Protective Groups in Organic Synthesis, 4th Edition \ Wiley.

Claims

1. CLAIMS1. A compound or a pharmaceutically acceptable salt thereof, according to Formula I:wherein,A is 6-10 membered monocyclic or bicyclic aryl, or 5-10 membered monocyclic or bicyclic heteroaryl comprising one, two or three heteroatoms independently selected from N, O, and S;RN .OK,0 N ORzY is independently selected from ' * , ' ' and ' ‘Ryand Rzare each independently hydrogen or C 1-3 alkyl;X is N or CH;R1is Ci -e alkyl, C1-3 alkoxy(Ci-3)alkyl, 3-6 membered monocyclic cycloalkyl, 4-6 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, -NH2, -NH(CI-3alkyl), -N(CI-3alkyl)2, -NHC(=O)(CI.3alkyl), -N(CI-3alkyl)C(=O)(Ci-3alkyl), or hydroxy(Ci.4)alkyl, wherein said cycloalkyl, heterocycloalkyl, alkyl and alkoxy groups are optionally substituted with one or more halogen, C1-6 alkoxy, -NIL. -NH(CI-3 alkyl), -N(CI-3 alkyl)2;n is 0, 1, or 2;each R2is independently selected from halogen and Ci-e alkyl, which alkyl is optionally substituted with halo or C1-4 alkoxy;or R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic cycloalkyl, or a fused 5-8 membered monocyclic heterocycloalkyl comprising Y in formula I and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro) or C1-4 alkyl;R3is hydrogen or C1-6 alkyl;R4aand R4bare each independently hydrogen or C1-6 alkyl optionally substituted with one or more independently selected halo or C1-4 alkoxy;or R4aand R4b, together with the carbon to which they are attached, form a C3-6 cycloalkyl or 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, which cycloalkyl or heterocycloalkyl is optionally substituted with one or more halo or C1-4 alkoxy;Li is a bond or C1-4 alkyl;B is phenyl or 5-6 membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S,Cy is a 5 -membered monocyclic heteroaryl comprising one, two, or three heteroatoms independently selected from N, O, and S, which heteroaryl is optionally substituted with one or more independently selected -L2-R5groups;L2 is a bond or Ci-e alkyl;Each R5is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- -OS(O)2O(Ci.4 alkyl),- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CONR9aR9b,- -CO2R9a,- C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- C1-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9a, C1-4 alkoxy, or C3-6 cycloalkyl,- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, C1.4 alkoxy, , -S(=O)2Ci.4alkyl, -C(=O)Ci.4alkyl, or -CO2R9a, - 4-8 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, -S(=O)2Ci-4 alkyl, -C(=O)Ci-4 alkyl, or -CO2R9a, and- phenyl optionally substituted with one or more independently selected halo, -OH, -CN, C1-4 alkyl, Ci-4alkoxy, , -S(=O)2Ci.4alkyl, -C(=O)C 1.4 alkyl, or -CO2R9a;R6is hydrogen, halo, or C1-6 alkyl;The subscript m is 0, 1 or 2;Each R7is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CH=CHCO2R9a,- -CONR9aR9b,- -CO2R9a,- Ci-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- Ci-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or C1-4 alkoxy,- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and- 4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, andeach R8ais independently hydrogen or C1-4 alkyl;each R8bis independently hydrogen, C1-4 alkyl or -C(O)Ci.2alkyl;each R9ais independently selected from hydrogen and C1-4 alkyl; andeach R9bis hydrogen, C1-4 alkyl, or C1-4 alkoxy; orR9aand R9btogether with the atoms onto which they are attached form a 4-7 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, Ci -4 alkyl.

2. The compound according to claim 1 or claim 2, wherein the compound is according to Formula III:CyO R41 / Y.R'R2or a pharmaceutically acceptable salt and / or solvate thereof.

3. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to claim 1, or 2, wherein R3is H.

4. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one ofclaims 1-3, wherein Bism, wherein m is 0, 1, 2, 3, or 4.

5. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one ofclaims 1-4, wherein Bismwherein m is 0, 1, 2, or 3.

6. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one of7. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one ofclaims 1-6, wherein1 nis selected from:substituted with 1 R2a, wherein R2ais selected from halogen (preferably fluoro) and C 1-4 alkyl.The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one of8. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one ofclaims 1 to 5, wherein Yis9. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one ofclaims 1 to 5 or 9, wherein is selected from:0 Oand10. The compound according to any one of claims 1-4 and 6-10, wherein the compound is according to Formula IVa or IVb:(IVa) (IVb)11. The compound according to claim 1, wherein the compound of Formula I is a compound according to Formula XII, XlVa, or XlVb:XlVbor a pharmaceutically acceptable salt and / or solvate thereof,whereinnl is 0 or 1;n2 is 0, 1, 2, 3, or 4; andR2ais selected from halogen (preferably fluoro) and C1.4 alkyl.

12. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one of claims 1 to 12, wherein R7is selected from:- -CN,halo,Ci-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or C1.4 alkoxy, and4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy.optionally wherein R7is C1-2 alkoxy optionally substituted with one or more independently selected - OH or C1-2 alkoxy.

13. A compound pharmaceutically acceptable salt thereof, according to any one of claims 1-14, wherein R5bZN— R5aCy is ' , wherein each Raand R is as defined for R in claim 1.

14. A compound selected from Table III of the description, or a pharmaceutically acceptable salt and / or solvate thereof.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof according to any one of claims 1-14.

16. A compound, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, according to any one of claims 1 - 14, or a pharmaceutical composition according to claim 15 for use in medicine.

17. A compound, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, according to any one of claims 1 - 14, or a pharmaceutical composition according to claim 15 for use in the prophylaxis and / or treatment of proliferative diseases.

18. A compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one of claims 1-14, or a pharmaceutical composition according to claim 15, for use in the prophylaxis and / or treatment of a disease, disorder or condition that is selected from metastatic tumors (such as but notlimited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, prostate cancer and uterine leiomyosarcoma), acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T -Cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Burkitt lymphoma, cutaneous T-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, chronic myelogenous leukemia, myeloid leukemia, multiple myeloma, asopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, kaposi, Sezary syndrome, skin cancer, small cell Lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, T -cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, Wilms tumor, a neoplastic disease of the blood and blood forming organs, including but not limited to: acute myeloid leukaemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukaemia (CLL), breast cancer (e.g. invasive ductal cancer, invasive lobular cancer), lung cancer (e.g. non-small-cell lung cancer, lung adenocarcinoma, squamous cell lung cancerand small-cell lung cancer), urothelial cancer, bladder cancer (e.g. urothelial bladder cancer, nonmuscle invasive bladder cancer, muscle invasive bladder cancer), upper tract cancer (e.g. urothelial upper tract cancer), urethral cancer, gastric cancer, pancreatic cancer, prostate cancer, colorectal cancer, multiple myeloma, liver cancer, melanoma (e.g. cutaneous melanoma), head and neck cancer (e.g. oral cancer), thyroid cancer, renal cancer (e.g. renal pelvis cancer), glioblastoma, endometrial cancer, cervical cancer, ovarian cancer, and testicular cancer.